Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Heterogeneous or solid phase assay system (e.g., ELISA, etc.)

Subclass of:

435 - Chemistry: molecular biology and microbiology

435004000 - MEASURING OR TESTING PROCESS INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITION OR TEST STRIP THEREFORE; PROCESSES OF FORMING SUCH COMPOSITION OR TEST STRIP

435700100 - Involving antigen-antibody binding, specific binding protein assay or specific ligand-receptor binding assay

435700900 - Assay in which an enzyme present is a label

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
435700940 Sandwich assay 148
435700930 Competitive assay 52
435700950 Indirect assay 5
20120178113DETECTION OF IGFBP-4 FRAGMENTS AS A DIAGNOSTIC METHOD - The present invention relates to a method for diagnosing a cardiovascular or cancer disease by detecting IGFBP-4 (Insulin-like Growth Factor Binding Protein-4) fragments in a patient sample. Antibodies specifically recognizing novel epitopes originated by enzyme-dependent cleavage of IGFBP-4 are also disclosed.07-12-2012
20120040382METHOD OF DETECTING PROGRESSION OF A NEURODEMENTING DISEASE - Isolated, monoclonal, human, anti-β-amyloid antibodies are provided which bind to dimeric forms of Ab with higher affinity than to monomeric forms of Ab and when bound to an Aβ polypeptide comprising Aβ(21-37) shield Aβ(21-37) from proteolytic digestion. The antibodies were shown to inhibit fibril formation and reduce plaque size in vivo and to not bind brain vessel walls. Accordingly, the antibodies are useful in human and veterinary medicine for the treatment and prophylaxis of Alzheimer's disease and other neurodementing diseases. Methods of detecting or measuring the progression of a neurodementing disease also are provided.02-16-2012
20120107848POLYCLONAL-MONOCLONAL ELISA ASSAY FOR DETECTING N-TERMINUS PRO-BNP - A specific and sensitive in vitro ELISA assay and diagnostic test kit is disclosed for determining levels of NT-proBNP protein in a variety of bodily fluids, non-limiting examples of which are blood, serum, plasma, urine and the like. The NT-proBNP ELISA assay test employs the sandwich ELISA technique to measure circulating NT-proBNP in human plasma. In order to obtain antibodies with specific binding properties for targeted amino acid sequences within human proBNP, recombinant human proBNP (or rhproBNP) was expressed and purified for use as an immunogen. Polyclonal antibodies (PAb) to specific amino acid sequences were subsequently purified from goat serum by sequential affinity purification. Monoclonal antibodies were raised against specific polypeptides. Recombinant human NT-proBNP (or rhNT-proBNP) was expressed and purified in order to obtain material for use in calibration of a quantitative method for measurement of human NT-proBNP.05-03-2012
20120129200PRODEFENSIN-A6 ASSAY METHOD FOR THE IN VITRO DIAGNOSIS OF COLORECTAL CANCER - The present invention relates to a method for the in vitro diagnosis of colorectal cancer by determining the presence of the Prodefensin-A6 tumour marker in a biological sample taken from a patient suspected of having colorectal cancer, it being possible for said method to be used both in early diagnosis, screening, therapeutic follow-up and prognosis, and in relapse diagnosis in relation to colorectal cancer.05-24-2012
20120214187Method for Enhancing the Sensitivity of Antibody Based Assays - There is a constant need for increased sensitivity of antibody-based assays as well as a need for high affinity antibodies. Higher affinity molecules such as antibodies increase the specificity and sensitivity of assays. Both increased sensitivity and higher affinity can be achieved when multiple copies of a binding molecule are coupled to a flexible backbone. According to one embodiment of the invention, multiple copies of a detection molecule, such as, for example, an antibody or antibody fragment, are covalently linked to a high molecular weight water soluble polymer creates multivalent antibody constructs. The affinity or avidity increases markedly as multivalency increases and also, multiple copies of a signal molecule can be similarly added to the polymer. Thus, the construct comprises multiple copies of detection and signal molecules on a high molecular weight, water soluble, flexible polymer. Broadly, the invention comprises a multiplicity of detection molecules (D) and a multiplicity of signal molecules (S) on a polymer (P), such that P08-23-2012
Entries
DocumentTitleDate
20130045492Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain - A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that express just one or a few immunoglobulin light chain variable domains from a limited repertoire in their germline. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided. Bispecific antibodies capable of binding first and second antigens are provided, wherein the first and second antigens are separate epitopes of a single protein or separate epitopes on two different proteins are provided.02-21-2013
20110177535METHOD OF DETECTING OR MONITORING A MALIGNANT PLASMA CELL DISEASE - A method of detecting or monitoring a malignant plasma cell disease comprising detecting in a sample the ratio between the relative amounts of immunoglobulins having: 07-21-2011
20110177534DIAGNOSTICS FOR MEMBRANOUS NEPHROPATHY - The invention relates to immunoassays, reagents, therapeutics and methods of diagnosing and prognosis evaluation of idiopathic membranous nephropathy (MN). Immunoassays comprise enzyme-linked immunoabsorbent assays and nephelometric immunoassays for serum auto-antibodies reactive against a phospholipase A2 receptor (PLA2R). Therapeutic methods include removal of the auto-antibodies by absorbance or administration of soluble PLA2R or fragments to sequester the auto-antibodies.07-21-2011
20110201034METHOD AND KIT FOR DETECTING ANTIBODY TO AVIBACTERIUM PARAGALLINARUM - A method and a kit for detecting an antibody to 08-18-2011
20110207154METHOD FOR DETERMINATION OF MARINOBUFAGENIN LEVELS AND COMPOUNDS EMPLOYABLE IN SUCH METHOD - The present invention is directed toward a method for determination of marinobufagenin concentration in a body specimen through conjugation of marinobufagenin to a suitable protein, thereby creating a conjugate which will trigger an antibody response in a host. The conjugated marinobufagenin is immunogenic. The antibodies so produced may be employed in an ELISA test to ascertain the concentration of marinobufagenin in a body specimen. A number of unique compounds are created in the process and are disclosed. An ELISA assay may be employed.08-25-2011
20110207153METHODS FOR DETECTING THE PRESENCE OF EXPANDED CGG REPEATS IN THE FMR1 GENE 5' UNTRANSLATED REGION - The invention provides improved methods for detecting the presence of expanded CGG repeats in the fragile X mental retardation 1 (FMR1) gene and for quantifying the amount of protein produced by the gene.08-25-2011
20110183363ASSAYS FOR DETECTING ANTIBODIES SPECIFIC TO THERAPEUTIC ANTI-IGE ANTIBODIES AND THEIR USE IN ANAPHYLAXIS - The invention provides methods and reagents useful for detecting anti-drug antibodies of IgE isotype to therapeutic anti-IgE antibodies, and methods for assessing risk of anaphylaxis to administration of a therapeutic anti-IgE antibody.07-28-2011
20100099123Soluble Human M-CSF Receptor and Uses Thereof - Soluble human M-CSF receptor is provided, along with pharmaceutical compositions containing such receptor, kits containing a pharmaceutical composition, and methods of diagnosing and treating diseases and disorders associated with M-CSF such as bone loss in a subject afflicted with an osteolytic disease.04-22-2010
20090317842Methods and Tools for The Therapy of Neurodegenerative Pathologies - The present invention concerns compositions and methods for the treatment of neurodegenerative diseases in which the cognitive functions are altered, such as observed in Alzheimer's disease. More particularly, the invention presents a strategy for human clinical monitoring of the activity and/or effectiveness of neuroprotective treatments, based on biochemical assay of certain platelet parameters, and thus can be done by blood sampling. The invention also concerns methods, tools, constructions and compositions suitable for implementing these strategies.12-24-2009
20080261249Detecting and Quantifying Host Cell Proteins in Recombinant Protein Products - A single-step immunoassay method, kit, and reagents for detecting and quantifying contaminant host cell proteins in a recombinant protein sample are described. The method includes the step of adding to immobilized medium comprising a capture reagent including anti-host cell protein antibodies, both the recombinant protein sample and a detection reagent comprising anti-host cell protein antibodies and a detectable moeity. The recombinant protein sample and two reagents are added simultaneously. This single-step format provides greater interaction between the capture antibody, the contaminant host cell proteins that may be present in the recombinant protein sample, and the detection antibody. By providing the opportunity for both antibodies and HCPs to interact at the same time, the one step format allows the formation of the “capture antibody-HCP-detection antibody” complex with all possible HCPs present. Thus, the HCP assay sensitivity is significantly improved, and the possibility of a false negative is significantly reduced. In addition, the one step format shortens the assay turnaround time and provides a convenient tool for measuring the HCP in the product during the course of the entire purification procedure. Quality control of the process is increased and the protein purification efficiency during process development can be measured.10-23-2008
20080261250Methods for Assessing the Risk for Development of Cardiovascular Disease - The present invention relates to diagnostic tests, methods and kits that are useful to assess a subject's risk of developing a pathologic condition related in part to the presence of HDL oxidation product. Measuring the quantity of one or more HDL oxidation products present in the blood is useful in evaluating risk for developing or evaluating the severity of a disease or evaluating response to treatment for such a disease as, for instance, cardiovascular disease.10-23-2008
20090208983Diagnose device for measuring the ratio of proteins with similar structure - The present invention relates to a diagnostic device for measuring the ratio of similar structural proteins among the proteins secreted in a liquid test sample taken from diagnosis subject. In further detail, the test device according to the present invention comprises detection marker-antibody conjugate recognizing the same site on two or more similar structural proteins and a detection zone in which antibody specifically recognizes each of said proteins via formation of sandwich type complex, wherein said antibodies form a set, and the present Invention relates to a diagnostic device for early diagnosis of polycystic ovary syndrome, abnormal pregnancy, prostatic carcinoma etc. based on determination of the ratio of follicle stimulating hormone and luteinizing hormone in case of polycystic ovary syndrome, the ratio between hCG isomers in case of abnormal pregnancy, and the ratio of prostate-specific antigens (PSA) in case of prostatic carcinoma.08-20-2009
20100015645IL-8 AS BIOMARKER FOR THE DETECTION OF UROLITHIASIS - Disclosed herein is a method for the detection or preliminary screening of urolithiasis, comprising: detecting the IL-8 level and the creatinine level in a urine sample taken from a human subject suspected to have urolithiasis; obtaining a creatinine-normalized IL-8 level in the urine sample by normalizing the detected IL-8 level to the detected creatinine level; and comparing the creatinine-normalized IL-8 level in the urine sample with a predetermined standard; wherein an elevation of the creatinine-normalized IL-8 level in the urine sample as compared to the predetermined standard is indicative of urolithiasis.01-21-2010
20100015647METHOD AND KIT FOR THE DETECTION OF HEPARIN-DEPENDENT ANTIBODIES AND THE DIAGNOSIS OF IMMUNE OR AUTOIMMUNE PAHTOLOGIES POTENTIATED BY HEPARIN SUCH AS HEPARIN-INDUCED THROMBOCYTOPENIA - The invention relates to a method for the detection of heparin-dependent antibodies and the diagnosis of immune or autoimmune pathologies potentiated by a heparin substance, such as thrombocytopenia induced by heparin (HIT type II) as inducer drug. The invention is characterized in that said method comprises the steps consisting in: 1) reacting: at least one substance with high affinity for a heparin substance (SFA), consisting of any molecule or complex having a high affinity for a heparin substance, with at least one heparin substance (SH) so as to form a substance with high affinity for heparin-heparin substance (SFA-SH) complex, wherein the heparin substance is in slight or large excess, so as to be able to bind other substances with affinity for heparin; then with at least one potential antigenic substance capable of reacting with the heparin substance, thus forming a complex (Ag-SH; and, finally, with the plasma or the serum of a patient to be tested (preferably diluted to a dilution of the order of 1:100) potentially containing: an anti(Ag-SH) antibody material generated in the organism after administration of a heparin substance, and/or at least one immune complex consisting of an Ag-SH/anti(Ag-SH) antibody complex present in the plasma or serum of the patient capable of reacting with the substance with high affinity for the heparin substance-heparin substance (SFA-SH) complex, and then, 2) revealing the resulting (Ag-SH)-anti(Ag-SH) complex produced.01-21-2010
20120183978ANTIBODIES TO DISULFATED HEPARIN DISACCHARIDE IN THE DIAGNOSIS OF NEUROPATHY - Methods aiding in the diagnosis of certain neuropathies are disclosed, in which the titer of antibodies to a disulfated heparin disaccharide is assessed in a test sample from an subject. Also disclosed are apparatus and kits that can be used in the methods of the invention.07-19-2012
20120183977SAMPLE PLATE SYSTEMS AND METHODS - A sample plate comprising a sample well is disclosed. The sample well can comprise one or more bead retaining chambers. A method of using the sample plate and a kit comprising the sample plate is also disclosed.07-19-2012
20120183979PROTEIN FRAGMENTS OF VIRB10 AND SERO-DETECTION OF ANAPLASMA PHAGOCYTOPHILUM - Disclosed are cloning and expression of a plurality of protein fragments of virB10, a Type IV Secretion System (TIVSS) in 07-19-2012
20100159490Multiplexed Assay Methods - The present invention is directed to methods for conducting multiplexed assays. The methods are particularly well suited for measuring a plurality of analytes that may be present in very different abundances. The invention also relates to systems, devices, equipment, kits and reagents for use in such methods.06-24-2010
20110195438INSULIN ASSAY - The present invention provides an insulin-specific assay and an assay reagent capable of sensitively and specifically assaying insulin using an antibody having a property of reacting with insulin bound to an anti-insulin antibody while not reacting with insulin not bound to an anti-insulin antibody, without being affected by proinsulin and insulin analogs.08-11-2011
20110195437METHOD FOR CHARACTERIZING, IN PARTICULAR FOR QUANTIFYING, MOLECULAR MARKERS THAT ARE INTRACELLULARLY ABSORBED FROM TISSUES BY BLOOD MACROPHAGES THAT ARE RECIRCULATED FROM THE TISSUES INTO THE CIRCULATORY SYSTEM - The invention relates to a method for characterizing, in particular for quantifying molecular marker(s) that are intracellularly absorbed from tissues by blood macrophages that are recirculated from the tissues into the circulatory system, wherein the following steps are carried out: application of an agent to whole blood, said agent inhibiting coagulation and/or agglomeration of whole blood; selecting and/or enriching and/or separating blood macrophages or leukocyte populations that contain blood macrophages from whole blood; perforating and/or lysing the selected blood macrophages or leukocyte populations containing the blood macrophages, optionally after previous permeabilization thereof; qualitatively and quantitatively determining non blood macrophage markers, namely molecular markers arising from tissue, after previously perforating and/or lysing the blood macrophages or leukocyte populations containing the blood macrophages, and an apparatus for carrying out the method.08-11-2011
20100047830COMPOSITIONS AND METHODS FOR DETECTING CANCERS IN A SUBJECT - Disclosed are compositions and methods for detecting oral and gastrointestinal cancers in a subject. Autoantigen p90 was shown to be overexpressed in oral cancer cells, and this protein, as well as its companion autoantigen p62 and antibodies directed to both proteins, can be used as markers for detecting oral digestive and other cancers in a subject at an early stage.02-25-2010
20130078653ANTIBODIES, COMPOSITIONS, AND ASSAYS FOR DETECTION OF CARDIAC DISEASE - The present invention provides antibodies, devices, and immunoassays for detection of ischemic cardiac events (unstable angina and heart attack) in patients experiencing chest pain. The invention allows for rapid determination of the cause of chest pain, and allows for differentiation of chest pain due to ischemic cardiac events and other causes. The invention provides antibodies that specifically bind to the epitope f-MII and the epitope f-MLF.03-28-2013
20100112607METHODS FOR DETERMINING ACTIVE INGREDIENTS IN PRO-DRUG PEG PROTEIN CONJUGATES WITH RELEASABLE PEG REAGENTS (IN VITRO DE-PEGYLATION) - The invention relates to the development of in vitro assay systems that force the release of a water-soluble polymer, such as polyethylene glycol (PEG) and polysialic acid (PSA), from proteins modified with a reversibly-linked water-soluble polymer. The invention includes methods for analyzing the release of the water-soluble polymer and measuring regained protein activity. The invention further includes methods appropriate for the quality control of proteins modified with releasable water-soluble polymers, including polymers like PEG and PSA.05-06-2010
20100075349RAPID ELISA PROCESSES AND RELATED COMPOSITIONS - The present invention provides improved and rapid detection methods for an antigen such as a chemical compound, a peptide, a nucleic acid, or a protein released from cells or virus particles in situ. The detection time for an antigen can be dramatically reduced relative to conventional technologies. The technology can particularly be used, for example, to modify and reduce the detection time significantly in traditional ELISA, and also Western blot or Dot blot assays. The improved ELISA method is rapid, economical, reproducible, simple and automatable. Also provided are compositions and kits for using the improved ELISA methods for the rapid detection of antigens.03-25-2010
20100075348METHOD FOR DIAGNOSIS OF A DISEASE INVOLVING AN ANTI-ENDOTHELIN-RECEPTOR ANTIBODY - The invention relates to a method for diagnosis of a disease, wherein presence or absence of an anti-endothelin-receptor antibody is determined in a sample from a patient to be diagnosed more in particular an anti-endothelin-receptor-A antibody. The disease according to the invention is in particular selected from diabetes, preferably type I diabetes, graft rejection, pre-eclampsia, hypertension, vasculitis, collagenosis, Raynaud-Syndrom (Morbus Raynaud), and inflammatory rheumatic disease and arteriosclerosis. The invention further relates to the use of an inhibitor of an anti-endothelin-receptor antibody or an inhibitor of an endothelin-receptor for the production of a medicament as well as a method for removing anti-endothelin-receptor antibodies from isolated blood by means of plasmapheresis.03-25-2010
20120244561BIOCHEMICAL SERUM MARKER - The present invention relates to a method for detecting the presence and/or concentration of the soluble BAG3 protein in an unknown biological sample and the assay is preferably carried by ELISA assay with antibodies, preferably monoclonal antibodies. The presence of said protein in a soluble form is associated with heart disease or with the presence of pancreatic tumors.09-27-2012
20120244557IMMUNOASSAYS USING ANTIBODIES SPECIFIC TO CARBAMAZEPINE - The present disclosure is directed to antibodies specific to carbamazepine, immunogens used to produce the antibodies, and immunoassay kits and methods for using the antibodies.09-27-2012
20130078652METHODS AND KITS FOR DETERMINING VON WILLEBRAND FACTOR ACTIVITY IN THE ABSENCE OF RISTOCETIN AND FOR DETERMINING THE ACTIVITY OF ADAMTS-13 PROTEASE - Described herein are method(s), kit(s), reagent(s) and the like for determining von Willebrand factor (VWF) activity in a sample in the absence of ristocetin.03-28-2013
20130078654Methods For Diagnosing Rheumatoid Arthritis - The present invention relates to methods of diagnosing, prognosing, preventing or delaying onset of or treating rheumatoid arthritis, methods of distinguishing between different types or stages of rheumatoid arthritis, of identifying an individual at risk of developing rheumatoid arthritis, and of monitoring efficacy of a treatment regime in an individual being treated for rheumatoid arthritis, using a citrullinated enolase peptide to detect or capture antibodies associated with rheumatoid arthritis.03-28-2013
20130078651INDIVIDUAL INFORMATION DETERMINING METHOD, INDIVIDUAL INFORMATION DETERMINING DEVICE, ELECTRONIC APPARATUS, AND INDIVIDUAL INFORMATION DETERMINING PROGRAM - Disclosed in an individual information determining method in which individual information of a subject is determined based on one or a plurality of pieces of biomolecule data collected from a surface of a body surface of the subject.03-28-2013
20100035285RAPID ELISA - A step in the enzyme-linked immunosorbent assay (ELISA) is changed from a heterogeneous phase to a homogeneous phase, to give a much shorter overall completion time. The new assay comprises the steps of (i) mixing in a homogeneous phase a sample and a first binding partner to an analyte to form a first mixing product; and (ii) exposing the first mixing product to a second binding partner to the analyte.02-11-2010
20130084585IMMUNOASSAY FOR CHROMOGRANIN A, ANTIBODIES AND KIT - The invention relates to monoclonal antibodies which are reactive with an epitope in the polypeptide represented by amino acid sequence 236 to 251 or 264 to 279 of the human CGA amino acid sequence. The invention further relates to the use of these monoclonal antibodies in an immunoassay for CGA, to immunoreagents comprising any of these two antibodies, and to test kits for the determination of CGA containing immunoreagents based on both of the monoclonal antibodies.04-04-2013
20130084584METHOD TO DETECT TISSUE DEGRADATION LEADING TO INFLAMMATION - This invention relates generally to a method, an assay and a kit for determining a tissue degradation process that leads to inflammatory responses opening up for a vicious circle of increased tissue destruction. More specifically the invention relates to kits and methods for an assay that can analyzee human samples, for the presence of a COMP fragment complex that have activated complement exemplified by the complex between COMP and complement factor C3b or natural breakdown fragments of C3b.04-04-2013
20130034868METHOD AND USE FOR ASSESSING RADIATION THERAPY IN ACCORDANCE WITH SAA - A method for assessing a subject to receive radiation therapy in accordance with the present invention includes the steps of obtaining a body fluid sample from the subject, measuring the concentration of serum amyloid A proteins of the body fluid sample and comparing the concentration of the serum amyloid A proteins with a range of values to determine whether the subject is suitable to receive radiation therapy. Additionally, the present invention also provides a use of serum amyloid A proteins for assessing whether a subject is suitable to receive radiation therapy.02-07-2013
20130034869DEVICES AND METHODS FOR MULTIPLEXED ASSAYS - The disclosure provides low cost, portable three-dimensional devices for performing multiplexed assays. The devices comprise at least two substantially planar layers disposed in parallel planes, wherein one of the layers is movable relative to each other parallel to the planes to permit the establishment of fluid flow communication serially between the two layers.02-07-2013
20130034867METHODS FOR ISOTOPICALLY LABELING BIOMOLECULES USING MAMMALIAN CELL-FREE EXTRACTS - Methods for producing an isotope-labeled mammalian, including a human, biomolecule, such as polypeptides and proteins, in a cell-free protein synthesis system. A biomolecule standard is produced having at least one isotope different in abundance than that of the naturally occurring isotopes in the biomolecule. Methods for quantifying biomolecules standards expressed using mammalian cell-free extracts are disclosed. Methods for producing such standards, kits, systems and reagents, relating to the use of isotope-labeled biomolecule as quantification standards in mass spectrometric and nuclear magnetic resonance analysis.02-07-2013
20130040324PERIFUSION DEVICE - A perifusion device includes at least one sample container for cells, the sample container having an inlet and an outlet. The container receives test liquid through the inlet and discharges the liquid through the outlet. A manifold having a plurality of liquid inlets, control valves, and liquid outlets can be provided. A receptacle housing has a plurality of receptacles. A drive is connected to the receptacle housing for moving the receptacle housing. A programmable controller can be provided to control movement of the receptacle housing. The test liquid includes at least one stimuli for the cells. The liquid collected in the receptacles is analyzed to determine the response of the cells to the stimuli.02-14-2013
20130040322Method of Diagnosing Sjogren's Disease - Provided are methods and compositions for determining whether an individual has Sjögren's disease (SD). The method entails determining in a biological sample from the individual the presence of antibodies directed to salivary gland protein 1 (SP-I), parotid secretory protein (PSP), carbonic anhydrase 6 (C A6), or determining a combination of the antibodies. Determining that the individual has SD is based on the presence of the antibodies. The method provides for detection of early SD. Kits for antibody detection containing the antigens to which the antibodies of SD patients are directed are also provided.02-14-2013
20130040321Method for Diagnosing Streptococcus, Enterococcus and Pepstostreptococcus Genera Infections - The invention concerns a method to determine if an individual is infected by a bacterium selected from the group consisting 02-14-2013
20130040319DETECTION OF INFECTIOUS PRION PROTEIN BY SEEDED CONVERSION OF RECOMBINANT PRION PROTEIN - The present disclosure relates to methods and compositions for the detection of infectious proteins or prions in samples, including the diagnosis of prion related diseases. One embodiment is an ultrasensitive method for detecting PrP-res (PrP02-14-2013
20130040320Method for Diagnosing Gram-Negative Infections - The invention concerns an in vitro method for determining if an individual is infected by a gram-negative bacterium preferably on prosthesis comprising: (i) detection of antibodies directed against a polypeptide of sequence SEQ ID NO: 2 and antibodies directed against a polypeptide of sequence SEQ ID NO: 4, in a biological sample of the individual, and (ii) deduction therefrom that the individual is infected by a gram-negative bacterium. The invention further concerns the kit for diagnosing of such an infection.02-14-2013
20130040323DETECTION KIT CONTAINING A NOVEL RECOMBINANT 15-kDA POLYPEPTIDE USEFUL FOR DETECTING HUMAN INFECTION WITH BARTONELLA HENSELAE - Disclosed are the cloning and expression of a novel antigen of 02-14-2013
20120208212METHODS OF ASSESSING CROHN'S DISEASE PATIENT PHENOTYPE BY I2, OMPC AND ASCA SEROLOGIC RESPONSE - The invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease in a subject having Crohn's disease by determining the presence or absence of IgA anti-I2 antibodies in the subject, where the presence of the IgA anti-I2 antibodies indicates that the subject has a clinical subtype of Crohn's disease. In one embodiment, a method of the invention is practiced by further determining the presence or absence in the subject of a NOD2 variant, anti-08-16-2012
20120264147Diagnostic Marker for Hepatocellular Carcinoma Comprising Anti-FASN Autoantibodies and a Diagnostic Composition for Hepatocellular Carcinoma Comprising Antigens Thereof - The present invention relates to an autoantibody specifically recognizing the epitope sequence of FASN (fatty acid synthase), more particularly, to the autoantibody or a fragment comprising an antigen-binding site thereof, a diagnostic composition for hepatocellular carcinoma comprising an agent capable of assessing the expression level of the autoantibody, a hybridoma cell line producing the autoantibody, a diagnostic kit for hepatocellular carcinoma comprising the composition, a method for detecting the autoantibody of hepatocellular carcinoma patient using the composition, and a method for screening a therapeutic agent for hepatocellular carcinoma by administering candidate materials for hepatocellular carcinoma treatment to confirm a reduction in the expression level of autoantibody.10-18-2012
20120264146COMBINATION OF SPLA2 ACTIVITY AND LP(A) CARDIOVASCULAR RISK FACTORS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT - The present invention related to a method of identifying a subject having or at risk of having or developing a cardiovascular disease and/or a cardiovascular event, comprising: -measuring, in a sample obtained from said subject, at least two cardiovascular risk factors: a) s PLA2 activity and b) Lipoprotein(a), -combining said measurements, the combined value of s PLA2 activity and Lp(a) being indicative of having or a risk of having or developing a cardiovascular disease and/or cardiovascular event.10-18-2012
20090155825DETECTION OF ANAPLASMA PLATYS - The invention provides compositions and methods for the detection of 06-18-2009
20090155824METHODS FOR ANTIBODY ENGINEERING - The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications.06-18-2009
20090155823Automated Immunoassay Apparatus - An automated immunoassay apparatus is disclosed comprising a single optical reading device (06-18-2009
20090155822Process for diagnosing rheumatic diseases - The invention relates to polypeptides reacting with rheumatism-associated autoantibodies. The invention moreover relates to a diagnostic agent comprising any of said polypeptides, to a diagnostic kit comprising said diagnostic agent and to a process for in vitro detection of rheumatic diseases. The invention furthermore relates to a medicament comprising any of said polypeptides and to the use of said polypeptides for preparing a medicament for the prophylaxis and/or treatment of rheumatic diseases.06-18-2009
20100105085METHOD OF DIAGNOSING AND STRATIFYING ANTI-PHOSPHOLIPID SYNDROME - Disclosed are a method and reagents for diagnosis of anti phospholipid syndrome based on the levels of certain anti 1 can antibodies.04-29-2010
20100105087BIOMARKERS FOR BREAST CANCER - Low molecular weight (LMW) peptides have been discovered that are indicative of breast cancer. Evaluating patient samples for the presence of such LMW peptides is an effective means of detecting breast cancer and monitoring the progression of the disease, for example during treatment. The LMW peptides are particularly useful in detecting breast cancer during its early stages.04-29-2010
20100105086DIFFERENTIAL DIAGNOSIS FOR SCLERODERMA - Use of IFI16 protein, fragments or peptides thereof for differential diagnosis of the limited cutaneous form of scleroderma (Ic-SSc) in a subject suspected of or at risk of having an autoimmune disease and the corresponding method of diagnosis and kit.04-29-2010
20100105088 METHOD FOR DIAGNOSING ATHEROSCLEROTIC PLAQUES BY MEASUREMENT OF CD36 - The present invention relates to diagnosis, classification and monitoring of atherosclerotic plaques in an individual using measurement of the concentration of CD36 in a body fluid and/or the plaque as such. The present invention also relates to diagnosing the burden of atherosclerotic plaques in an individual. Furthermore, the invention relates to a method for diagnosing stenosis caused by atherosclerotic plaques. Within the scope of the present invention are also methods for determining the treatment regime of an individual. Kits and oligonucleotides for use in the methods are claimed.04-29-2010
20100105084METHODS AND KITS FOR THE RAPID DETERMINATION OF PATIENTS AT HIGH RISK OF DEATH DURING SEVERE SEPSIS AND SEPTIC SHOCK - The present invention provides for the in vitro establishing of a prognosis for a subject in severe sepsis with at least two organ failures or in septic shock with at least two organ failures. Embodiments of the invention comprise the steps of measuring the level of the S100A8/A9 complex from a biological sample from a subject, and comparing the measured level to a predetermined threshold in which the measured level of the S100A8/A9 complex above the predetermined threshold is indicative of a bad prognosis and a measured level of the S100A8/A9 complex below the predetermined threshold is indicative of a good prognosis.04-29-2010
20100041079METHOD FOR PREDICTING CARDIOVASCULAR EVENTS - A novel method for assessing the risk of a cardiovascular event is provided. The concentration of 11-dehydro thromboxane in a urine sample is measured and compared to a set of standardized quartile concentrations. A concentration of urinary 11-dehydro thromboxane that falls within the fourth quartile is indicative of a greatly increased risk of a recurrent cardiovascular event.02-18-2010
20100041078ANTIBODY-BASED GAMMA-HYDROXYBUTYRATE (GHB) DETECTION METHOD AND DEVICE - Gamma-hydroxybutyrate (GHB) can be used as a recreational party drug, aphrodisiac, and attenuator of other drugs and make a person a vulnerable target of robbery or rape. The present invention provides methods and kits for detection of GHB in a sample using an antibody-based assay. Antibodies that specifically bind to GHB or the conjugates of GHB and its derivatives to larger molecules and methods for detecting GHB or its derivatives in bodily fluids and non-alcoholic and alcoholic drinks by employing such antibodies in ELISA or RIA assays are provided by the present invention.02-18-2010
20100041077PESTICIDE BIOMARKER - Provided are methods, compositions and articles of manufacture for detecting biomarkers indicative of exposure of a mammal to organophosphate compounds. The interaction of such a biomarker with a receptor bound to a biopolymer results in an optical readout that reports the presence of the biomarker.02-18-2010
20100041076Reagents, Methods and Kits for the Universal Rapid Immuno-Detection - This invention relates to a novel immuno-detection methods, kits and reagents. The Combination of this invention, combining at least two of the following reagents of a Non-specific Competitor, a Specific Indicator, a primary antibody and an antigen, provides a faster and easier method for an immuno-detection, combining at least two of the following steps of blocking, antigen binding, primary antibody binding and 202-18-2010
20090142782Identification of Actinobacillus actinomycetemcomitans Antigens for Use in the Diagnosis, Treatment, and Monitoring of Periodontal Diseases - Antibodies, polypeptides, and polynucleotides are provided for the detection, prevention, amelioration and treatment of diseases caused by 06-04-2009
20100330595DIAGNOSTIC METHOD FOR DISEASES BY SCREENING FOR HEPCIDIN IN HUMAN OR ANIMAL TISSUES, BLOOD OR BODY FLUIDS AND THERAPEUTIC USES THEREFOR - The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin.12-30-2010
20130029361DISC-SHAPED ANALYSIS CHIP - A disc-shaped analysis chip has an internal space. The internal space includes: a first reservoir for accommodating a first liquid; a second reservoir and a third reservoir arranged nearer to an outer peripheral portion of the analysis chip than the first reservoir; a fourth reservoir, a fifth reservoir and a sixth reservoir for accommodating a second liquid, a third liquid and a fourth liquid, respectively, and being arranged nearer to the outer peripheral portion of the analysis chip than the second and the third reservoir; a seventh reservoir arranged nearer to the outer peripheral portion of the analysis chip than the fourth to the sixth reservoir; an eighth reservoir arranged nearer to the outer peripheral portion of the analysis chip than the seventh reservoir; and a first to an eighth flow path for appropriately interconnecting the first to the eighth reservoir.01-31-2013
20130029362MARKERS AND ASSAYS FOR DETECTION OF NEUROTOXICITY - A process and assay for diagnosing neurotoxicity in a subject is provided. The extent of a neurotoxic insult to a subject is assessed through the measurement of one or more biomarkers in a biological fluid, such as CSF or serum. Other uses and advantages afforded include pre-market drug discovery, monitoring, drug neurotoxicity screening and post market assessment of safety and monitoring for drug of known potential neurotoxicity.01-31-2013
20130029359MONOCLONAL ANTIBODIES AND DIAGNOSTIC USES THEREOF - The disclosure relates to antibodies to the preferentially expressed antigen in melanoma (PRAME), and the synovial sarcoma X breakpoint 2 (SSX-2) antigens, methods of use, and diagnostic kits thereof. In exemplary embodiments, the disclosure relates to monoclonal antibodies to specific epitopes of the PRAME and SSX-2 antigens and methods of using such antibodies.01-31-2013
20130029360DIMERIC CORE-SHELL NANOSTRUCTURE LABELED WITH RAMAN ACTIVE MOLECULE LOCALIZED AT INTERPARTICLE JUNCTION, USE THEREOF, AND METHOD FOR PREPARING THE SAME - The present invention relates to a nanoparticle dimer in which Raman-active molecules are located at a binding portion of the nanoparticle dimer, and more particularly, to a core-shell nanoparticle dimer comprising: a gold or silver core having a surface to which oligonucleotides are bonded; and a gold or silver shell covering the core. In addition, the present invention relates to the core-shell nanoparticle dimer, to a method for preparing same, and to the use thereof.01-31-2013
20090123951Method Of Diagnosing A Body Weight Condition Or Predisposition - A method for diagnosing a body weight condition or predisposition to a body weight condition in an animal by determining observed level(s) of at least one biomarker in a tissue or biofluid sample from the animal and comparing the observed level(s) to reference level(s) for the biomarker; wherein the observed level(s) relative to the reference level(s) are individually or collectively indicative of the body weight condition or predisposition.05-14-2009
20130052666ANTIBODY AGAINST HUMAN TSH AND CANINE TSH - It is an object of the present invention to provide an antibody that recognizes a canine TSH and binds thereto, without obtaining a large amount of canine TSH antigen. The present invention provides a monoclonal antibody produced by a hybridoma having Accession No. FERM BP-11490.02-28-2013
20130052665METHODS FOR DIAGNOSIS OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS - Methods for diagnosis of systemic juvenile idiopathic arthritis (SJIA) are disclosed. In particular, the invention relates to the use of biomarkers for diagnosis of SJIA, which can be used to distinguish SJIA from other inflammatory diseases, including infectious illness, acute febrile illness, Kawasaki disease, and similar juvenile idiopathic arthritis (JIA) disease subtypes, and to predict inflammatory flares in SJIA patients in advance of clinical symptoms.02-28-2013
20130089876CAPILLARY BIOSENSOR SYSTEM AND ITS METHOD OF USE - A portable biosensor system includes at least one capillary tube extending longitudinally along a major axis between a proximal inlet end and a distal end. The at least one capillary tube has an interior surface coated with a capture material and forms a waveguide. At least one collimated light emitting diode is disposed proximate and perpendicular to the major axis of the at least one capillary tube and is positioned relative to the at least one capillary tube so that energy enters the at least one capillary tube from its exterior along the entire length of the at least one capillary tube to project a line of energy along substantially the entire longitudinal extent of the at least one capillary tube. A photosensor is disposed proximate the distal end of the at least one capillary tube for receiving emissive radiation therefrom. The photosensor generates an output voltage (or, optical output) representative of the emissive radiation, and a means for measuring the output voltage is provided. Also disclosed is a method of detecting target molecules in a sample using the biosensor of the present invention.04-11-2013
20130089875PEGylated insulin-like-growth-factor assay - The current invention reports an immunoassay for the determination of PEGylated insulin-like-growth-factor employing an anti-(polyethylene glycol) antibody and an anti-digoxygenin antibody for the detection of an insulin-like-growth-factor/insulin-like-growth-factor-binding-protein-complex.04-11-2013
20130089874RECIRCULATING FLUIDIC NETWORK AND METHODS FOR USING THE SAME - The present invention provides a variety of microfluidic devices and methods for conducting assays and syntheses. The devices include a solid substrate layer having a surface that is capable of attaching ligand and or anti-ligand, and an elastomeric layer attached to said surface. Preferred embodiments have deflectable membrane valves and pumps, for example, rotary pumps associated therewith.04-11-2013
20090208984DETECTION OF FOOD SPECIFIC HUMAN IgG4 ANTIBODIES - This invention particularly discloses an improved immunoassay method for the sensitive and specific detection of food specific human IgG4 antibodies. A sample diluent comprising a chaotrophic agent is used to reduce the occurrence of nonspecific antibody-dietary antigen interactions. To reduce competition between IgE and IgG4 antibodies for specific epitopes on dietary antigens a heat denaturing step is included to inactivate IgE antibodies. Finally, a signal amplification step is included in the assay to reduce the amount of sample required to perform the assay.08-20-2009
20130089878GLP-1 RECEPTOR AGONIST BIOASSAY - Provided herein are cell-based bioassays for measuring GLP-I receptor agonist activity of test compounds, such as GLP-I receptor agonist compounds. Exemplary GLP-I receptor agonist compounds include exendins, exendin analogs, GLP-1(7-37), and GLP-1(7-37) analogs. The bioassays are useful for quantitatively determining cAMP generated in samples containing GLP-I receptor agonist compounds (e.g., exenatide) and 6-23 (clone 6) cells having GLP-I receptors, whereby the amount of cAMP generated can be correlated to the GLP-I receptor agonist activity of the GLPI receptor agonist compounds (e.g., exenatide). Suitable cell-based bioassays include enzyme-linked immunosorbent assays and homogeneous time-resolved fluorescence assays.04-11-2013
20130089877THE NOVEL ABETA22(pE)-42 PEPTIDE THAT BINDS TO AMYLOID-BETA ANTIBODY SPECIFICALLY IN BLOOD AND PHARMACEUTICAL COMPOSITION FOR THE DIAGNOSIS OF DEMENTIA DISEASE CONTAINING THE SAME AS AN ACTIVE INGREDIENT - The present inventors screened peptides having a specific sequence specifically binding to amyloid-beta antibody and accordingly confirmed that Aβ22(pE)-42 peptide showed higher reactivity to amyloid-beta antibody in serum of Alzheimer's disease patients. Therefore, the said Aβ22(pE)-42 peptide can be used as an active ingredient for the kit for diagnosing dementia and thus it can be said that the peptide can be effectively used for the diagnosis of dementia whose early diagnosis is hardly possible.04-11-2013
20130089879COMPOSITIONS AND METHODS FOR DIAGNOSING AND MONITORING DISEASE AND TREATMENT VIA ANTIGEN-SPECIFIC MOLECULES - This document provides methods and materials related to compositions and methods for diagnosing and monitoring treatment for sensitivity to an antigen. Compositions of substantially pure polypeptides, or antigenic fragments thereof, and methods of using such compositions for diagnosing Lyme disease, infections, exposure to toxic environmental agents, and food sensitivities, and monitoring a subject's response to treatment of the same are provided.04-11-2013
20090305314Upregulation of Adamts4 Protease Activity for the Treatment of Alzheimer's Disease - The invention provides methods of identifying compounds suitable for treating Alzheimer's disease and related conditions by means of modulation of ADAMTS4.12-10-2009
20130071863Sulfur-Containing Amino Acid Derivative - The present invention provides a method of measuring an endogenous low-molecular-weight compound specifically and conveniently with high sensitivity. Using the particular sulfur-containing amino acid derivative, a method of measuring an endogenous low-molecular-weight compound specifically and conveniently with high sensitivity can be provided.03-21-2013
20130071862FUSION PROTEINS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF LEISHMANIASIS - The present invention relates generally to a fusion protein made from a synthetic gene construct comprising of elements derived from the 03-21-2013
20130071864COLORECTAL CANCER MARKER VITRONECTIN AND METHOD FOR ANALYZING VITRONECTIN CONCENTRATION IN BLOOD SAMPLE - The present invention provides a tumor screening marker that can be actually used in clinical practice to detect colorectal cancer, and a tumor progression marker that can complement CEA or CA03-21-2013
20130071861METHODS AND KITS FOR DETECTING ITA IN A BIOLOGICAL SAMPLE - Methods for detecting invasive trophoblast antigen (ITA) in biological samples comprise screening the samples for ITA using antibodies that bind to the ITA. The methods are useful to detect pregnancy, trophoblastic diseases, and Down's syndrome in fetuses of pregnant women. Some methods include screening the samples with a plurality of capture antibodies that specifically bind ITA. Chemiluminescent immunoassays are disclosed. The methods may be practiced with the diagnostic kits of the invention.03-21-2013
20090093005PROTEIN-BASED BIOMARKERS FOR ABDOMINAL AORTIC ANEURYSM - The present invention encompasses compositions and methods useful for diagnosing subjects with abdominal aortic aneurysms. The invention relates to the use of protein biomarkers whose levels are different in subjects with abdominal aortic aneurysms relative to normal subjects.04-09-2009
20110212470BIOMARKERS FOR RHEUMATOID ARTHRITIS - The present invention relates to the diagnosis of autoimmune disorders, more specifically to the diagnosis of rheumatoid disorders, chronic autoimmune arthritis and even more specifically to the diagnosis of rheumatoid arthritis. A biomarker panel is provided which can be used to detect if a subject has rheumatoid arthritis. Also described are methods of identification of such biomarkers.09-01-2011
20120309034METHOD FOR MEASURING IMMUNITY OF COMPLEX OF Ku86 AND AUTOANTIBODY THEREOF, KIT USED THEREFOR, AND METHOD FOR DETERMINING CANCER USING SAME - A reaginic antibody of Ku86 and a substance capable of binding with the autoantibody of Ku86 are acted on a complex of Ku86 and the autoantibody thereof in a subject. Said complex can be measured by measuring the obtained immune complex of the aforementioned complex, reaginic antibody, and substance capable of binding with the autoantibody of Ku86. As a consequence, it is possible to determine whether the cancer is a primary hepatoma, colon cancer, stomach cancer, pancreatic cancer, breast cancer, lung cancer, or an esophageal cancer.12-06-2012
20110014638SOLUBLE FAS IN ACUTE CORONARY SYNDROMES DIAGNOSIS - The present technology provides methods and materials for the early clinical detection of acute coronary syndromes in a subject. The methods and materials comprise measuring the amount of soluble Fas in a sample obtained from a subject, comparing the amount of soluble sFas with a reference value and detecting the presence of acute coronary syndromes.01-20-2011
20080274484Method for Diagnosing Renal Disorder, Hemolytic Uremic Syndrome and Enterohemorrhagic Infectious Disease Caused by Escherichia Coli - Methods for diagnosing renal disorder, hemolytic uremic syndrome and enterohemorrhagic 11-06-2008
20090286268Assays for Cancer Patient Monitoring Based on Levels of Analyte Components of the Plasminogen Activator System in Body Fluid Samples - The present invention describes clinically and medically important methods of examining, screening over time, and monitoring the outcome of a cancer patient who is undergoing treatment or therapy for his or her disease. More specifically, the invention provides a method of monitoring the progression of disease, or the effectiveness of cancer treatment, in a cancer patient by measuring the levels of one or more analytes of the plasminogen activator (uPA) system, namely, uPA, PAI-1 and the complex of uPA:PAI-1, in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment. As a result of performing the method, an increase or elevation in the levels of one or more of the PA system analytes in the cancer patient compared with the levels one or more of the respective PA system analytes in normal control individuals serves as an indicator of cancer advancement or progression and/or a lack of treatment effectiveness for the patient.11-19-2009
20090269790Method and Apparatus for Determining Hemocompatibility - Provided herein are techniques for screening materials for hemocompatibility. Hemocompatible materials may be advantageous when incorporated into devices that may come into direct contact with blood or other bodily fluids. Such techniques take advantage of conformational changes in fibrinogen when adsorbed onto certain materials. As a result of conformational changes, the fibrinogen has altered responsiveness to cleavage by thrombin. Accordingly, the products of thrombin cleavage of fibrinogen may be assessed to determine the hemocompatibility of a material.10-29-2009
20090081712ATM-Dependent Phosphorylation of Sp1 Is Involved in the Cellular Response to DNA Damage and Enhances Cellular Survival After DNA Damage - The present invention is related to the discovery that phosphorylation of SP1 (SEQ ID NO.: 2) at serine residue 101 (known herein as phosphoserine03-26-2009
20090068691Endothelial-monocyte activating polypeptide II, a biomarker for use in diagnosis and treatment of brain injury - A diagnostic tool and method of diagnosing brain injury and brain injury type (traumatic vs. ischemic) by detecting the level of expression of endothelial monocyte-activating polypeptide II (EMAP-II) and comparing to a control. An increase of EMAP-II indicates the presence of traumatic brain injury and a decrease of EMAP-II indicates the presence of ischemic brain injury. Detection of EMAP-II can be done in brain tissue, biofluids such as cerebrospinal fluid or blood (including plasma and serum)03-12-2009
20130065258COLORECTAL CANCER MARKER GALECTIN, METHOD FOR ANALYZING GALECTIN CONCENTRATION IN BLOOD SAMPLE, AND KIT FOR DETECTING COLORECTAL CANCER MARKER GALECTIN - The present invention provides a tumor screening marker that can be actually used in clinical practice to detect colorectal cancer, and a tumor progression marker that can complement CEA or CA19-9. Galectin-1 used as a tumor screening marker or a tumor progression marker for colorectal cancer. Galectin-3 used as a tumor screening marker. Galectin-4 used as a tumor progression marker, a tumor screening marker, or a prognostic prediction marker for colorectal cancer. A method of analyzing the galectin concentration in a collected blood sample using the galectin. A colorectal cancer marker detection kit comprising a detection antibody selected from the group consisting of a fluorescently labeled galectin-1 antibody, a fluorescently labeled galectin-3 antibody, and a fluorescently labeled galectin-4 antibody.03-14-2013
20130065256ASSAY SYSTEM - An assay apparatus comprising: i) an assay cartridge (03-14-2013
20130065257ENZYME-LOGIC BIOSENSING - Techniques, apparatus and systems are disclosed for implementing enzyme-logic based diagnosis that uses patterns of multiple markers and biochemical processing of the signal information for reliably identifying cardiac abnormalities and providing a final digital binary answer. In one aspect, a biochemical logic sensing system includes a network of enzyme-biocatalyzed logic gates adapted to receive biomarker input signals and perform an enzyme-biocatalyzed reaction resembling a Boolean logic operation using the received biomarker input signals to generate an output signal of the enzyme-biocatalyzed reaction. A signal processing unit is connected to the network of enzyme-biocatalyzed logic gates. The signal processing unit processes the generated output signal of the enzyme-biocatalyzed reaction and generates a digital binary output having a value of zero or one. The generated digital binary output indicates a type of an injury.03-14-2013
20130065255Biomarker to Measure Drug Efficacy in Enteropathic Disease - The diagnosis of a patient with an enteropathic disease or the response of a patient with an enteropathic disease to therapy, particularly a candidate therapy in a clinical trial setting, is assessed by detecting the ability of the patient to metabolize an orally administered CYP3A substrate. The CYP3A metabolism may be monitored in a variety of ways. Conveniently, the appearance of a metabolite of the CYP3A substrate is detected in a patient sample over a period of time following oral administration, e.g. in urine, plasma, serum breath, saliva, etc. The CYP3A substrate is optionally labeled, e.g. with an isotopic, fluorescent, etc. label.03-14-2013
20130065254NOVEL EPIGENETIC MECHANISMS RELATED TO DNA DAMAGE AND AGING - This invention pertains to markers of cellular senescence. In particular methylation of histone H1 (or isoforms thereof) at residue 172 and/or at residue 180 is a marker of cellular senescence. Antibodies specific to histone H1 (or isoforms thereof) methylated at residue 172 and/or at residue 180 are provided.03-14-2013
20110020848METHOD FOR DETECTION OF PNEUMOCOCCUS - To provide an immunological detection method which can detect or quantify a pneumococcal antigen in a sample derived from a living body conveniently, rapidly, and with high sensitivity, and an antibody for use in the method. The present invention provides an antibody which specifically recognizes a pneumococcal F-antigen; a method for detecting or quantitating a pneumococcal antigen, characterized in that the method detects or quantitates a pneumococcal F-antigen in a sample derived from a living body through immunological assay employing the antibody; and a kit for detecting a pneumococcal antigen, the kit containing the antibody.01-27-2011
20110020847Direct Enzyme Immunoassay and Kit for Measurement of Serum Progesterone Levels - Compositions, methods and kits for determining progesterone levels in mares are disclosed.01-27-2011
20110020846Oral cancer biomarker and inspection method using the same - The present invention discloses an oral cancer biomarker and an inspection method using the same. The biomarker is Mca-2 binding protein (Mac-2BP), which can be directly detected in the specimen of the body fluid of a testee, and which can realize a fast and effective clinical diagnosis of oral cancer.01-27-2011
20110045510PEGYLATED INSULIN-LIKE-GROWTH-FACTOR ASSAY - The current invention reports an immunoassay for the determination of PEGylated insulin-like-growth-factor employing an anti-(polyethylene glycol) antibody and an anti-digoxygenin antibody for the detection of an insulin-like-growth-factor/insulin-like-growth-factor-binding-protein-complex.02-24-2011
20110045506Chemiluminescent Enzyme Assay Method and Apparatus - A chemiluminescent enzyme immunoassay method for quantifying antigen or antibody using 1,1′-oxalyldiimidazole (ODI) derivative or 1,1′-oxalyldisodium benzoate (ODB) derivative chemiluminescence (CL) detection was developed. Also, various enzymes were quantified using ODI derivative or DOB derivative CL detection. Fluorescent compound formed from a substrate (non-fluorescent compound) through the enzyme assay methods emitted CL when the fluorescent compound received energy from high-energy intermediate formed in ODI derivative or ODB derivative CL reaction.02-24-2011
20090233319Method for Evaluating Skin Condition Using Squamous Cell Carcinoma Antigen as Marker - The invention provides a method for evaluating skin condition using squamous cell carcinoma antigen (SCCA) expression in skin stratum corneum cells as a marker.09-17-2009
20130164767ASSAYS FOR HUMAN NT-PRO B-TYPE NATRIURETIC PEPTIDE, HUMAN PRO B-TYPE NATRIURETIC PEPTIDE AND HUMAN B-TYPE NATRIURETIC PEPTIDE - The present disclosure relates to assays for detecting and/or quantifying the amount of human NT-pro B-type natriuretic peptide, human pro B-type natriuretic peptide and human B-type natriuretic peptide in a test sample.06-27-2013
20120115174URINARY TRYPSIN INHIBITORS AS DIAGNOSTIC AID FOR INTERSTITIAL CYSTITIS - A method aiding the diagnosis of interstitial cystitis involving the combination of an infection marker and an inflammation marker. More specifically, the method includes correlating the presence of urinary trypsin inhibitors in urine with the absence of traditional infection markers in urine to aid in the diagnosis of interstitial cystitis. The method provides for a differential diagnosis between kidney disease, infection and chronic inflammation with a noninvasive urine test. Assay devices and kits, as well as analyzers and systems are also described that utilize the methodology.05-10-2012
20120115173BIOMARKERS FOR MOTOR NEURON DISEASE - The invention provides methods of determining a diagnosis or prognosis of motor neuron disease in a mammal comprising determining the expression level of one or more proteins or polypeptides of the renin-angiotensin system in a sample taken from a subject. Similarly, aberrant post-translational modification of the proteins or polypeptides as compared to a negative control indicates a diagnosis of disease.05-10-2012
20120115172PTEN/AKT METHODS AND COMPOSITIONS RELATING TO BMP - The present invention relates to a purified molecules, including antibodies, that bind specifically to murine β-catenin phosphorylated at amino acid position Serine05-10-2012
20120115171Method For Diagnosing Thrombophilia - The invention relates to a method for diagnosing thrombophilia in a subject suffering from HIV or from a systemic auto-immune disease, said method comprising determining in a blood sample obtained from said subject the level of free Protein S having Activated Protein C (APC) cofactor activity and the level of total Protein S.05-10-2012
20120115170SERUM MG53 AS A DIAGNOSTIC MARKER FOR TISSUE INJURY - Disclosed herein are compositions and methods for measuring the level of MG53 found in a biological fluid as a biomarker for a disease or disorder, e.g., tissue damage, exercise capacity or a muscle-related disease or disorder. In addition, the invention relates to targeting the native MG53 found in the blood as a therapeutic approach.05-10-2012
20120115169HYDROXYCHOLESTEROL IMMUNOASSAY - Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Additionally, a method of making antibodies that specifically bind to 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Also, a method of assaying for 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Additionally provided is a kit for detecting 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. A method of detecting an enzyme or enzymes utilized in phase II drug metabolism is also provided. Also, a method of detecting an enzyme that synthesizes 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol is provided. Further provided is a method of evaluating progression of multiple sclerosis in a patient. Also provided is a method of determining whether a treatment for multiple sclerosis in a patient is effective. Further, a method of evaluating progression of Huntington's disease in a patient is provided. Additionally provided is a method of determining whether a treatment for Huntington's disease in a patient is effective.05-10-2012
20120115168BIOASSAY AND PEPTIDES FOR USE THEREIN - The invention provides a bioassay for detection of 05-10-2012
20090011445METHOD AND APPARATUS FOR IN VIVO COLLECTION OF CIRCULATING BIOLOGICAL COMPONENTS - The invention relates generally to in vivo collection of circulating molecules, tumor cells and other biological markers using a collecting probe. The probe is configured for placement within a living organism for an extended period of time to provide sufficient yield of biological marker for analysis. In some embodiments of the invention, active attraction of biological markers are provided. A partial or complete analytic/detection assembly may also be integrated with the probe.01-08-2009
20090011444DETECTION AND DIAGNOSIS OF INFLAMMATORY DISORDERS - Soluble H4 (sH4) levels have been discovered to correlate with the stage or severity of inflammatory disorders including autoimmune disorders. In particular, circulating levels of sH4 can be used as a diagnostic for determining the severity of an inflammatory disorder or the propensity for developing an inflammatory disorder. The severity of an inflammatory disorder can be determined by assaying the levels of sH4 in a subject and comparing the levels of sH4 to reference sH4 concentrations that correlate to specific stages of an inflammatory disorder. The therapeutic efficacy of treatments for inflammatory disorders can also be determined by comparing levels of sH4 before and during treatment. Methods and devices for measuring sH4 are also provided.01-08-2009
20090011443METHODS FOR SIMULTANEOUSLY DETECTING BOTH MEMBERS OF A BINDING PAIR - Methods and kits for simultaneously measuring both members of a binding pair are described.01-08-2009
20080311602RAPID ELISA PROCESSES AND RELATED COMPOSITIONS - The present invention provides improved and rapid detection methods for an antigen such as a chemical compound, a peptide, a nucleic acid, or a protein released from cells or virus particles in situ. The detection time for an antigen can be dramatically reduced relative to conventional technologies. The technology can particularly be used, for example, to modify and reduce the detection time significantly in traditional ELISA, and also Western blot or Dot blot assays. The improved ELISA method is rapid, economical, reproducible, simple and automatable. Also provided are compositions and kits for using the improved ELISA methods for the rapid detection of antigens.12-18-2008
20080311600ROUNDWORM COPROANTIGEN DETECTION - A composition, device, kit and method for detecting the presence or absence of roundworm in a fecal sample. The composition, device, kit and method of the present invention may be used to confirm the presence or absence of roundworm in a fecal sample from a mammal that may also be infected with one or more of hookworm, whipworm, and heartworm.12-18-2008
20080311599ANTIBODIES AGAINST CASPASE-8, THEIR PREPARATION AND USE - The invention relates to antibodies to a specific region in caspase-8, and to their use.12-18-2008
20130164764Methods of Detection of Coccidioides Species in Bodily Fluid - Coccidioidomycosis (Valley Fever) is currently diagnosed by relying on infected individuals (humans, dogs, etc.) to generate antibodies against the fungus. Since the immune response against Valley Fever can be delayed or absent in many cases, methods that detect a polypeptide or peptide component of the 06-27-2013
20130164765METHOD AND SYSTEM FOR DIAGNOSIS OF LAWSONIA INTRACELLULARIS - A method, system, and kit are provided for diagnosing 06-27-2013
20130164766Isolation and Application of BAD-1 For Diagnosing Infections With Blastomyces Dermatitidis - Methods for obtaining highly pure native, recombinant or modified BAD-1 protein include the steps of culturing a population of microbes expressing BAD-1 protein in a culture medium, collecting the population of microbes from the culture medium, obtaining a BAD-1 protein-containing solution, and purifying the BAD-1 protein from the solution by combining the BAD-1 protein-containing solution with a nickel-chelating resin, washing the nickel-chelating resin to remove unbound matter, and eluting the BAD-1 protein from the nickel-chelating resin. Highly pure native BAD-1 protein may be used in diagnostic kits for detecting 06-27-2013
20120237958METHODS FOR IDENTIFYING ANIMALS WITH A REDUCED ABILITY TO DIGEST LIPID AND PROTEIN - The invention provides methods for identifying animals with a reduced ability to digest fat or protein by determining various blood and physical factors for the animals and comparing the determined values to standard values that are indicative of a reduced ability to digest fat and protein.09-20-2012
20120237957Method For Enhancing Enzyme Assays - Additives capable of controlling the reaction rate between substrate and enzyme to form a dye in enzyme assays with absorbance, chemiluminescence, and fluorescence are effective tools for optimizing enzyme assays. A dye can be formed rapidly from the reaction between enzyme and substrate in the presence of a catalyst. Using relatively high concentration of dye formed from the rapid reaction, trace levels of analytical materials can be quantified using absorbance, chemiluminecence and fluorescence detection. A dye can be formed from a relatively slow reaction between enzyme and substrate in the presence of a surfactant such as Triton X-100 and β-cyclodextrin. Using relatively low concentration of dye from the slow reaction, a high concentration of analytical material can be quantified without any dilution using absorbance, chemiluminescence, and fluorescence.09-20-2012
20120237956TREPONEMA PALLIDUM TRIPLET ANTIGEN09-20-2012
20120270245DIAGNOSIS AND RISK STRATIFICATION OF INFECTIONS AND CHRONIC DISEASES OF THE RESPIRATORY TRACT AND LUNGS BY MEANS OF PROVASOPRESSIN, PARTICULARLY COPEPTIN OR NEUROPHYSIN II - The invention relates to a method for diagnosing and/or stratifying the risk of infections or chronic diseases of the respiratory tract and lungs, particularly lower respiratory tract infections and chronic obstructive pulmonary disease. In said method, provasopressin (proAVP) or fragments or partial peptides thereof, especially copeptin or neurophysin II, is/are determined. The invention further relates to suitable biomarker combinations for in-vitro diagnosis.10-25-2012
20090208982ASSAY METHOD FOR HUMAN OROTATE PHOSPHORIBOSYLTRANSFERASE PROTEIN - To establish an immunoassay method for human OPRT.08-20-2009
20120258479Assay Device Having Rhombus-Shaped Projections - An assay device includes: a liquid sample receiving zone; a capture zone in fluid communication with the sample receiving zone having capture elements bound thereto, the capture zone having a substrate and projections which extend substantially vertically from the substrate, the projections having a rhombus-shaped cross-section and the projections arranged on the substrate with the corners of the projections facing upstream in a direction toward the sample receiving zone. The projections have a height, cross-section and a distance between one another that defines a capillary space between the projections capable of generating capillary flow parallel to the substrate surface; and a sink in fluid communication with the capture zone having a capacity to receive liquid sample flowing from the capture zone. The sample receiving zone, the capture zone and the sink define a fluid flow path. Preferably, the rhombus-shaped cross-section is a square or a diamond.10-11-2012
20120219975Galactose-Alpha-1,3-Galactose-Macromolecule Conjugates And Methods Employing Same - Methods and reagents are disclosed for conducting assays for IgE. Embodiments of the present reagents comprise a conjugate of a macromolecule and a compound comprising a galactose-α-1,3-galactose epitope. Embodiments of the present methods are directed to determining the presence and/or amount of an IgE specific for a galactose-α-1,3-galactose epitope in a sample. A combination is provided in a medium, which comprises the sample and a reagent for determining the presence and/or amount of an IgE specific for a galactose-α-1,3-galactose epitope in a sample wherein the reagent comprises a conjugate of a macromolecule and a compound comprising a galactose-α-1,3-galactose epitope. The combination is subjected to conditions for binding of the IgE to the reagent to form a complex. The presence and/or amount of the complex are detected and the amount of the complex is related to the presence and/or amount of IgE in the sample.08-30-2012
20110111440ELISA KIT FOR DETECTING LINCOMYCIN - The present invention provides an ELISA kit for detecting lincomycin comprising a coating antigen and an enzyme labeled reagent, wherein the coating antigen is selected from the group consisting of a lincomycin hapten-carrier protein conjugate, a lincomycin antibody and a lincomycin anti-antibody; when the coating antigen is the lincomycin hapten-carrier protein conjugate, the enzyme labeled reagent is an enzyme-labeled lincomycin anti-antibody; when the coating antigen is the lincomycin antibody, the enzyme labeled reagent is an enzyme-labeled lincomycin hapten-carrier protein conjugate; and when the coating antigen is the lincomycin anti-antibody, the enzyme labeled reagent is an enzyme-labeled lincomycin hapten-carrier protein conjugate; and the lincomycin hapten is obtained through the condensation reaction between lincomycin and succinic anhydride. The ELISA kit according to the present invention can be used for detecting the content of lincomycin remained in a sample such as an animal tissue (muscle, liver), honey, etc.05-12-2011
20090098583METHODS OF DETECTING EARLY RENAL DISEASE IN ANIMALS - The present invention provides a method for the detection of early renal disease in animals. The method includes the steps of (a) obtaining a sample from an animal to be tested and (b) determining the amount of albumin in the sample. An amount of albumin in the range of from 10 μg/ml to about 300 μg/ml indicates the presence of early renal disease. The present invention also provides antibodies to canine, feline and equine albumin which can be used to detect the presence of early renal disease.04-16-2009
20110281284NOVEL LIVER CANCER MARKER - According to the present invention, HDGF in the blood of patients with chronic liver disease is measured to diagnose whether the patients have liver cancer. A measurement kit for the diagnosis is also provided.11-17-2011
20110281285Assay for Detecting Cathepsin K Activty in Bone, Cartilage and/or Soft Tissue - There is provided a method for detecting cathepsin K activity in bone, cartilage and/or connective tissue, the method comprising providing a biological sample, contacting the sample with an antibody having binding specificity for a neoepitope comprising EAGKPG (SEQ ID NO: 9), and detecting an immunocomplex formed between the antibody and the neoepitope, wherein presence of the immunocomplex is indicative of cathepsin K activity in bone, cartilage and/or connective tissue. There is also provided a kit for detecting cathepsin K activity in bone, cartilage and/or connective tissue.11-17-2011
20110086371URINE AND SERUM BIOMARKERS ASSOCIATED WITH DIABETIC NEPHROPATHY - Use of urine and serum biomarkers in diagnosing diabetic nephropathy, staging diabetic nephropathy, monitoring diabetic nephropathy progress, and assessing efficacy of diabetic nephropathy treatments. These biomarkers include urine precursor alpha-2-HS-glycoprotein, urine alpha-1 antitrypsin, urine alpha-1 acid glycoprotein, urine osteopontin, serum osteopontin, their fragments, and combinations thereof.04-14-2011
20100267060High sensitivity secretagogin assays and their uses for diagnosis and/or prognosis - The present invention relates to methods and compositions for measuring secretagogin in test samples, particularly patient samples. Preferred methods comprise performing a sandwich immunoassay, most preferably using a pair of monoclonal antibodies that bind to secretagogin.10-21-2010
20090068688PVDF membranes - The invention provides a method of treating a polyvinyl difluoride (PVDF) membrane comprising: (a) contacting said membrane with an alcohol and a wetting agent; and (b) drying said membrane.03-12-2009
20110117582MULTI-BIOMARKER BIOSENSOR - Nanosubstrates as biosensors, methods of making such nanosubstrates, and methods of using such nanosubstrates to detect biomarkers are described.05-19-2011
20080268479FETUIN-A AS A BIOMARKER FOR MULTIPLE SCLEROSIS - Biomarkers are disclosed that facilitate the mechanisms associated with central nervous system disease worsening or activity, specifically multiple sclerosis. Methods are also disclosed for identification of biomarkers associated with disease worsening or activity in multiple sclerosis.10-30-2008
20100159488METHOD FOR THE MULTIPLEX SEROLOGICAL DIAGNOSIS IN VITRO OF SPIROCHETE INFECTIONS - A method for the serological diagnosis, in vitro, of an infection with a spirochete bacterium which is pathogenic in humans, chosen from bacteria of the 06-24-2010
20090104633Kit for Highly Sensitive Detection Assays - The present invention relates to kits comprising 2,4-dichlorophenoxyacetate derivatives as well as antibodies that bind to these derivatives. Inter alia, the kits can be used to label biomolecules for analytical and diagnostic applications. Some of the compounds described here can be used to label biomolecules under physiological conditions and without having to apply in situ activation. Furthermore, the presence of spacers within the 2,4-dichlorophenoxyacetate derivatives improves their binding to antibodies.04-23-2009
20110008805Markers Associate with Arteriovascular Events and Methods of Use Thereof - Disclosed are methods of identifying subjects with arteriovascular disease, subjects at risk for developing arteriovascular disease, methods of differentially diagnosing diseases associated with arteriovascular disease from other diseases or within sub-classifications of arteriovascular disease, methods of evaluating the risk of arteriovascular events in patients with arteriovascular disease, methods of evaluating the effectiveness of treatments in subjects with arteriovascular disease, and methods of selecting therapies for treating arteriovascular disease.01-13-2011
20110300562GDF15 AS A DIFFERENTIAL MARKER FOR SPONDYLOARTHROPATHY - In vitro methods for differential diagnosis of spondyloarthropathy are disclosed which involve determining the levels of GDF15 in biological samples.12-08-2011
20110300564DIAGNOSIS OF PRE-ECLAMPSIA - The present invention relates to a method of predicting pre-eclampsia (PE). The present invention also relates to a diagnostic kit for performing a method of predicting PE. In particular, the method determining the level of two or more markers selected from placenta growth factor (PlGF), plasminogen activator inhibitor-1 (PAI-1), plasminogen activator inhibitor-2 (PAI-2) and leptin.12-08-2011
20110300563METHODS OF PREPARING AND OPERATING PORTABLE, POINT-OF-CARE, USER-INITIATED FLUIDIC ASSAY SYSTEMS - Methods of preparing assays and of assaying, using substantially self-contained, portable, user-initiated fluidic assay systems. Example assays include diagnostic assays and chemical detection assays. Diagnostic assays may include, without limitation, enzyme-linked immuno-sorbent assays (ELISA), and may include one or more sexually transmitted disease (STD) diagnostic assays. An assay system may include one or more fluid chambers, one or more fluid paths amongst the fluid chambers and/or between the fluid chambers, a sample portion, and/or an assay portion. The assay system may include a fluid controller system to dispense fluid from the one or more fluid chambers, and a user-initiated actuator to control the fluid controller system. The fluid controller system may be configured to dispense fluids serially, and may be configured to mix a plurality of fluids. The user-initiated actuator system may include an external user-operated trigger mechanism. The assay apparatus may include a display window to view assay results.12-08-2011
20120107845Disrupting FCRN-Albumin Interactions - Provided herein are, inter alia, methods for identifying a candidate compound for treating the toxic effects of compounds or molecules that bind to albumin in a subject. The methods include identifying test compounds that inhibit the binding between FcRn and albumin.05-03-2012
20120009607DIFFERENTIATING CARDIAC- AND DIABETES MELLITUS-BASED CAUSES OF KIDNEY DAMAGE - Disclosed is a method for differentiating in a subject suffering from kidney damage between kidney damage caused by (i) heart failure and/or (ii) diabetes mellitus type 1 or type 2 including the steps of: a) determining the amount of liver-type fatty acid binding protein (L-FABP) and the amount of kidney injury molecule 1 (KIM-1) in a urine-sample of a subject and forming the L-FABP/KIM-1 ratio; b) determining the amount of adiponectin in a urine-sample of said subject; and c) comparing the ratio determined in a) and the amount determined in b) with reference amounts, and establishing the predominant cause of the kidney damage. Also disclosed are a device and a kit for carrying out the method.01-12-2012
20120009606PEPTIDE BIOMARKERS PREDICTIVE OF RENAL FUNCTION DECLINE AND KIDNEY DISEASE - The presently-disclosed subject matter provides methods for diagnosing a kidney disease, or the risk thereof, in a subject. The methods comprise determining an amount of at least one peptide biomarker disclosed herein in a biological sample from the subject and comparing the amount of the at least one peptide in the sample with a control level, wherein if the amount determined is different than the control level, the subject is diagnosed as having, or at an increased risk of developing, the kidney disease.01-12-2012
20110287457COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AN INFLAMMATION - A method of reducing an inflammatory response in a subject is provided. The method comprising providing to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of a scavenger receptor or of an effector thereof, thereby reducing the inflammatory response in the subject.11-24-2011
20110287456SYNTHETIC PEPTIDES, METHODS AND KITS FOR DIAGNOSING AUTOIMMUNE DISEASES - Provided herein are synthetic peptides, methods and kits for easy detecting or diagnosing an autoimmune disease, particularly, Henoch-Schönlein purpura (HSP), based on the detection of autoimmune antibodies with peptides derived from β-2-glycoprotein-1 (β2-GPI).11-24-2011
20110287455Methods, Devices and Kits for Detecting or Monitoring Acute Kidney Injury - Methods for detecting acute kidney injury in an individual comprise (a) contacting a body fluid sample from the individual with an assay device including neutrophil gelatinase-associated lipocalin (NGAL) antibody and a detectable label, to allow complexing of NGAL protein in the sample with NGAL antibody, and determining an amount of complex formed between NGAL protein from the sample and NGAL antibody in the assay device using the detectable label, wherein NGAL antibody in the device has binding capacity with more than two NGAL protein epitopes, and wherein the amount of the formed complex represents a level of acute kidney injury. Methods for determining an origin of NGAL protein in a sample from an individual include the step of determining relative amounts of monomeric, dimeric and heterodimeric forms of NGAL protein in the sample and allow improved diagnosis and therefore better targeted treatment.11-24-2011
20110287453ANTIBODY BINDING SPECIFICALLY TO TDP-43 AGGREGATE - The present invention provides an antibody that specifically binds to an abnormal TDP-43 protein aggregate, an agent comprising the antibody for detecting a TDP-43 proteinopathy lesion, and a method for detecting or diagnosing a TDP-43 proteinopathy lesion by using the antibody.11-24-2011
20120083009Rheumatoid Arthritis Test Method And Treating Method - To evaluate the prognosis of rheumatoid arthritis based on the evaluation of the disease severity of the patient to select a treatment method suitable for each rheumatoid arthritis patients, and to measure HSC71 protein levels of the patients before and after the administrations of therapeutic agents to determine the efficacy of various therapeutic agents for each of rheumatoid arthritis patients and to use thereof as a remedy for preventing onset and progression of rheumatoid arthritis.04-05-2012
20100255514TUMOR CELL-DERIVED MICROVESICLES - The present invention relates to a method for diagnosis of cancer and for monitoring the progression of cancer and/or the therapeutic efficacy of an anti-cancer treatment in a sample of a subject by detecting oncogenic and cancer related proteins in microvesicles, and to the use of an agent blocking exchange of microvesicles for treating cancer.10-07-2010
20080206794Systems And Methods For Characterizing Contrast Induced-Nephropathy - The present invention relates to methods of diagnosing, predicting and monitoring kidney disorders. In particular, the present invention relates to the diagnosis, prediction and monitoring of contrast-induced nephropathy by detection of cytokines, cytokine-related compounds, and chemokines in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat contrast-induce nephropathy.08-28-2008
20110294144SCREENING METHOD - The present invention provides a cell model system capable of sufficiently reproducing a series of tau lesions, and provides a screening method for a prophylactic or therapeutic drug for a neurodegenerative disease using phosphorylation, insolubilization or aggregation of tau, or neurite denaturation or cell death in the cell model as an index.12-01-2011
20090104632MODIFIED TWO-STEP IMMUNOASSAY EXHIBITING INCREASED SENSITIVITY - The present invention relates to immunoassays for detecting or quantifying at least one analyte of interest in a test sample which exhibits improved sensitivity and/or a reduction in non-specific background compared to the immunoassay formats known in the art.04-23-2009
20100304412METHODS FOR DETERMINING THE RISK OF PRENATAL COMPLICATIONS - The disclosure relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual has for developing pre-eclampsia based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. The disclosure also relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual is carrying a fetus having a chromosomal abnormality based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers.12-02-2010
20100196935TREATING PRE-ECLEMPSIA AND CARDIOVASCULAR DISEASES - This document relates to methods and materials involved in identifying, predicting, and treating pre-eclampsia or a cardiovascular disease (e.g., atherosclerosis) in mammals. For example, methods and materials involved in using serum levels of HtrA polypeptides to identify pre-eclampsia or a cardiovascular disease, using HTRA polymorphisms to predict pre-eclampsia or a cardiovascular disease, and using HtrA antibodies to treat pre-eclampsia or a cardiovascular disease in mammals (e.g., humans) are provided.08-05-2010
20110294145REAGENTS AND METHODS FOR DETECTING A POLYMORPHIC PROTEIN - The present invention provides antibodies that differentially react with allelic variants of a polymorphic protein, methods of identifying same, an antigen binding fragment comprised therein, proteins, cells, viral particles, compositions, and kits comprising same. The invention also provides methods for determining a haptoglobin type of a subject and methods for testing a subject for susceptibility to diabetic complications.12-01-2011
20110294146Identification of Actinobacillus actinomycetemcomitans Antigens for Use in the Diagnosis, Treatment, and Monitoring of Periodontal Diseases - Antibodies, polypeptides, and polynucleotides are provided for the detection, prevention, amelioration and treatment of diseases caused by 12-01-2011
20100285507PLASMA KALLIKREIN FRAGMENTS AS DIAGNOSTIC BIOMARKERS FOR LUNG CANCERS - Disclosed herein are diagnostic markers for lung cancer, isolated from serum glycoproteins. The disclosed diagnostic markers for lung cancer are specifically expressed only in the sera of lung cancer patients at high levels, and thus will be very useful for diagnosing lung cancer and estimating disease progression and treatment.11-11-2010
20100062462IMMUNODEFICIENCY VIRUSES - This document relates to methods and materials involved in detecting, monitoring, and prognosing immunodeficiency virus infections. For example, methods and materials for determining whether or not a mammal (e.g., a human) has an immunodeficiency virus infection (e.g., an HIV infection), methods and materials for determining whether or not a mammal with an immunodeficiency virus infection is improving, and methods and materials for determining whether or not a mammal with an immunodeficiency virus infection has an advanced immunodeficiency virus infection are provided.03-11-2010
20100035284Urinary Proteomic Biomarker Patterns in Preeclampsia - The invention relates, in part, to methods of using proteomic biomarkers to diagnose preeclampsia. In some aspects the invention, in part, relates to the detection of serpina-1 polypeptide and/or albumin polypeptide in samples from pregnant subjects. Samples from subjects may be compared to control samples to diagnose preeclampsia and/or to determine the onset, progression, or regression of preeclampsia in a subject. The invention also relates, in part, to screening methods to identify agents that can be used to treat preeclampsia and to determine the efficacy of a preeclampsia treatment. The invention, in part, also includes kits that are useful to diagnose and assess preeclampsia in a subject.02-11-2010
20090098584Biomarkers and Methods for Determining Sensitivity to Vascular Endothelial growth factor Receptor-2 Modulators - VEGFR-2 biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an VEGFR-2 modulator, wherein the method comprises (a) exposing the mammal to the VEGFR-2 modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the VEGFR-2 modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a VEGFR-2 modulator indicates that the mammal has responded therapeutically to the method of treating cancer.04-16-2009
20080311603Diagnostic Test for Inflammatory Endothelial Dysfunctions in Pregnancies - The present invention relates to a diagnostic test for inflammatory endothelial dysfunctions in pregnant women. Particularly, the present invention relates to a method of diagnosing or evaluating the risk of contracting an inflammatory endothelial dysfunction of the maternal compartment comprising the following steps: a) detecting the plasma levels of long pentraxin PTX3 in blood samples taken from a pregnant woman; b) comparing the PTX3 plasma level data, obtained according to step a), with statistically significant PTX3 plasma level data of normal pregnant population.12-18-2008
20080311601Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy - The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of VEGF as a biomarker for multi-kinase inhibitors.12-18-2008
20090162876MYELOPEROXIDASE ASSAYS - The present invention relates to methods and kits for determining autoantibodies to myeloperoxidase or a myeloperoxidase fragment and myeloperoxidase or a myeloperoxidase fragment in a test sample.06-25-2009
20100112608METHOD OF DIAGNOSING LAWSONIA INTRACELLULARIS - The present invention relates to the field of animal health and in particular to 05-06-2010
20100112606MEASUREMENT AND ANALYSIS OF LEUKOTRIENES - The present invention provides a new analytical method for measuring leukotrienes in a clinical sample using liquid chromatography and tandem mass spectrometry (LCMSMS). The method provides a simple, rapid and low-cost assay for the measurement of leukotriene levels in a clinical sample with high accuracy and precision over the physiological range. The present invention further provides a method to determine the susceptibility of a subject to treatment with a leukotriene modifier, as wells as methods for diagnosis of a chronic obstructive disease of the airways and for predicting the risk of exacerbation of the same.05-06-2010
20100267062Osteopontin as Novel Prognostic Biomarker for Heart Failure - The present invention relates to methods for providing a diagnosis, prognosis and/or risk stratification of a subject with heart failure, comprising determining the concentration of osteopontin (OPN) in the biological sample, preferably in a plasma sample. An OPN cut-off value is discloses as a valuable reference value. The present invention furthermore relates to the use of osteopontin as marker for diagnosis, prognosis and/or risk stratification of a subject with heart failure, the use of the determination of the osteopontin plasma concentration in a biological sample of a subject for diagnosis, prognosis and/or risk stratification of heart failure as well as kits for performing the methods and uses of the invention. The present invention allows particularly for risk stratification of patients with heart failure, such as mortality prediction and prognosis of heart failure severity.10-21-2010
20080268476Nectin 4 (N4) as a Marker for Cancer Prognosis - The present invention relate for a method for prognosis cancer, in particular metastatic breast cancer comprising doing a dosage of Nectin 4, in a soluble form or in transmembrane form, in a sample, the presence of Nectin 4 being indicative of a cancer.10-30-2008
20080268477Antibody Reactive Specifically to Age Derived from 3,4-Dge - The present invention provides antibodies against AGEs derived from carbonyl compounds that are highly reactive with proteins or peptides, and methods of detecting the AGEs derived from the carbonyl compounds. 3,4-dideoxyglucosone-3-ene (3,4-DGE) is allowed to react with proteins, a host animal is immunized with the reaction product thereof, AGEs, and antibodies against the AGEs (anti-AGE antibodies) are isolated from serum recovered from the host animal. These anti-AGE antibodies thus isolated are allowed to react with a sample, and then the antigen-antibody reaction between the AGEs in the sample and the anti-AGE antibodies is detected. Thereby the presence or amount of the AGEs in the sample can be detected.10-30-2008
20110171668Determination Of Equilibrium Constants In Solution By Multi-Step Kinetics - The invention relates to a method for determining a first equilibrium constant of a first equilibrium reaction via MSK analysis of a second equilibrium reaction, whereby the first and the second equilibrium reaction share at least one reactant.07-14-2011
20110151490Compositions for the Detection and Treatment of Colorectal Cancer - The invention provides methods of identifying proteins and polypeptides and their cognate polynucleotides that are expressed by cells under one environmental condition and not under a second environmental condition. The invention also provides compositions for the treatment and detection of cancer, including colorectal cancer.06-23-2011
20090275060DETERMINATION OF SERUM ANTI-MULLERIAN HORMONE AS A DIAGNOSTIC TEST FOR SPAY IN COMPANION ANIMALS - This invention relates to non-surgical assays that can be used to determine whether an animal that has a non-postpartum anestrous period of three months or greater, such as a dog or a cat, has been spayed. In particular, the present invention relates to devices, kits and methods that allow correlation of levels of Anti-Müllerian Hormone with the state of being spayed.11-05-2009
20120142033METHOD FOR EXTRACTION AND PURIFICATION OF RECOMBINANT PROTEINS FROM TRANSGENIC PLANTS - Extraction and purification of recombinant proteins rendered difficult to extract from transgenic plants by using an extraction solution containing reducing agents and surfactants or an extraction solution containing reducing agents and organic solvents.06-07-2012
20120107847TESTING EFFICACY FOR CELIAC DISEASE - We describe a method to determine effectiveness of a compound or composition in treatment of celiac disease or gluten intolerance, the method comprising: 05-03-2012
20120107846MEASURING CIRCULATING THERAPEUTIC ANTIBODY, ANTIGEN AND ANTIGEN/ANTIBODY COMPLEXES USING ELISA ASSAYS - The present invention relates to the field of immunology and hyperproliferative diseases. More specifically, the present invention relates to a method of detecting and monitoring therapeutic antibody:antigen complex, soluble antigen and soluble therapeutic antibody, wherein a patient has undergone at least one course of immunotherapy. Yet further, levels of therapeutic antibody:antigen complexes, soluble antigens or soluble therapeutic antibodies may be measured and used to stage or monitor a hyperproliferative disease.05-03-2012
20120107844IMMUNOSORBENT ASSAY SUPPORT AND METHOD OF USE - Embodiments of the present invention provide an immunosorbent assay support immobilized with an intermediate binding antibody and their method of use in an improved immunoassay format.05-03-2012
20120107843ANTI BONE-LOSS AND ANTI ATTACHMENT-LOSS EFFECTS OF AN ORAL COMPOSITION - Methods for identifying compounds useful for treating diseases and conditions of the oral cavity are described herein.05-03-2012
20120107842METHOD FOR DETECTING ANTIBODY AGAINST SITH-1 IN BIOLOGICAL SAMPLE - The present invention provides a method for detecting an antibody against a small protein encoded by the intermediate stage transcript of HHV-6 (SITH-1) in a biological sample.05-03-2012
20120107841Serum Diagnostic Method, Biomarker and Kit for Early Detection and Staging of Alzheimer's Disease - A laboratory method for screening, diagnosing, monitoring and/or staging early onset Alzheimer's disease which consists of mild cognitive impairment entails conducting a blood test after an oxidative exposure of serum to assay for the presence of an elevated level of redox-reactive autoantibodies.05-03-2012
20110201036ENDOMETRIOSIS MARKERS - The present invention relates to methods for determining a risk or identifying a condition associated with the presence of endometriosis in a subject as well as testing a candidate compound for a therapeutic activity for the treatment of endometriosis and sorting patients based on the risk of having endometriosis. Specifically, the methods utilize novel markers for assessing the risk of the patient having endometriosis.08-18-2011
20090263838Method for determining a lung cancer treatment and method for determining the effectiveness of an agent for treatment of lung cancer - The present invention provides a method of determining a lung cancer treatment, the method comprising: measuring an amount of KL-6 in a sample of body fluid from a subject, and determining the treatment based on the amount of KL-6 measured, and a method of determining the effectiveness of an agent for treatment of lung cancer on a subject, the method comprising: measuring an amount of KL-6 in a sample of body fluid from the subject, determining the effectiveness of an EGFR inhibitor on the subject should the EGFR inhibitor be administered as the agent for treatment of lung cancer, based on the amount of KL-6 measured.10-22-2009
20090263837METHOD OF MINIMIZING REAGENT CONSUMPTION IN MICROPLATE-BASED REACTIONS - A method is provided for performing a reaction, such as the synthesis of concentrated cDNA, in the wells of a microplate while minimizing the volume of the solution of reagents required to perform the reaction. In the method, a pestle is inserted into the well of a microplate to which a substance has been immobilized. A volume of reagent solution is introduced into the well that is insufficient to cover the portion of the well onto which the substance is immobilized. The insertion of the pestle displaces reagent solution and increases the surface area of the solution in contact with the portion of the well to which the substance has been immobilized when the pestle is inserted.10-22-2009
20120270243Diagnosing and Managing Venous Thromboembolism and Intracardiac Thrombi Using a Provoked D-dimer Test - The present invention provides methods for diagnosing a venous thromboembolism or intracardiac thrombi in an individual in need of such treatment. A representative method of the present invention comprises the steps of: obtaining a plasma sample from said individual; determining the baseline level of D-dimer in said sample; contacting said sample with a compound that catalyzes the conversion of plasminogen into plasmin; and measuring the level of D-dimer is said sample after administering or contacting said sample with a compound that catalyzes the conversion of plasminogen into plasmin, wherein a significantly greater concentration of D-dimer after contact with a compound that catalyzes the conversion of plasminogen into plasmin than prior to contact with a compound that catalyzes the conversion of plasminogen into plasmin indicates that said individual has pulmonary embolism or venous thromboembolism.10-25-2012
20090170134BIFUNCTIONAL AND TRIFUNCTIONAL NITRONE SPIN TRAPPING COMPOUNDS AND USES THEREOF - Methods and compositions for detecting free radicals, the compositions being spin trapping compounds comprising a nitrone having a detecting moiety and optionally having a targeting moiety for targeting the nitrone to an organ, a cell, an organelle or a molecule of interest for directly detecting free radicals, especially free radicals in biological samples.07-02-2009
20130217043HUMANIZED TRANSGENIC MOUSE MODEL - Provided is a transgenic animal model for testing immunogenicity and protective efficacy of human vaccines and the method for generating such a multitransgenic animal. Also disclosed are methods for screening compositions for human vaccine development. More specifically, a mouse model capable of expressing human leukocyte antigen DR4, and human costimulatory molecules (CD80) upon infusion of human HLA-matched hematopoietic stem cells, which can develop into a functional man immune system is provided.08-22-2013
20100099124Method for Diagnosing Diseases Based on Levels of Anti-Glycan Antibodies - Disclosed are methods for diagnosing Crohn's disease (CD) or anti-phospholipid syndrome by measuring levels of antibodies to glycans in a biological sample.04-22-2010
20110201033G IMMUNOGLOBULIN USED AGAINST ANTHRAX TOXINS - An immunoglobulin of the G class (IgG) directed against the protective antigen (PA) of the anthrax toxin, includes: 08-18-2011
20090170135DETERMINING FELINE proBNP - Methods and compositions are disclosed for determining feline proBNP or fragments thereof in a sample. In one method, feline proBNP or fragments thereof are determined by providing a feline sample, contacting the sample with at least one antibody that binds an epitope in the region from amino acids 1 to 20 of feline proBNP, and determining the presence of the feline proBNP or fragments thereof present in the sample. Antibodies that bind feline proBNP and kits comprising such antibodies are also disclosed.07-02-2009
20110269157Immunological Test For Detecting Autoantibodies Against Testicular Antigens - The present invention discloses an immunological test for the detection and specific determination of autoantibodies against testicular antigens which are associated with inflammation-related fertility disorders of male mammals in a biological sample of a male mammal, in particular the detection of testicular ER-60 autoantibodies and/or transferrin autoantibodies. The immunological test is utilized to detect the presence of immunologically-caused and infection-related infertility in male mammals, particularly in humans.11-03-2011
20090286267Methods for Determining Drug Responsiveness - The invention provides a diagnostics assay for measuring the responsiveness to a drug by comparing the protein levels of a gene that responds to the drug, such as a steroid, to the protein levels of a gene that does not respond to the drug. Methods according to the invention are useful for predicting the ability of a patient (or a tissue, body fluid or cell sample in vitro) to respond to a drug or steroid at any stage of their treatment (i.e., before, during or after), and to monitor the patient (or a tissue, body fluid or cell) over time to assess continued responsiveness to the drug or steroid.11-19-2009
20110201035COMPOSITIONS AND METHODS FOR THE DETECTION OF HIV-1/HIV-2 INFECTION - This invention relates to compositions and methods or the detection of immunodeficiency virs infection, especially immunodeficiency virus-1 (HIV-1) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies.08-18-2011
20090170133Intact IGFBP-3 as a Colon Cancer Risk Factor in Patients With Inflammatory Bowel Disease - The subject invention provides a method for determining whether a human subject afflicted with long-lasting irritable bowel disease (IBD) has an increased risk for developing colon cancer comprising: (a) determining the concentration of intact IGFBP-3 in a suitable cell-free bodily fluid sample taken from the subject; and (b) determining whether the concentration of intact IGFBP-3 determined in step (a) is indicative of an increased risk of colon cancer in a human subject afflicted with long-lasting IBD. This invention also provides a kit for performing the instant method.07-02-2009
20100216173CITRULLINATED FIBRIN-FILAGGRIN CHIMERIC POLYPEPTIDE CAPABLE OF DETECTING THE ANTIBODIES GENERATED IN RHEUMATOID ARTHRITIS - The present invention concerns a chimeric polypeptide, capable of detecting the antibodies generated in rheumatoid arthritis, comprising at least two citrulinated peptide subunits: (i) one derived from the α or β chain of the fibrin and (ii) a second derived from the filaggrin. In addition, the invention comprises an antigenic composition, a method and a kit for the diagnosis of rheumatoid arthritis, from the detection of the autoantibodies generated during the course of said disease.08-26-2010
20100279325USE OF MODIFIED EXTRACELLULAR MATRIX PROTEINS IN DIAGNOSIS AND TREATMENT OF ATHEROSCLEROSIS - The present invention relates to the use of fibronectin, tenascin, collagens type I, III, VI and/or VIII modified by aldehyde or by glycosylation in ELISA for detection of antibodies in plasma and serum to diagnose atherosclerosis as well as the use of induction of tolerance and active as well as passive immunization against glycosylated or aldehydemodified fibronectin, tenascin, collagen type I, III, VI and/or VIII for prevention and treatment of atherosclerosis.11-04-2010
20100143952BIOCHIP, AND METHOD FOR THE SELECTIVE IDENTIFICATION OF CHLAMYDIA TRACHOMATIS INFECTIONS - The present invention relates to a method for the selective identification of 06-10-2010
20080274482BETA 1 INTEGRIN ACTIVATION AS A MARKER FOR ASTHMA - Methods are provided in which β11-06-2008
20120058495Recombinant fragments and synthetic peptides of 17-kDa polypeptide useful in detecting Bartonella henselae - The present disclosure describes recombinant and synthetic polypeptides of 03-08-2012
20080268480Methods of Evaluating Baff - The present disclosure provides compositions and methods relating to the evaluation of BAFF in a biological sample from a subject.10-30-2008
20090269791NON-PROTEOLYTIC METHOD FOR THE DETERMINATION OF ANALYTES IN KERATINIZED STRUCTURES - Methods that permit the rapid release of one or more analytes from head or body hair or other keratinized structures of an individual (who may previously have ingested one or more of the analytes) are provided. The methods can include contacting the keratinized structure with a reducing agent but not with a proteolytic agent. The methods can further include identification and quantification of the one or more analytes by known analytical techniques such as immunoassays. The described methods do not damage the analyte and do not cause harmful effects on a subsequently-used analyte detection probe (e.g., an antibody).10-29-2009
20080206795Novel Supports, in Particular for Immunodetection of Molecules of Interest - The invention concerns supports or receptacles for solubilized or suspended biological entities whereof the walls are made of plastics surface-treated by an electromagnetic plasma followed by a polymer deposition. It can be in the form of tubes or multiple-well plates. It provides among other things the possibility of storing, transferring and performing reactions in the context of microassays of biological entities, more particularly the prion protein, with enhanced sensitivity.08-28-2008
20080248507C-erbB-2 external domain: GP75 - Disclosed are methods and compositions for identifying malignant tumors that overexpress the c-erbB-2 oncogene. Assays useful for diagnosis and prognosis of neoplastic disease are provided which detect the external domain of c-erbB-2, the glycoprotein gp75 and quantitate the level of gp75 in the biological fluids of mammals carrying a tumor burden.10-09-2008
20080286817NOVEL ALLERGENS AND TREATMENT - The present invention is related to novel nucleotide sequences encoding a louse allergen and a methods for diagnosing, treating and preventing lice infestation and associated allergic disease with the nucleotide sequences and protein allergen of the invention. The present invention also relates to kits for diagnostic assays.11-20-2008
20100143951NOVEL MARKERS FOR CHRONIC KIDNEY DISEASE - The present invention relates to a method for the determination or prediction of the progression of chronic kidney disease in a subject suspected to suffer from chronic kidney disease, said method comprising the step of determining the expression levels of at least one marker selected from (a) FGF23; and (b) adiponectin in a biological sample. Furthermore, the present invention relates to a use of a specific detection molecule for FGF23 or use of a specific detection molecule for adiponectin for the preparation of a diagnostic composition for the detection of chronic kidney disease or the progression of chronic kidney diseases in a subject suspected to suffer from said disease. In particular, the present invention also provides for use of FGF23 and/or of adiponectin as an in vitro marker for the presence, absence or progression of a chronic kidney disease and kits comprising a specific detection molecule for FGF23 or a specific detection molecule for adiponectin for use in the method of the present invention.06-10-2010
20080213807Methods of Using Bone Morphogenic Proteins as Biomarkers for Determining Cartilage Degeneration and Aging - Methods are provided for determining cartilage degeneration, regeneration, or aging in a joint tissue in a patient by measuring levels of osteogenic protein-1 (OP-1) protein and/or mRNA in synovial fluid or joint tissue. The methods according to the invention are useful for detecting, diagnosing, predicting, determining a predisposition for, or monitoring joint tissue degeneration, regeneration, or aging in a patient including inflammatory joint disease or age-related disorders.09-04-2008
20110207156Biomarkers for Diagnosis of Breast Cancer - The present invention provides methods and kits for determining breast cancer. The invention includes the identification and use of biomarkers that are present in different amount or differentially expressed in breast cancer versus normal controls.08-25-2011
20110207152GELSOLIN BINDING AGENT COMPOSITIONS AND USES OF SAME - The invention relates generally to gelsolin binding agents (e.g., antibodies) which can bind to gelsolin polypeptides. Gelsolin binding agents of the invention are useful, alone or in combination, to detect a gelsolin polypeptide (a.k.a., the target polypeptide) in a test sample as well as to purify native gelsolin proteins. Gelsolin binding agents are also useful to diagnose, a gelsolin related medical condition in subjects in need thereof. Kits to detect gelsolin in biological samples are provided by the present invention.08-25-2011
20090136972METHODS FOR THE DIAGNOSIS OF GENITOURINARY CANCER - Methods for the diagnosis of genitourinary (GU) cancer are provided. In particular, urine has been found to contain significant levels of thromboxane receptor β (TPβ) methods for diagnosing GU cancer. Methods for assessing treatment, prognosing and staging GU cancers, as well as kits therefor, also are provided.05-28-2009
20110207155Method for the preparation of immunoconjugates and use thereof - The present invention concerns a method for the preparation of molecular conjugates comprising immunoglobulins and biomarkers occurring in neoplastic diseases characterized by high levels of reproducibility.08-25-2011
20090258379ISOLATION OF MEMBRANE VESICLES FROM BIOLOGICAL FLUIDS AND METHODS OF USING SAME - Methods of isolating membrane vesicles from a biological fluid sample are provided. In some embodiments, the methods comprise providing a biological fluid sample comprising membrane vesicles; filtering the biological fluid sample through a filtration module comprising a filter having an average pore diameter of between about 0.01 um and about 0.15 um; and collecting from the filtration module a retentate comprising the membrane vesicles, thereby isolating the membrane vesicles from the biological fluid sample.10-15-2009
20090325204COMPOUNDS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CHAGAS DISEASE - Compounds and methods are provided herein that provide for diagnosis and treatment of Chagas disease.12-31-2009
20110223623METHODS FOR DIAGNOSING CANCER AND DETERMINING THE OVERALL SURVIVAL AND DISEASE-FREE SURVIVAL OF CANCER PATIENTS - The invention provides methods for prognosis of patients afflicted with cancer, comprising determining the level of GP88 expression in a biological sample obtained from said patient.09-15-2011
20110223622Methods and Kits for Predicting the Onset of Labour - The present invention relates to methods and kits useful for predicting the time of onset of labour in a pregnant subject. In particular, the invention relates to methods and kits for predicting the time of onset of labour wherein the levels of at least two hormones, selected from estriol, estradiol and progesterone, are determined and a ratio of said levels is calculated, and wherein the time of onset of labour is predicted by comparison of said ratio with a predetermined ratio. The invention further contemplates methods for preventing preterm delivery of an infant/offspring.09-15-2011
20110223621COMBINATIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS - The invention features pharmaceutical compositions that include dipyridamole and a corticosteroid.09-15-2011
20130217046METHOD FOR DETERMINING PREDISPOSITION TO ESOPHAGEAL-RELATED DISORDERS - Provided herein are methods and materials for diagnosing an esophageal or esophageal-related disorder, or a predisposition for such disorders, in a subject. The methods center on detecting a genetic or protein esophageal marker. An esophageal marker has been identified in the PLCE1 gene and may be useful in predicting disease progression and assessing the subject's response to therapy.08-22-2013
20130217047KITS FOR DETECTING BREAST OR OVARIAN CANCER IN A BODY FLUID SAMPLE AND USE THEREOF - The present invention relates to a method for the accurate, rapid and sensitive detection of breast or ovarian cancers from body fluid samples of a mammalian subject and related assay, kits and peptides suitable for such a method.08-22-2013
20130217048Immunizing Compositions and Methods of Use - The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccharide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.08-22-2013
20120244560MONOCLONAL ANTIBODY AGAINST HUMAN HIG-1 POLYPEPTIDE - This invention relates to a monoclonal antibody against a human HIG-1 polypeptide, the antibody binding to at least one epitope included in the amino acid sequence at positions 1-19 of a human HIG-1 polypeptide; an antibody fragment derived from the antibody; a DNA comprising a base sequence encoding a variable region of the antibody; an expression vector comprising the DNA; a cell line producing the antibody; a reagent for detecting a human HIG-1 polypeptide comprising the antibody or the antibody fragment, and a method for detecting a human HIG-1 polypeptide using the antibody or the antibody fragment.09-27-2012
20120244559Nanobeads covered with plasminogen as a direct support for cyclic amplification of the prion protein PrPSC - The present invention relates to an in vitro method for detecting a pathogenic conformational isomer of the prion protein in a sample, said method comprising a preliminary step for capturing the pathogenic conformational isomer by putting the sample into contact with nanobeads covered with a ligand of the pathogenic conformational isomer, and then applying a cyclic amplification of the misfolded prion protein directly on the solid support having captured the pathogenic conformational isomer, and detecting the presence of the pathogenic conformational isomer. The invention also relates to a kit for applying this method and to a method for decontaminating a biological sample.09-27-2012
20120244558METHODS FOR DIAGNOSING IRRITABLE BOWEL SYNDROME - The invention provides an ELISA assay for the determination of serum mast cell β-tryptase levels using rabbit anti-tryptase as the capture antibody and alkaline phosphatase conjugated G3 as the detecting antibody. Luminescent substrate CPSD was used to enhance the assay sensitivity. Also provided are methods for aiding in the diagnosis of irritable bowel syndrome by detecting the serum level of β-tryptase, histamine and/or prostaglandin E09-27-2012
20080233600Method and Kit for the Measurement of Neutrophil Cell Activation - The present invention is related to accurate detection methods for the measurement only of myelopexidase (MPO) levels or neutrophils, preferably equine neutrophils, in complex biological samples. The present invention is further related to ELISA and SIEFED assays for such detection. SIEFED detection sensitivity of active peroxidase activity was found to be enhanced by the addition of nitrite. Such MPO measurement finds its use in many applications such as the prediction, diagnosis and/or monitoring of pathologies correlated with neutrophil activation and/or destruction; the evaluation of drugs and/or immunomodulators; the assessment of immune responses, either natural and/or after treatment with immunomodulators and/or drugs; and the study of cells and their ability to fight microorganisms and/or to destroy them.09-25-2008
20090081713PEPTIDE BIOMARKERS PREDICTIVE OF RENAL FUNCTION DECLINE AND KIDNEY DISEASE - The presently-disclosed subject matter provides methods for diagnosing a kidney disease, or the risk thereof, in a subject. The methods comprise determining an amount of at least one peptide biomarker disclosed herein in a biological sample from the subject and comparing the amount of the at least one peptide in the sample with a control level, wherein if the amount determined is different than the control level, the subject is diagnosed as having, or at an increased risk of developing, the kidney disease.03-26-2009
20110143381DIAGNOSIS AND MONITORING OF CHRONIC RENAL DISEASE USING NGAL - A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.06-16-2011
20110143380ALZHEIMER'S DISEASE BIOMARKERS AND METHODS OF USE - The invention encompasses biomarkers for AD, a method for detecting AD, a method of monitoring AD, and a kit for quantifying biomarkers for AD.06-16-2011
20110143378MICROFLUIDIC METHOD AND APPARATUS FOR HIGH PERFORMANCE BIOLOGICAL ASSAYS - The present invention provides a disposable microfluidic assay cartridge (06-16-2011
20090053742Capture and release based isotope tagged peptides and methods for using the same - The invention provides non-affinity based isotope tagged peptides, chemistries for making these peptides, and methods for using these peptides. In one aspect, tags comprise a reactive site (RS) for reacting with a molecule on a protein to form a stable association with the peptide (e.g., a covalent bond) and an anchoring site (AS) group for reversibly or removably anchoring the tag to a solid phase such as a resin support. Anchoring may be direct or indirect (e.g., through a linker molecule). Preferably, the anchoring site comprises a biotin compound. Preferably, the tag comprises a mass-altering label, such as a stable isotope, such that association of the tag with the peptide can be monitored by mass spectrometry. The reagents can be used for rapid and quantitative analysis of proteins or protein function in mixtures of proteins.02-26-2009
20090208985Method Of Evaluating Degree Of Skin Sensitivity Using Squamous Cell Carcinoma Antigen As An Indicator Thereof - The present invention provides a method for evaluating the degree of skin sensitivity by using the expression of squamous cell carcinoma antigen (SCCA) in skin corneocytes as an indicator thereof.08-20-2009
20100291597SECRETOGRANIN AND VGF PEPTIDE BIOMARKERS AND USES THEREOF - Secretogranin II and VGF peptides are biomarkers for major depressive disorder. They are useful in methods of diagnosing, monitoring and screening.11-18-2010
20110229915METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Epidermal growth factor, Complement C3, Interleukin-4, Interleukin-1 alpha, Tubulointerstitial nephritis antigen, Transforming growth factor beta-1, Bone morphogenetic protein 7, Osteopontin, Netrin-1, and Growth-regulated alpha protein as diagnostic and prognostic biomarkers in renal injuries.09-22-2011
20110229914Use of Antibody Secreting Cell Elispot To Assess Antibody Responses Following Antigen Exposure - Disclosed are methods and kits for early detection of antigen exposure through the presence or absence of antigen-specific antibodies.09-22-2011
20090004679METHOD FOR DETERMINING PLASMINOGEN ACTIVATOR INHIBITOR - A method is provided for determining active plasminogen activator inhibitor—Type 1 (PAI-1) in a biological fluid, the method comprising the steps of (i) providing a sample of a biological fluid; and (ii) measuring the amount of PAI-1/multimeric vitronectin complex in the sample to determine active PAI-1 in the sample. A kit for carrying out the method is also provided.01-01-2009
20090208986Method and kit for diagnosing acute myocardial infarction - Disclosed herein are method and kit for diagnosing acute myocardial infarction which is capable of predicting and diagnosing whether coronary artery disease is proceed to myocardial infarction or not by using an increase in triglyceride level in high density lipoprotein (HDL) or low density lipoprotein (LDL), a decrease in cholesterol level in HDL, increase of interleukin-6, CETP (cholesteryl ester transfer protein) and apo (apolipoprotein) C-III as a biomarker that are characteristic changes occurred only in sera of myocardial infarction patients among patients with coronary artery disease.08-20-2009
20120142035Calibrator/Control for Simultaneous Assay of Proteins Capable of Complexing With One Another - Disclosed herein are compositions and methods comprising two or more proteins in which at least one of the proteins has been altered to reduce their mutual recognition and binding. Such compositions are useful as reference, calibrators or controls in methods and assays for determining the amount of one or more of the proteins that may be present in a sample of interest or in confirming the presence of one or more of the proteins in the sample. More particularly, it relates to compositions and methods comprising altered placental growth factor-1 (PlGF-1) and soluble fms-like tyrosine kinase (sFlt-1) and methods for determining the amount or confirming the presence of sFlt-1 and/or PlGF-1 in a sample of interest.06-07-2012
20110143377Protein fragments of virB10 and sero-detection of anaplasma phagocytophium - Disclosed are cloning and expression of a plurality of protein fragments of virB10, a Type IV Secretion System (TIVSS) in 06-16-2011
20080261252Soluble Interleukin-1 Receptor Accessory Molecule - The present invention relates to a novel soluble IL-1 receptor accessory molecule (IL-1R AcM) protein which is a member of the Ig superfamily. In particular, isolated nucleic acid molecules are provided encoding the human IL-1R AcM protein. IL-1R AcM polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Screening methods are further provided for identifying agonist and antagonists of IL-1 signal transduction. The invention further relates to methods for treating physiologic and pathologic disease conditions with IL-1R AcM antagonists.10-23-2008
20080261251Monoclonal Antibodies, Hybridomas, Improved Method for Determining the Protein Ptx3 and Kit for Said Determination - Method for determining the level of PTX3 protein in a sample of a biological fluid; hybridoma capable of producing a rat anti-PTX3 monoclonal antibody where said hybridoma is selected from the group comprising MNB10 and Pen-3; specific anti-PTX3 rat monoclonal antibody selected from the monoclonal antibodies produced by the hybridomas MNB10 and Pen-3; kit for determining the level of PTX3 protein in a biological fluid wherein the said kit includes a rat anti-PTX3 monoclonal antibody.10-23-2008
20090253155Method For Diagnosing Irritable Bowel Syndrome and Monitoring Inflammatory Bowel Disease - A method for aiding in differentiating irritable bowel syndrome from inflammatory bowel disease by determining the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, wherein an elevated level of lactoferrin substantially precludes diagnoses of IBS and other noninflammatory etiologies, and a kit usable in such method are provided. Further provided is a method for quantitating the level of total endogenous human lactoferrin in clinical specimens, such as feces, mucus and bile, to monitor gastrointestinal inflammation in persons having inflammatory bowel disease.10-08-2009
20090253154Blood and saliva test for detection of delayed food allergy and intolerance against modified foods - A method for determining the presence of delayed food allergy and intolerance against antigens extracted from modified foods. The method includes determining a level of antibodies against a modified dietary food antigen in blood and mucosal samples from the patient and comparing the level with normal levels of the antibodies. Dietary antigens that were tested include milk and modified milk products; eggs and modified egg products; meat and modified meat products; fish, mollusks, and crustaceans and their modified products; oils, fats and their modified products; grains and modified grain products; pulses, seeds kernels, nuts and their modified products; vegetables and modified vegetable products; fruits and modified fruit products; sugar, modified sugar products, modified chocolate products and confectionery; and spices and their modified forms.10-08-2009
20090221008NEUTROKINE-ALPHA AND NEUTROKINE-ALPHA SPLICE VARIANT - The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.09-03-2009
20090258377Method of Measuring Enzymatic Activity of Adsorbed Allergenic Enzyme - The invention relates to a method of measuring the immunological activity of a vaccine preparation in the form of a mixture of one or more allergenic enzyme(s) and an oxygen-containing metal salt adjuvant, wherein the mixture comprises a liquid phase and a solid phase, and wherein at least a part of the allergenic enzyme(s) is adsorbed to the solid phase, the method comprising the steps of measuring the enzymatic activity of the mixture in an enzyme activity assay, and using the measurement obtained as an indication of the immunological activity of the vaccine preparation, or using the measurement obtained for quantifying the amount of allergenic enzyme.10-15-2009
20100015644Potency assays for antibody drug substance binding to an fc receptor - The invention relates to a method of characterizing an antibody, which method is suitable as a potency assay for batch release of a pharmaceutical composition comprising an antibody, specifically for use when applying for marketing authorization for said pharmaceutical composition. The assay provided is a method for determining the potency of a drug product comprising an FcR binding peptide, wherein at least one mechanism of action of the FcR binding peptide of the drug product is mediated through the binding of the FcR binding peptide of the drug product to a Fc receptor, wherein said method comprises determining the binding of the FcR binding peptide of the drug product to an Fc receptor.01-21-2010
20100015648DETECTION OF NGAL IN CHRONIC RENAL DISEASE - Methods of assessing the ongoing kidney status in a subject afflicted with chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in fluid samples over time is disclosed. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine and serum as a result of chronic renal tubule cell injury. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.01-21-2010
20100015646PORTABLE, POINT-OF-CARE, USER-INITIATED FLUIDIC ASSAY METHODS AND SYSTEMS - Methods and systems to perform point-of-care, user-initiated fluidic assays, using substantially self-contained, portable, user-initiated fluidic assay systems. Exemplary assays include diagnostic assays and chemical detection assays. Diagnostic assays may include, without limitation, enzyme-linked immuno-sorbent assays (ELISA), and may include one or more sexually transmitted disease (STD) diagnostic assays. An exemplary assay system includes a housing having one or more fluid chambers, a fluid controller system to dispense fluid from the one or more fluid chambers, and a user-initiated actuator to control the fluid controller system. The actuator may be configured to move fluid controllers from functionally closed positions to functionally open positions, to control fluid flow from the fluid chambers. The fluid controller system may be configured to dispense fluids serially, and may be configured to mix a plurality of fluids. The housing may include one or more fluid paths amongst the fluid chambers and/or between the fluid chambers and an assay portion, and the fluid controller system may be configured to serially align fluid chamber outlets with corresponding fluid paths. The user-initiated actuator system may include an external user-operated trigger mechanism to initiate the actuator system. The actuator system may include a mechanical actuator system, and may include a compressible spring actuator system. The assay apparatus may include a display window to view assay results. Exemplary methods of preparing portable, user-initiated fluidic assay systems, and methods of using portable, user-initiated fluidic assay systems are disclosed.01-21-2010
20130137122DIAGNOSIS AND MONITORING OF CHRONIC RENAL DISEASE USING NGAL - A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.05-30-2013
20100167321EPITOPE/PEPTIDE RECOGNIZED BY HLA-A2402-RESTRICTED EP-CAM-SPECIFIC CTL AND USE OF THE SAME - A peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:1; a peptide consisting essentially of the amino acid sequence represented by SEQ ID NO:2; or a mutant peptide consisting essentially of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:1 or 2 by addition, deletion or substitution of one or more amino acids, the peptide being capable of forming a complex with an HLA-A2402 molecule to be recognized by HLA-A2402-restricted cytotoxic T lymphocytes or induce such lymphocytes. Such a peptide is useful as a cancer vaccine for epithelial cancer patients having HLA-A2402.07-01-2010
20120196305Detection of a specific DEK isoform as a urine-based biomarker for bladder cancer - The present invention is directed to a method of detecting a DEK protein isoform 2 in a human urine sample using ELISA. Methods and compositions for detection of DEK isoform 2 in human urine are provided herein. The presence of DEK isoform 2 in urine is shown to correlate with bladder cancer in humans.08-02-2012
20120196304DETECTION APPARATUS - The present invention relates to, in part, methods, reagents and apparatuses for the detection of agents. The present invention also relates, in part, to compositions including, but not limited to, flow cells, assay chambers, reagent reservoir delivery units and devices for holding an assay chamber. The present invention also provides various components and combinations of components for various detection apparatuses. The present invention also relates to a portable agent detection apparatus that can be used in the field or at a point of care and is not limited to specialized laboratories or limited to use by highly skilled users.08-02-2012
20130122526METHOD OF PREPARING A FUSION PROTEIN FOR THE INHIBITION OR REDUCTION OF SECRETION OF AN EXTRACELLULAR MEDIATOR FROM A TARGET CELL - The present invention provides a method for designing a re-targeted toxin conjugate for use in treating a medical condition or disease. Also provided, is the use of said conjugates in the manufacture of a medicament for treating medical conditions or diseases. The conjugates include a Targeting Moiety, which directs the conjugate to a desired target cell, and are characterised by a Targeting Moiety that increases exocytic fusion in the target cell. The present invention also provides methods for identifying agonists suitable for use as Targeting Moieties, and methods for preparing conjugates comprising said Targeting Moieties.05-16-2013
20130122527Methods and Compositions for Monitoring and Risk Prediction in Cardiorenal Syndrome - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to monitor cardiorenal syndrome using assays that detect NGAL, preferably together with assays that detect natriuretic peptides such as BNP. Such methods and compositions can provide early indications of a deterioration in cardiorenal syndrome status, including prognosis regarding mortality and worsening renal function.05-16-2013
20100184104NANOELECTRONIC-ENZYME LINKED IMMUNOSORBENT ASSAY SYSTEM AND METHOD - The present invention relates to a device and method for determining the presence of a specific compound in solution. The device includes a nanosensor having an electrically conducting pathway between at least a first and second contact. The device also includes a first receptor, suitable for binding a specific compound in the solution, attached to the nanosensor, and a second receptor also suitable for binding the specific compound while the specific compound is bound to the first receptor. The second receptor is attached to an enzyme added to the solution. When the solution having the second receptor is added to the device, and a second compound that is a substrate for the enzyme is subsequently added to the solution, a measured difference in an electrical property in the device before and after the application of the second compound is indicative of the presence of the specific compound in the solution.07-22-2010
20100184105ASSESSING NEURONAL DAMAGE FROM BLOOD SAMPLES - Neuronal damage is detected by providing a biological sample derived from the subject, detecting in the sample the presence of a neurofilament subunits or their breakdown products, and correlating the presence and level of the neurofilament subunits and their breakdown products detected with the degree of neuronal injury.07-22-2010
20100261209BIOMARKERS FOR LIVER DISEASES AND METHOD FOR USING THE SAME - Biomarkers for liver diseases and method for using the same are provided. For detecting liver cirrhosis and liver cancer, the biomarkers are selected from any one of the amino acid sequences with SEQ ID NO:1 to SEQ ID NO:24 or derivatives or fragments or variants or the combination thereof or the antibodies against the amino acid sequences. Then the biomarkers are further developed into detection kits, such that by detecting the existence of autoantibodies or autoantigens in screened specimens, liver diseases are detected with higher accuracy and sensitivity.10-14-2010
20100261208ELISPOT METHOD HAVING TWO FILTER SYSTEMS - An ELISPOT method for in vitro diagnosis and/or in vitro therapy monitoring of infections and/or infectious diseases comprising incubating eukaryotic cells with an antigen, measuring the number of immunocompetent cells which secrete at least two different cytokines as a reaction to the antigen, and in measuring the immunocompetent cells, visualizing the cells with the aid of at least two different dyes and at least two different filter sets, the filter sets comprising narrowband filters.10-14-2010
20100261207NEUTROKINE-ALPHA AND NEUTROKINE-ALPHA SPLICE VARIANT - The present invention relates to nucleic acid molecules encoding Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies or portions thereof that specifically bind Neutrokine-alpha and/or Neutrokine-alphaSV and diagnostic and therapeutic methods using these antibodies. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders using the compositions of the invention.10-14-2010
20100261210COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING PROSTATE CANCER - A method of treating prostate cancer is provided. The method comprising administering to a subject in need thereof a therapeutically effective amount of an agent capable of reducing activity and/or expression of MCP-1 or of an effector thereof, thereby treating the prostate cancer in the subject.10-14-2010
20100261205MICROCHIPS, KITS, AND METHODS FOR IMMUNOASSAYS - An objective of the present invention is to provide immunoassay microchips in which microstructures of beads having a sufficient reaction area were constructed within microchannels while suppressing flow path resistance, and to provide simple and highly-sensitive immunoassay methods for microsamples. The objective was achieved by immunoassay microchips comprising microchannels with microstructures arranged in at least a portion of the microchannels, the microstructures retaining microbeads uniformly dispersed in photo-cured hydrophilic resins, and the microbeads having a primary antibody immobilized on their surfaces, and by immunoassay methods using the microchips.10-14-2010
20100196934PRION ASSAY - The invention relates to an assay method for detecting the presence of PrP08-05-2010
20100190191MULTI-STAGE NUTRIGENOMIC DIAGNOSTIC FOOD SENSITIVITY TESTING IN ANIMALS - A multi-stage method for diagnosing an immunologic food sensitivity or intolerance in a companion animal. Firstly a saliva or other non-serum bodily fluid sample is collected. The screening the saliva or other non-serum bodily fluid sample detects the presence of at least one of IgA or IgM antibody to a particular food ingredient or composition. An immunologic food sensitivity or intolerance based on the presence of the antibody is diagnosed. Secondly a blood sample is collected and serum from the sample is screened to detect the quantitative presence of at least one of an IgA, IgM or IgG antibody or immune complex to a particular food ingredient or composition. An immunologic food sensitivity or intolerance based on the presence of the antibody or immune complex is diagnosed. Thirdly a biologically active nutrient in relation to the animal from a molecular dietary signature is determined. The molecular dietary signature for the animal is a variation of expression of a set of genes, proteins or metabolites which may differ for the genotype of each animal.07-29-2010
20120270244Means and Methods for Diagnosing and/or Treating a Subject at Risk of Developing Heart Failure - The present invention relates to a method for identifying a subject at risk of developing heart failure, comprising: (a) determining the level of one or more biological markers in a biological sample of the subject; (b) comparing the level of the biological marker to a standard level of the same biological marker; and (c) determining whether the level of the marker is indicative of a risk for developing heart failure, wherein the biological marker is Krüppel-Like Factor 15 (KLF-15) and/or lysosomal integral membrane protein-2 (LIMP-2) and/or fragments and/or variants thereof, and/or wherein the biological marker is a gene coding for KLF 15 and/or LIMP-2, and/or fragments and/or variants thereof. The invention further relates to use of the KLF15 and/or LIMP-2 protein, and/or the gene coding for KLF15 and/or LIMP2, and/or fragments, and/or variants of the genes and/or proteins, for the preparation of a medicament for a prophylactic and/or a therapeutic medicament for prevention and/or treatment of heart failure.10-25-2012
20110104724BIOMARKERS OF MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE - A method for quantifying a neurodegenerative disorder in a patient that includes obtaining a fluid sample from the subject; measuring a protein biomarker complex in said fluid sample and correlating the measurement with mild cognitive impairment or Alzheimer's disease status. The biomarkers include those that comprise at least one of a transthyretin protein and/or a prostaglandin-H2 D-isomerase protein, and at least one second, different protein selected from a transthyretin, prostaglandin-H2 D-isomerase, beta-2-microglobulin, cystatin C, superoxide dismutase [Cu—Zn], plasma retinol-binding protein, phosphatidylethanolamine-binding protein, carbonic anhydrase 2, prostaglandin-H2 D-isomerase, and/or serotransferrin protein;05-05-2011
20100151503METHOD OF DETECTING LIVER CANCER, DIAGNOSTIC FOR LIVER CANCER AND REMEDY FOR CANCER - Disclosed are a method for detecting liver cancer capable of detecting liver cancer with high specificity and a diagnostic therefor, as well as a novel therapeutic drug for cancer having an excellent anticancer effect. The method for detecting liver cancer cells in a sample utilizes as an index the expression of dlk gene. The expression of dlk gene may be measured by immunoassay using an anti-dlk antibody or by measuring mRNA of dlk gene. The therapeutic drug for cancer comprises as an effective ingredient an antibody which undergoes antigen-antibody reaction with Dlk expressing on surfaces of cancer cells and which exerts anticancer action against the cancer cells.06-17-2010
20100167319Diagnose of Mycobacterial Infections by Determination of IFN-Gamma - The present invention provides a method for diagnosing a mycobacterial infection in a subject, involving the following steps: (i) collection of a sample from the subject; (ii) incubation of the sample from (i) with an antigen preparation for 12 hours or less; and (iii) analysis of γ-IFN in the sample from (ii). The invention also provides a diagnostic kit for use in such a method.07-01-2010
20100227340METHOD OF ANALYSIS, DETECTION AND CORRECTION OF FOOD INTOLERANCE IN HUMANS - A method of detection and correction of latent food intolerance (LFI) in humans is described. The method allows, through utilizing a dynamic analysis of a specific test for LFI, assessing the degree of food intolerance and devising an individualized diet that excludes food items which cause latent food intolerance, as well as food items which cause classic allergic reactions. Thus, this method promotes health throughout an individual's life by avoiding and correcting the negative effects of food items that act as immune antagonists.09-09-2010
20110059473PROTEINS WITH PTERIDINE GLYCOSYLTRANSFERASE ACTIVITY AND ANALYSIS METHOD USING THE SAME - The present invention relates to proteins with pteridine glycosyltransferase activity and an analysis method using the same. Since the proteins glycate tetrahydrobiopterin selectively through an enzyme reaction, the method enables quantitative analysis of tetrahydrobiopterin and oxides thereof at the same time or quantitative analysis of tetrabiopterin selectively.03-10-2011
20120196306COMPOSITIONS AND METHODS FOR THE DETECTION OF HIV-1/HIV-2 INFECTION - This invention relates to compositions and methods for the detection of immunodeficiency virus infection, especially immunodeficiency virus-1 (HIV-I) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies.08-02-2012
20100227341Diagnosing Pneumococcal Pneumonia - Compositions and methods for eliciting an immune response against 09-09-2010
20100227339DIFFERENTIAL IMMUNOASSAY FOR PRRS VACCINE ANTIBODY - The present invention relates to immunoassays for serologically differentiating animals naturally infected with PRRS virus from animals vaccinated against PRRS. The immunoassays provide detection of at least a portion of the N terminal region of the 2b portion of PRRSV. The immunoassay is preferably an enzyme-linked immunosorbent assay (ELISA).09-09-2010
20100255513SEROLOGICAL MARKERS OF INFLAMMATORY BOWEL DISEASE PHENOTYPE AND DISEASE PROGRESSION - Disclosed are novel biomarkers and methods related to diagnostic tests for the detection and characterization of inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. In particular, the instant invention relates to novel biomarkers and methods of using such biomarkers to predict disease behavior and severity, to differentiate among disease types, and to optimize selection of treatment options in individuals suspected of having an inflammatory bowel disease.10-07-2010
20100240076IMMUNOASSAY INVOLVING MUTANT ANTIGENS TO REDUCE UNSPECIFIC BINDING - A method for a quantitative in vitro analysis to diagnose, to categorise, to predict and/or to monitor the progression of a condition comprising the following steps: a) Obtaining a sample suspected of containing anti-A-antibodies from a subject to be analysed, b) Providing native and mutant antigen A, c) Contacting the sample suspected of containing anti-A-antibodies with mutant antigen A and with native antigen A, d) Detecting the amount of anti-A-antibodies bound to native antigen A after step c), wherein the presence of anti-A-antibodies bound to native antigen A allows the diagnosis, the categorisation, the prediction and/or the monitoring of the progression of a condition.09-23-2010
20130217044FACTOR INVOLVED IN LATENT INFECTION WITH HERPESVIRUS, AND USE THEREOF - Disclosed are a protein and a gene each of which is a factor involved in latent infection with a herpesvirus. An antibody against the factor was detected in approximately 50% of patients suffering from mental disorders, whereas the antibody was hardly detected in healthy persons. Further, a mouse having SITH-1 introduced therein developed a mental disorder such as a manic-depressive illness or depression-like disorder. Based on these findings, it is possible to provide a method for objectively determining a mental disorder and an animal model of a mental disorder.08-22-2013
20130217045Use of Functional Autoantibodies in Alzheimer Disease - Provided herein is a method for diagnosing Alzheimer's disease in a subject comprising detecting an increase in an amyloidogenic Aβ08-22-2013
20100136589Methods and Kits for Determining von Willebrand Factor Activity in the Absence of Ristocetin and for Determining the Activity of ADAMTS-13 Protease - Described herein are method(s), kit(s), reagent(s) and the like for determining von Willebrand factor (VWF) activity in a sample in the absence of ristocetin.06-03-2010
20100233736DETECTION METHOD AND KIT - The present invention relates to a method of detection and/or quantification of an antigen linked to a metal salt. The antigen may be present within a mixture of different antigens, such as in a multivalent vaccine composition. The invention further provides a kit for use in the method of the invention.09-16-2010
20120070853YKL-40 AS A MARKER FOR GASTROINTESTINAL CANCERS - The present invention relates to gastrointestinal cancers and methods for selecting a treatment for said gastrointestinal cancer in a subject. The present invention further relates to a methods of diagnosing the presence of and/or classifying the severity of a gastrointestinal cancer; together with methods for determining the effect of a therapy administered and/or the prognosis for a subject suffering from a gastrointestinal cancer, before, during or after administering the treatment. For all the methods applies that a determined level of YKL-40 above one or more reference levels indicates the treatment, the severity of the disease, the effect of the treatment and/or the prognosis of the subject. The reference level is typically a level obtained from healthy individuals or a level previously obtained from the same subject. The subject may suffer from any one or more gastrointestinal cancers, such as upper gastrointestinal cancers, and metastatic colorectal cancer. The present invention further relates to a kit and a device that may be used in the method of the present invention.03-22-2012
20080286816Detection of Methamphetamine Group Drugs - The present invention provides immunoassays which are highly specific for detection in biological samples of methamphetamine and other drugs of abuse of the methamphetamine group such as ecstasy and other ecstasy class drugs. More particularly, competitive assays are provided comprising: (a) contacting said sample with (i) a pseudoephedrine/carrier conjugate in which pseudoephedrine is linked via its hydroxyl group to the carrier and (ii) an antibody which is capable of binding both one or more drugs of the methamphetamine group and said conjugate; and (b) determining whether the binding of said antibody to said conjugate is reduced by the presence of said sample, a reduction in binding being indicative that the sample contains a methamphetamine group drug.11-20-2008
20100136587Method of Identifying Risk for Thyroid Disorder - A method for identifying a patient that is at risk for developing a thyroid disorder that occurs subsequent to treatment with a regimen that depletes lymphocytes, comprising determining whether antibodies directed against thyroid peroxidase or thyroid microsomes are present in the patient, wherein if the antibodies are present in the patient then the patient is at increased risk for developing a thyroid disorder. A particular embodiment is a method for identifying a patient with multiple sclerosis that is at risk for developing a thyroid disorder that occurs subsequent to treatment with a regimen that depletes CD52-positive cells, comprising determining whether antibodies directed against thyroid peroxidase or thyroid microsomes are present in the patient, wherein if the antibodies are present in the patient then the patient is at risk for developing the thyroid disorder.06-03-2010
20090042226Identification and cloning of a full-length human CLNK-related gene, MIST (MAST cell immunoreceptor signal transducer) - The present invention describes a newly discovered full-length polynucleotide encoding an SH2 domain-containing adapter protein, called human MIST, cloned, isolated and identified from a human spleen cDNA library. Also described are the MIST polypeptide sequence, expression vectors, host cells, agonists, antagonists, antisense molecules, and antibodies related to the polynucleotide and/or polypeptide of the present invention. Novel splice variant forms of human MIST are provided. Methods for screening for modulators, particularly inhibitors, of the MIST protein and use of the human MIST polynucleotide and polypeptide for therapeutics and diagnostics are described.02-12-2009
20090042224METHODS FOR DIAGNOSIS AND/OR PROGNOSIS OF OVARIAN CANCER - In one embodiment, methods are provided for assessing the presence of mesothelin-expressing tumor cells in a human subject. In another embodiment, methods are provided for monitoring the efficacy of treatment of a human cancer patient diagnosed with a mesothelin-expressing tumor.02-12-2009
20090042225Method for selecting therapeutic agents for cancer treatment - An improved system for screening a multiple of candidate therapeutic or chemotherapeutic agents for efficacy as to a specific patient, in which a tissue sample from the patient is harvested, cultured and separately exposed to a plurality of treatments and/or therapeutic agents for the purpose of objectively identifying. One particularly important tissue sample preparation technique is the initial preparation of cohesive multicellular particulates of the tissue sample. For assays concerning cancer treatment, a two-stage evaluation is contemplated in which both acute cytotoxic and longer term inhibitory effect of a given anti-cancer agent are investigated. The tissue sample technique of the present invention is also useful in assaying expression and/or secretion of various markers, factors or antigens present on or produced by the cultured cells for diagnostic purposes and for using such expression to monitor the applicability of certain candidate therapeutic or chemotherapeutic agents and the progress of treatment with those agents.02-12-2009
20090042223METHODS FOR DETECTION OF IMMUNOSUPPRESSANT DRUGS - Methods and reagents are disclosed for enhancing the bioavailability of a hydrophobic drug, and in some embodiments for determining a hydrophobic drug, in a sample suspected of containing a hydrophobic drug. A combination is formed in a medium where the combination comprises the sample, a hemolytic agent where a determination of the hydrophobic drug is conducted, and a bioavailability agent for the hydrophobic drug. The bioavailability agent comprises an ionic detergent comprising a chain of at least 10 carbon atoms or a non-ionic detergent comprising a chain of at least 15 repeating ethylene oxide units or propylene oxide units or a combination of ethylene oxide units and propylene oxide units. The concentration of the bioavailability agent in the medium is sufficient to enhance the bioavailability of the hydrophobic drug. The medium is incubated under conditions for enhancing the bioavailability of the hydrophobic drug, and in a determination of the hydrophobic drug under conditions for hemolyzing cells in the sample. For determination of the hydrophobic drug, reagents for determining the presence and/or amount of the hydrophobic drug in the sample are added to the medium. The reagents comprise at least one antibody for the hydrophobic drug. The medium is examined for the presence of a complex comprising the hydrophobic drug and the antibody for the hydrophobic drug. The presence and/or amount of the complex indicates the presence and/or amount of the hydrophobic drug in the sample.02-12-2009
20120196308Methods and Kits for Measuring Von Willebrand Factor - Methods and kits for measuring levels of von Willebrand factor function in a sample without using a platelet aggregation agonist, such as ristocetin, comprising recombinant glycoprotein Iba having at least two of a G233V, D235Y and M239V mutations and an agent to detect a complex between the recombinant glycoprotein Iba and von Willebrand factor.08-02-2012
20120196307SYNAPTOTAGMIN AND COLLAPSIN RESPONSE MEDIATOR PROTEIN AS BIOMARKERS FOR TRAUMATIC BRAIN INJURY - Collapsin response mediator proteins (CRMPs) decreased in tissue and increased in biological samples after neural injury from traumatic brain injury (TBI). Significant decreases of CRMP1, CRMP2, CRMP4 and CRMP5 were accompanied by the appearance of distinct 58 kDa (CRMP-2) or 55 kDa (CRMP-4) breakdown products from proteolytic cleavage by calpain. Synaptotagmin breakdown products were also associated with TBI and could be detected along with intact protein in human cerebral spinal fluid (biological samples). Both biomarkers were detected in human biofluid and related to recovery from traumatic brain injury.08-02-2012
20090075305Diagnostic serum antibody profiling - The invention is directed to a microarray assay procedure that can be used for profiling the antibodies present in serum, plasma or blood. The assay may be used to identify antibodies and antigens that are characteristic of particular diseases or conditions. In addition, the invention includes specific antigens that are associated with prostate cancer, progressive benign prostate hyperplasia (BPH) and ovarian cancer.03-19-2009
20120196303CYBP AS A MARKER FOR LUNG CANCER - The present invention relates to the assessment of lung cancer. It discloses the use of protein CYBP in the assessment of lung cancer. It also relates to a method for assessing lung cancer in vitro using a liquid sample, derived from an individual by measuring CYBP in said sample. Measurement of CYBP can, e.g., be used in the early detection or in the follow-up of patients with lung cancer.08-02-2012
20120142034PVDF MEMBRANES - The invention provides a method of treating a polyvinyl difluoride (PVDF) membrane comprising: 06-07-2012
20120034630Circovirus Sequences Associated With Piglet Weight Loss Disease (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.02-09-2012
20110027812ASSAY FOR ANTIBODIES TO MYCOBACTERIUM PARATUBERCULOSIS - A method of detecting an immune response to a paratuberculosis-specific antigen, comprising incubating a sample from a subject with the paratuberculosis-specific antigen and detecting the presence of an antibody in the sample as an indication of an immune response to the paratuberculosis-specific antigen. The antigen may be obtained from a novel 02-03-2011
20090176256Methods and Products for Evaluating an Immune Response to a Therapeutic Protein - The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titre of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titre of untreated patients increased by the double of the standard deviation of this control antibody titre.07-09-2009
20090075307METHODS FOR IDENTIFYING PATIENTS WITH AN INCREASED LIKELIHOOD OF HAVING OVARIAN CANCER AND COMPOSITIONS THEREFOR - Screening methods for identifying patients with an increased likelihood of having ovarian cancer are provided. The screening methods involve the detection of expression of a plurality of biomarkers in a body sample, wherein overexpression of the biomarkers is indicative of an increased likelihood of having ovarian cancer. The screening methods may further comprise a two-step analysis. Biomarkers of interest include genes and proteins that are, for example, involved in defects in DNA replication/cell cycle control, cell growth and proliferation, escape from apoptosis, angiogenesis or lymphogenesis, or the mechanisms of cancer cell motility and invasion. In some aspects of the invention, expression of a biomarker is detected at the protein level using a biomarker-specific antibody or at the nucleic acid level using nucleic acid hybridization techniques. Methods for detecting ovarian cancer in patients are further disclosed herein. Kits for practicing the methods of the invention are further provided.03-19-2009
20090111131Method of detecting protein losing enteropathy in animals - The present invention provides a method and kit for the detection of Protein Losing Enteropathy (PLE) in animals. The method includes the steps of (a) obtaining a biological sample from an animal to be tested and (b) determining the absence or presence of albumin in the biological sample via a kit comprising an immunoassay utilizing a species-specific anti-albumin antibody.04-30-2009
20110129859BIOMARKER FOR DIAGNOSIS OF LIVER DISEASE - Disclosed are: a marker for the diagnosis of a liver disease, which can determine the disease in a simple manner; an antibody directed against the marker; a diagnostic agent; a diagnosis method; and a method for marker detection in blood or serum. Proteome analysis revealed that quantities of the full-length kininogen and three partial peptides thereof (sequence A: position-440 to position-456, sequence B: position-439 to position-456, and sequence C: position-438 to position-456) in sera of patients with non-alcoholic fatty liver disease are significantly different from those in sera of healthy individuals; and a diagnostic agent and a detecting method for the non-alcoholic fatty liver disease that can be conveniently used for medical examination are established. The use of a combination of a kininogen-based marker and a C4-based marker (the full length sequence or partial peptides thereof) enables identification of chronic hepatitis and an asymptomatic virus carrier, as well as non-alcoholic fatty liver disease.06-02-2011
20130130283Methods for Identifying Inhibitors of the Type III Secretion System - A method for determining whether a test compound has the ability to inhibit the function of the type 3 secretion system. In a first step, the compound is tested for its ability to inhibit secretion of an effector and/or a translocator protein, in a second step, it is further tested for its ability to inhibit the assembly of the structural components to form the needle complex. By this method, drug candidates can be identified that are highly specific anti-bacterial agents for treating diseases caused by Gram-negative bacteria with a T3SS.05-23-2013
20100304409METHOD FOR DETECTING PREMATURE SENESCENCE IN TUMOR CELLS AND A KIT FOR DETECTING PREMATURE SENESCENCE IN TUMOR CELLS - The present invention provides a method for detecting senescence in tumor cells and a kit for detecting senescence in tumor cells. eEF1A1 and CD markers are provided, wherein changes in the levels of the markers are correlated with premature senescence of tumor cells.12-02-2010
20110177533ASBESTOS EXPOSUSRE, PLEURAL MESOTHELIOMA, AND OSTEOPONTIN LEVELS - The present invention provides prognostic and diagnostic methods related to pleural mesotheliomas based on levels of osteopontin in bodily fluids.07-21-2011
20100304410METHOD OF ASSESSING COLORECTAL CANCER STATUS IN AN INDIVIDUAL - The invention relates to a method of screening a patient to identify and quantify risk of colorectal cancer, and thereby identify patients suitable for further invasive investigation such as a colonoscopy. The method employs auto-antibodies that are shown to correlate with colorectal cancer risk method and involves of assaying a biological sample from the individual for a combination of a plurality of biomarkers selected from SEQUENCE ID NO's: 1 to 12, where the combination of biomarkers is chosen such that detection of all biomarkers in the patient correlates to at least a 50% risk of the patient being positive for colorectal cancer. Detection of all of the combination of biomarkers indicates that the patient should undergo a colonoscopy. Kits for performing the method of the invention are also provided.12-02-2010
20100311089COMPOSITIONS AND METHODS FOR DIAGNOSING PATIENTS WITH ACUTE ATHEROSCLEROTIC SYNDROME - The present invention is in the field of autoimmunity. More specifically, the present invention relates to the detection of autoantibodies to domain 4 of beta 2-glycoprotein I (β12-09-2010
20100317041NEURAL PROTEINS AS BIOMARKERS FOR NERVOUS SYSTEM INJURY AND OTHER NEURAL DISORDERS - The present invention identifies biomarkers that are diagnostic of nerve cell injury and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury.12-16-2010
20130143243REAGENT AND REAGENT KIT FOR MEASUREMENT OF FDP, AND MEASUREMENT METHOD - The present invention relates to a reagent for the measurement of FDP comprising a carrier sensitized with at least two monoclonal antibodies selected from three monoclonal antibodies having different reactivity towards FDP. The present invention also relates to a reagent kit comprising the reagent and a method for measurement of FDP using the reagent or reagent kit.06-06-2013
20100323374Serum Biomarkers for Diagnosing Liver Fibrosis and Method for Measuring the Same - Disclosed are serum biomarkers for diagnosing liver fibrosis and methods for measuring the same. The serum biomarkers obtained from human serum include alpha2-macroglobulin (“A2M”), vitamin D binding protein (“VDBP”), apolipoprotein AI (“ApoAI”). The methods involve with immunoassay using specific antibodies to detect the biomarkers, including enzyme-linked immunosorbent assay (“ELISA”), radio immune assay (“RIA”) and flexible multi-analyte profiling (“xMAP”). ELISA, RIA or xMAP is used to measure changes of protein concentration for the specific protein biomarkers in serum for diagnosing liver fibrosis with suffering hepatitis B or C or other liver diseases. The measurement is safe and accurate. The method can be used before and after treatment of liver fibrosis. Thus, it is possible to achieve early diagnosis and treatment advocated in the preventive medicine.12-23-2010
20090068690METHODS FOR IDENTIFYING PATIENTS WITH AN INCREASED LIKELIHOOD OF HAVING OVARIAN CANCER AND COMPOSITIONS THEREFOR - Screening methods for identifying patients with an increased likelihood of having ovarian cancer are provided. The screening methods involve the detection of expression of a plurality of biomarkers in a body sample, wherein overexpression of the biomarkers is indicative of an increased likelihood of having ovarian cancer. The screening methods may further comprise a two-step analysis. Biomarkers of interest include genes and proteins that are, for example, involved in defects in DNA replication/cell cycle control, cell growth and proliferation, escape from apoptosis, angiogenesis or lymphogenesis, or the mechanisms of cancer cell motility and invasion. In some aspects of the invention, expression of a biomarker is detected at the protein level using a biomarker-specific antibody or at the nucleic acid level using nucleic acid hybridization techniques. Methods for detecting ovarian cancer in patients are further disclosed herein. Kits for practicing the methods of the invention are further provided.03-12-2009
20090068689Molecular phenotyping of severe asthma - The present invention discloses a method for classifying individuals into those who have airway hyperreactvitiy and those with asthma based on cytokine expression patterns. It is contemplated that such a method will enable rapid identification of individuals requiring intensive treatment for asthma, thereby reducing morbidity and improving quality of life for those affected.03-12-2009
20090068687Screening platform for discovery of immunomodulatory activities in traditional medicine - The present invention relates to a method of screening traditional medicines for immunomodulating activity and anti-tumor activity. The method involves applying techniques and tools used in the field of proteomics, isolating an active ingredient from a natural ingredient historically used as a traditional medicine, stimulating splenocytes, and measuring and determining biomarker indicators resulting from such stimulation.03-12-2009
20100323376Method for Measuring Lipoprotein-Specific Apolipoproteins - The present invention is directed to methods of measuring the concentration of lipoprotein particles and/or lipoprotein-specific apolipoproteins in a biological fluid using an immunoassay, without the need of preliminary physical separation of the various types of lipoprotein particles present in the biological fluid.12-23-2010
20090035793Microchip for cell response evaluation - In a microchip which enables cell cultivation and accurate cell count measurement, fine particles affixed with cells are trapped within a passage by making the minimum width of a solution and fine particle inlet into a cell culture portion larger than the maximum diameter of the fine particles, and making the width of an outlet smaller than the maximum diameter of the fine particles.02-05-2009
20090075306DIAGNOSTIC ASSAY FOR DETECTING AND MONITORING AGE RELATED AND NOISE INDUCED HEARING LOSS - A method of detecting age related and/or noise induced hearing loss in a subject includes detecting in a biological sample from the subject the presence of cochlin antibodies; and correlating the level of detected cochlin antibodies to the presence or absence of age related and/or noise induced hearing loss in the subject.03-19-2009
20110008806METHOD AND KIT FOR QUANTIFYING OF ALLERGEN-SPECIFIC HUMAN IGG SUBCLASSES FOR THE CONTROL AND ATTENDANCE OF SPECIFIC IMMUNOTHERAPY - A method for quantifying the levels of allergen-specific human IgG antibody subclasses, particularly of IgG1, IgG2, IgG3 or IgG4 subclasses, using a reverse ELISA immunoenzymatic technique. Also provided is a kit comprising microtitration plates for ELISA already sensitized/covered with monoclonal antibodies, for example, anti-Der p 1 or anti-Der p 2, total extract from corresponding allergens, labeled secondary antibodies, enzymatic conjugate, enzymatic substrate, and chromogenic buffer, as well as reference positive and negative control sera. The method provides high sensitivity for the detection of specific IgG antibody subclasses and is a potential tool for the control and attendance of allergen-specific immunotherapy in patients with allergic respiratory disease.01-13-2011
20110008807Composition Related to Rapid ELISA Process - The present invention provides improved and rapid detection methods for an antigen such as a chemical compound, a peptide, a nucleic acid, or a protein released from cells or virus particles in situ. The detection time for an antigen can be dramatically reduced relative to conventional technologies. The technology can particularly be used, for example, to modify and reduce the detection time significantly in traditional ELISA, and also Western blot or Dot blot assays. The improved ELISA method is rapid, economical, reproducible, simple and automatable. Also provided are compositions and kits for using the improved ELISA methods for the rapid detection of antigens.01-13-2011
20110039282METHOD OF DETECTING CALCIFYING NANOPARTICLES AND SUSCEPTIBILITY TO CALCIFYING NANOPARTICLE INFORMATION - A method of measuring the susceptibility of a subject to calcifying nanoparticle formation is disclosed. The method can include obtaining a cell culture comprising peripheral blood mononuclear cells, immune cells, or both, from a peripheral blood mononuclear fraction of a subject in a complete culture media; extracting a first aliquot and a second aliquot from the cell culture; and dispensing the first and second aliquot in different wells. The surface of the well containing the first aliquot can include a calcifying nanoparticle biofilm, while the well containing the second aliquot does not. The first and second aliquots can be incubated and the concentration of osteopontin in each aliquot determined. An osteopontin factor can be calculated and compared to osteopontin factors from a representative sample of other subjects. The osteopontin factor can be defined as the osteopontin concentration in the first aliquot divided by the osteopontin concentration in the second aliquot.02-17-2011
20110039281METHOD OF IMMUNOLOGICAL ANALYSIS FOR DETECTION OF ANTIBODIES AGAINST HUMAN GSTT1 (ANTI-HGSTT1) - The subject of the present invention is a method of immunological analysis for detection in biological fluids of anti-bodies against human GSTT1 (anti-hGSTT1). The present invention also concerns the use of said immunological analysis method for the diagnosis, prognosis, follow-up and monitoring of pathological conditions associated with the presence of anti-GSTT1 in biological fluids, and also concerns a tool kit for putting said method into practice.02-17-2011
20110027811ASSAY SYSTEM FOR THE ASSESSMENT OF ONCOGENICITY, TUMOR PROGRESSION, AND TREATMENT EFFICACY - Systems and kits are provided which are capable of determining the oncogenicity of a cancer, tumor progression, and effectiveness of a cancer treatment. Such systems and kits utilize assays to examine the levels of apoptotic markers, angiogenesis markers, immunomodulation markers, and cell cycle markers and can compare samples from a patient taken at different times to determine the oncogenicity of a cancer, tumor progression, and effectiveness of a cancer treatment. Methods for determining the oncogenicity of a cancer, tumor progression, and effectiveness of a cancer treatment with such systems and kits are also provided.02-03-2011
20110111438METHOD AND DEVICE FOR IMMUNOASSAY - The present invention relates to a method and a device for determining a concentration of a biological active substance in a sample by the means of an enzyme-linked immunosorbent assay (ELISA). The device comprises a solid support within a tubing (05-12-2011
20110111439Elevation of Induced Heat Shock Proteins in Patient's Cerebral Spinal Fluid: A Biomarker of Risk/Onset of Ischemia and/or Paralysis in Aortic Surgery - Provided are methods for intra-operatively predicting, detecting or diagnosing the risk or onset of spinal cord ischemia and/or associated permanent paralysis in a patient, based upon the stress-induced elevation of levels of heat shock proteins, specifically HSP70 and/or HSP27 in the cerebral spinal fluid of the patient, as measured during thoracic-aorta surgery, particularly thoracic aneurysm repair surgery, that will permit intra-operative medical intervention to try to prevent or attenuate severe, and often fatal, complications. Further provided are kits, assay devices and methods of analyzing biomarker data for use in pre-, intra- or post-operatively detecting the stress-induced elevations of the measured levels of HSP70 and/or HSP27, and the biomarker itself.05-12-2011
20110129860CALPROTECTIN AND HEMOGLOBIN/HAPTOGLOBIN COMPLEX FROM STOOL SAMPLE TO ASSESS COLORECTAL CANCER - The present invention relates to a method aiding in the assessment of colorectal cancer. The method especially is used in assessing the absence or presence of colorectal cancer in vitro. The method is for example practiced by analyzing biochemical markers, comprising measuring in a stool sample the concentration of the hemoglobin/haptoglobin complex and calprotectin and correlating the concentrations determined to the absence or presence of colorectal cancer. To further improve the assessment of colorectal cancer based on a method of this invention the level of one or more additional marker may be determined together with the hemoglobin/haptoglobin complex and calprotectin in a stool sample and be correlated to the absence or presence of colorectal cancer. The invention also relates to the use of a marker panel comprising the hemoglobin/haptoglobin complex and calprotectin in the early diagnosis of colorectal cancer and it teaches a kit for performing the method of the invention.06-02-2011
20110097750METHOD OF QUANTITATIVE ASSESSMENT ON REPRODUCTIVE EFFORT OF BLACK-LIP PEARL OYSTERS USING ANTIBODY SPECIFIC THERETO - Disclosed are an antigen protein of black-lip pearl oyster egg extract, an antibody specific thereto, and a method of quantitative assessment of the reproductive effort of black-lip pearl oyster using the antibody. The method accomplishes quantitative assessment of reproductive effort of black-lip pearl oysters easily and accurately. In addition, the method provides important information for the study of life cycles of black-lip pearl oysters, and allows efficient management of black-lip pearl oysters.04-28-2011
20110244493CELL-BASED DETECTION OF APF THROUGH ITS INTERACTION WITH CKAP4 FOR DIAGNOSIS OF INTERSTITIAL CYSTITIS - An assay system designed to detect a protein biomarker in urine that is diagnostic for interstitial cystitis (IC). The presence of a 9 amino acid glycopeptide, antiproliferative factor (APF), in urine is unique to patients with IC. Urine samples from patients who exhibit symptoms consistent with IC are added to the assay system. Binding of APF to the cytoskeletal associated protein 4 (CKAP4) is positive for the presence of APF in urine and diagnostic for IC. The diagnostic system is a significant and surprising advance in diagnosis of IC and has commercial applications relevant to women and men who suffer from symptoms consistent with IC.10-06-2011
20110244492IMMUNOASSAYS FOR CITRULLINATED PROTEINS - Methods and kits are provided for assessing radiation injury and exposure in a mammal. The methods comprise the steps of: obtaining one or more test samples from the mammal, contacting the test samples with an antibody immunoreactive with a citrullinated protein to form an immunocomplex; and detecting the immunocomplex with an ELISA; wherein a decrease in the quantity of the immunocomplex in the test samples, as compared to the quantity of immunocomplexes formed under identical conditions with the same antibody and a control sample from one or more mammals known to have a lower degree of radiation injury or exposure, indicates a higher degree of radiation injury and exposure to the mammal. The information obtained from such methods can be used by a clinician to accurately assess the extent of radiation injury/exposure in the mammal, and thus will provide a valuable tool for determining treatment protocols on a subject by subject basis.10-06-2011
20110244488CHITIN-INDUCED IMMUNE RESPONSE BASED METHOD FOR DIAGNOSING ALLERGIC ASTHMA IN PATIENTS - A method of diagnosing allergic asthma in patients, including the steps of: obtaining from a subject a first sample of peripheral blood immune cells and a second sample of peripheral blood immune cells; adding chitin to the first sample; measuring the average amount of IFN-γ in both the first sample and the second sample to get a first value and a second value respectively; and dividing the first value with the second value to get a ratio, wherein if the ratio is smaller than a threshold value, the subject is diagnosed as an allergic asthma patient.10-06-2011
20120135431TYPE IV COLLAGEN-LIKE IMMUNOREACTIVE PEPTIDE - A type IV collagen-like immunoreactive peptide and an antibody thereof which are useful for detecting nephritis, a method for selecting a type IV collagen-like immunoreactive peptide, a method for screening an immunoreactive antibody and an immunoreactive peptide, a nephritis model, a method for detecting chronic nephritis, a vaccine, and a therapeutic agent for nephritis are provided.05-31-2012
20110129858Prognosis Biomarker for Evaluating the Cure Level of Stroke Patient and a Method thereof - A method for evaluating the cure level of a stroke patient comprises following steps: (1) obtaining isolated blood sample from said stroke patient; (2) determining the concentration of serum granulocyte colony-stimulating factor (G-CSF) of said blood sample; (3) comparing the relationship between said concentration of granulocyte colony-stimulating factor (G-CSF) and the stroke severity ranking of said stroke patient; wherein United State National Institute of Health Stroke Scale (NIHSS) or modified Ranking Scale (mRS) is used in said stroke severity ranking; and (4) Using said concentration of granulocyte colony-stimulating factor (G-CSF) to predict the possible cure level of said stroke patient. The invention further provides a prognosis biomarker for evaluating the cure level of a stroke patient, and a kit containing said prognosis biomarker.06-02-2011
20110143379DETECTION AND QUANTITATION OF FULL-LENGTH THIOREDOXIN (TRX) AND TRUNCATED THIOREDOXIN (TRX 80) IN COMPLEX SAMPLES - The present invention relates, e.g., to a method for detecting a full-length protein and a truncated form (e.g., a naturally occurring cleavage product) thereof, in a sample, comprising 06-16-2011
20110244491PEPTIDES DERIVED FROM HUMAN BPLP PROTEIN, POLYNUCLEOTIDES CODING FOR SAID PEPTIDES AND ANTIBODIES DIRECTED AGAINST SAID PEPTIDES - The invention relates to an in vitro method for prognosis, diagnosis or determination of the evolution of a condition involving an altered production of Basic Proline-rich Lacrimal Protein (BPLP) or of any of its maturation products, by detecting, or quantifying in a biological sample of a test subject, a BPLP protein or a maturation product thereof, and comparing the production of BPLP protein or maturation product with the production of the same in a biological sample of a control subject.10-06-2011
20110244494REAGENTS, METHODS AND KITS FOR THE UNIVERSAL RAPID IMMUNO-DETECTION - Novel immuno-detection methods, kits and reagents are provided. The Combination of this invention, combining at least two of the following reagents of a Non-specific Competitor, a Specific Indicator, a primary antibody and an antigen, provides a faster and easier method for an immuno-detection, combining at least two of the following steps of blocking, antigen binding, primary antibody binding and 210-06-2011
20110244490DETECTION AND MONITORING OF LIVER DAMAGE - A method of detecting liver damage in a subject comprises measuring the level of caspase-3 generated cytokeratin-18 fragments in the bodily sample. The level of measuring the level of caspase-3 generated cytokeratin-18 fragments is then correlated with liver disease progression.10-06-2011
20110244489METHOD FOR THE EARLY DETECTION OF RENAL INJURY - A method and kit for detecting the immediate or early onset of renal disease and injury, including renal tubular cell injury, utilizing NGAL as an immediate or early on-set biomarker in a sample of blood serum. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctuate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.10-06-2011
20090311724USE OF ADDITIVES FOR THE REDUCTION OF NON-SPECIFIC BINDING IN ASSAYS - A method for reducing non-specific binding in an assay is provided herein. The method includes (a) providing a reaction mixture, which includes or is suspected to include a first component and a second component capable of binding to each other in a specific binding reaction, and (b) adding non-physiological amounts of at least one additive to the reaction mixture before, during or after binding in a sufficient amount to reduce non-specific binding in the reaction mixture. The method further includes (c) monitoring or measuring the presence and/or concentration of at least one of the first and second components after step (b).12-17-2009
20090311726Methods and compositions for categorizing patients - The disclosure provides, among other things, molecular markers for categorizing the neoplastic state of a patient, methods for using the molecular markers in diagnostic tests, nucleic acid and amino acid sequences related to the molecular markers, reagents for detection of molecular markers, and methods for identifying candidate molecular markers in highly parallel gene expression data.12-17-2009
20090311727RECOMBINANT DEAMIDATED GLIADIN ANTIGEN - The present invention provides a method for determining whether a subject is suffering from celiac disease by contacting a sample of bodily fluid from the subject, with an antigen formed from a gliadin fusion protein immobilized on a solid support. The gliadin fusion protein of the antigen includes a recombinant deamidated gliadin linked to a tag such as Glutathione-S transferase (GST) protein. The antigen is prepared by immobilizing on the solid support the gliadin fusion protein via the tag. The antigen can further include tissue Transglutaminase (tTG) cross-linked to the gliadin fusion protein. When tTG is present, the tTG and recombinant deamidated gliadin are mixed together prior to immobilization to the solid phase.12-17-2009
20100055722Methods of Detecting A Neurological Condition Via Analysis of Circulating Phagocytes - The present invention features methods of monitoring or detecting a neurological or inflammatory condition in a patient. The method comprises (1) obtaining from the patient a fluid sample from outside of a brain tissue of the patient, wherein the fluid sample contains a circulating phagocyte, and (2) detecting for one or more biomarkers (e.g., a panel of biomarkers) inside the phagocyte, wherein the biomarker is associated with the respective neurological or inflammatory condition.03-04-2010
20080268478Use of Eotaxin as a Diagnostic Indicator For Atherosclerosis and Vascular Inflammation - The invention disclosed herein relates to the detection or diagnosis of atherosclerosis by measuring the level of the protein eotaxin in an individual's serum. The presence of eotaxin above levels specified herein is indicative that atherosclerosis may be present. Detection of elevated eotaxin levels in serum may provide a means to diagnose atherosclerosis prior to the onset of symptoms.10-30-2008
20090035794METHOD FOR DETECTING, SCREENING, AND/OR MONITORING CANCER IN AN INDIVIDUAL - The invention relates to a method for screening and/or detecting and/or monitoring a cancer in an individual, said method comprising determining a first parameter represented by the concentration of TIMP-1 in at least one excreta, e.g. saliva, from the individual. The invention provides a method that without the need to use a blood sample is suitable for facilitating the early diagnosis of a cancer, monitoring the recurrence of a cancer, and/or monitoring the status of a cancer or the effect of cancer treatment in an individual.02-05-2009
20100068736Novel Nucleotide and Amino Acid Sequences, and Assays and Methods of Use Thereof for Diagnosis of Lung Cancer - Novel markers for lung cancer that are both sensitive and accurate. These markers are overexpressed in lung cancer specifically, as opposed to normal lung tissue. The measurement of these markers, alone or in combination, in patient samples provides information that the diagnostician can correlate with a probable diagnosis of lung cancer. The markers of the present invention, alone or in combination, show a high degree of differential detection between lung cancer and non-cancerous states.03-18-2010
20100068735MICROFLUIDIC DEVICE INCLUDING UNIT FOR EVALUATING CAPTURE MATERIAL AND METHOD OF EVALUATING CAPTURE MATERIAL - Provided are a microfluidic device including a unit for evaluating a capture material and a method of evaluating a capture material.03-18-2010
20100143950BINDING OF COMPLEMENT FACTOR H TO C-REACTIVE PROTEIN - The invention relates to a correlation between serum complement Factor H levels and binding to C-reactive protein (CRP) and risk of developing age-related macular degeneration. The invention provides methods for screening a subject to assess risk of developing AMD. The invention also provides methods for screening for agents useful to treat AMD.06-10-2010
20110097746Orthogonal Method for the Removal of Transmissible Spongiform Encephalopathy Agents from Biological Fluids - A method comprising contacting a biological fluid comprising hemoglobin and at least one pathogenic agent with a first filter and generating a first filtrate; contacting the first filtrate with a nanofiltration device and generating a second filtrate; contacting the second filtrate with a chromatographic material and isolating an eluted fraction; contacting the eluted fraction with a hydrophobic solvent and generating a hydrophobic and a hydrophilic phase; and isolating the hydrophilic phase wherein the biological fluids comprise components of interest of equal to or less than about 65 kDa. A method comprising contacting a biological fluid comprising high molecular weight components and at least one pathogenic agent with a first filter and generating a first filtrate; contacting the first filtrate with a hydrophilic membrane and generating a second filtrate; contacting the second filtrate with a chromatographic material and isolating an eluted fraction; contacting the eluted fraction with a hydrophobic solvent and generating a hydrophobic and a hydrophilic phase; and isolating the hydrophilic phase, wherein the high molecular weight components have molecular weights greater than about 65 kDa. A method comprising subjecting a biological fluid comprising hemoglobin and at least one pathogenic agent to at least two filtration steps and thereby reducing the amount of pathogenic agent associated with the biological fluid. A method comprising removing transmissible spongiform encephalopathy agents in a hemoglobin solution of human and/or animal origin by subjecting the hemoglobin solution to an orthogonal separation methodology comprising a plurality of filtration steps.04-28-2011
20110097748USE OF CELL LINES TO DETERMINE LEVELS OF EFFICACY OF PHARMACEUTICAL FORMULATIONS - The present invention provides methods and assays for determining the efficacy of pharmaceutical compositions. Through the use of cell lines to measure efficacy of a formulation, one can better measure characteristics such as half life, release rate and release profile of a product that may be informative to the FDA. These methods and assays may, for example, be of use when measuring the effect of anti-inflammatory agents on cytokine production that is being considered for local administration.04-28-2011
20110250625GAMMA SECRETASE NOTCH BIOMARKERS - The present invention relates to the biomarker TFF-3 that measures γ-secretase mediated Notch processing. TFF-3 has utility in predicting and/or determining in vivo Notch-related toxicity associated with inhibition of Notch processing mediated by γ-secretase. The reagents and methods of the invention can be utilized before, after, or concurrently with, pre-clinical, clinical, and/or post-clinical testing. The reagents and methods of the invention can be used to identify and maintain preferred doses of test compounds and thereby prevent medical complications, such as gastrointestinal cellular damage.10-13-2011
20110177536NOVEL ANTIBODIES RECOGNIZING NATIVE ANNEXIN A3 - The present invention refers to novel antibodies recognizing native annexin A3. These antibodies are suitable for diagnostic and therapeutic applications.07-21-2011
20110177532IMMUNOMODULATING COMPOSITIONS AND METHODS OF USE THEREOF - The invention is directed to β1-6 glucans, compositions, diagnostic kits, and devices comprising the same, and methods of use thereof in modulating immune response and treating, delaying progression of, reducing the incidence or severity of cancer, infection, inflammation, and autoimmune diseases. The β1-6 glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety. The β1-6 glucans of certain embodiments of the invention recruit immunoglobulin G antibodies to mediate complement and neutrophil killing. The conjugated β1-6 glucans of certain embodiments of the invention are targeted to cells to stimulate the immune response at the target location by activating complement-mediated lysis and recruitment of neutrophils.07-21-2011
20110177531Cell-Based Complement Activation Product Algorithm for Diagnosing Systemic Lupus Erythematosus - The present invention provides methods of diagnosing and monitoring systemic lupus erythematosus by measuring cell-based complement activation products (CB-CAPS) in a subject's blood. In particular, the invention describes a diagnostic method employing the measurement of multiple complement activation products on the surfaces of red blood cells, white blood cells, and platelets (e.g., EC4d, BC4d, PC4d, and ECR1). A diagnostic algorithm utilizing the determined levels of CB-CAPS is also disclosed.07-21-2011
20110177530Methods and Compositions for Detection of Biological Materials Using Microfluidic Devices - Provided herein are microfluidic devices and methods useful for sensitive detection of analytes. The methods and devices described herein are also useful for detecting direct or indirect binding of enzymes or catalysts to a surface, for example a surface having analytes bound thereon. Methods disclosed herein include embodiments utilizing a pre-concentration scheme to improve signal levels of corresponding reporter moieties.07-21-2011
20100068737Enzyme-linked Immunosorbent Assay (ELISA) for Canine Hepcidin - The present invention relates to the use of hepcidin-specific antibodies for the detection of hepcidin in biological samples for the diagnosis of diseases and disorders related to iron metabolism. Kits useful in screening various subjects suspected of having diseases or disorders associated with iron metabolism are also provided.03-18-2010
20090215094DIAGNOSIS AND MONITORING OF CHRONIC RENAL DISEASE USING NGAL - A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.08-27-2009
20110097749PROCESS FOR PRODUCING HEPCIDIN - The present invention provides a novel method for producing biologically functional hepcidin in 04-28-2011
20110250623BIOMARKER AND METHOD FOR DETECTING A CHRONIC INFLAMMATORY-ASSOCIATED DISEASE - The present invention in one embodiment uses detection of isoforms of CAP37 as an early detection marker for a chronic inflammatory-associated disease. Chronic inflammatory-related diseases may include, for example, atherosclerosis, psoriasis, and osteoarthritis. The invention is also directed to isoforms of CAP37 protein having apparent molecular weights of about 135 kDa (±15 kDa) and about 100 kDa (±15 kDa) as assessed by SDS PAGE under reducing conditions, and their use as biomarkers for the presence of a chronic inflammatory-associated disease in a subject. The invention is also directed to monoclonal and/or polyclonal antibodies raised against such isoforms of CAP37 protein and kits and diagnostic tests comprising these antibodies.10-13-2011
20110250624ELISA ASSAY FOR DETECTING ANTIBODIES AGAINST BLV SURFACE ANTIGEN GP 51 IN BOVINE SERUM - The subject of the present invention is a method of obtaining purified BLV gp10-13-2011
20110250622METHOD FOR DIAGNOSING AUTO-IMMUNE CHRONIC URTICARIA - In certain embodiments, the present invention relates to methods, compositions, and kits for diagnosing autoimmune chronic urticaria. For example, in certain embodiments, such methods generally comprise detecting the presence of auto-antibodies to cell-surface IgE receptors or cell-bound IgE in a patient. Such auto-antibodies may be detected by (a) obtaining donor basophils and associated leukocytes from one or more donors, (b) challenging the donor basophils and associated leukocytes with control serum and quantifying the amount of histamine released by the donor basophils and associated leukocytes, (c) calculating a normalized baseline of histamine release, wherein the normalized baseline of histamine release represents a mean percentage of histamine released by the basophils and associated leukocytes of an individual donor plus a specified amount above such mean, (d) reacting patient serum with the donor basophils and associated leukocytes, (e) measuring the percentage of histamine released by the donor basophils and associated leukocytes in response to the patient serum, and (f) comparing the percentage of histamine released by the donor basophils and associated leukocytes in response to the patient serum to the normalized baseline of histamine release.10-13-2011
20110097747Monoclonal antibody binds antigen associated with human tumors - The present invention is concerned with a novel antigen associated with human tumors, including carcinomas of the colon, pancreas, and lung, as well as novel monoclonal antibodies which binds strongly to said antigen. The antibodies bind to normal human cells to a much lesser degree than to tumor cells. The antibodies find use both in diagnostic methods such as the detection of malignant cells associated with tumors and in therapeutic methods for treatment of humans with tumors. The novel antigen disclosed is a 60,000 Dalton glycoprotein found on the cell surface of human tumor cells.04-28-2011
20110086372BIOMARKERS ASSOCIATED WITH NEPHROPATHY - Use of urine biomarkers for diagnosing nephropathy, monitoring nephropathy progress, and assessing efficacy of a nephropathy treatment. These urine biomarkers include leukocyte-associated Ig-like receptor-2, alpha-1 acid glycoprotein, their fragments, and combinations thereof.04-14-2011
20110081669SYSTEMS AND METHODS FOR DIAGNOSIS AND PROGNOSIS OF CANCER - Methods for diagnosing a cancer in a subject are provided that include determining an amount of autoantibodies immunoreactive to procathepsin D (pCD) in a sample obtained from the subject. Further provided are systems for diagnosing a cancer in a subject that include an autoantibody immunoreactive pCD antigen and a means for detecting binding of an autoantibody to the antigen.04-07-2011
20110076700ANTI-CRP ANTIBODY AND UTILIZATION OF THE SAME - It is intended to provide means capable of specifically recognizing CRP in a test sample and assaying it with high sensitivity. The present invention provides an anti-CRP antibody which reacts with a C-reactive protein (hereinafter referred to as CRP) and recognizes an epitope located at residues 147 to 172 in a CRP amino acid sequence represented by SEQ ID NO: 1.03-31-2011
20110076701MULTI-STAGE NUTRIGENOMIC DIAGNOSTIC FOOD SENSITIVITY TESTING IN ANIMALS - A multi-stage method for diagnosing an immunologic food sensitivity or intolerance in a companion animal. Firstly a saliva or blood spot or other non-serum bodily fluid sample is collected. The screening the saliva or blood spot or other non-serum bodily fluid sample detects the presence of at least one of IgA or IgM antibody to a particular food ingredient or composition. An immunologic food sensitivity or intolerance based on the presence of the antibody is diagnosed. Secondly a blood sample is collected and serum from the sample is screened to detect the semi-quantitative or quantitative presence of at least one of an IgA, IgM or IgG antibody or immune complex to a particular food ingredient or composition. An immunologic food sensitivity or intolerance based on the presence of the antibody or immune complex is diagnosed. Thirdly, a biologically active nutrient in relation to the animal from a molecular dietary signature is determined. The molecular dietary signature for the animal is a variation of expression of a set of genes, proteins or metabolites which may differ for the genotype of each animal.03-31-2011
20120149038DIAGNOSIS OF AUTISM - A method for diagnosing autism in a subject is performed by determining the presence and concentration of specific peptides in the body fluid. The peptides have the amino acid sequences SKITHRIHWESASLL, SSKITHRIHWESASLL, and SSKITHRIHWESASLLR with the molecular masses 1779+/−1 Da, 1865+/−1 Da and 2022+/−1 Da, respectively.06-14-2012
20120149040Adam12, A Novel Marker For Abnormal Cell Function - The present invention provides a method, an assay and a kit for providing an indication of abnormal cell function. The present inventors describes ADAM12 as a overall general marker for abnormal cell function, and the present inventor for the first time demonstrate that ADAM12 is an important indicator of fetal chromosomal disease and placenta function. Specifically ADAM12 is a good marker for e.g. Downs's syndrome, trisomy 18, preeclampsia, Turner syndrome in both first and second trimester. The present inventors developed an enzyme-linked immunosorbent assay (ELISA) and a time-resolved immunofluorometric assay for the quantification of ADAM12 in serum. The present application demonstrates in several examples the variation of the ADAM12 level in fetal abnormality and/or adverse pregnancy outcomes correlated gestational age when compared to normal controls. It is an object of the invention to provide an improvement of the existing marker tests that exhibits a decreased false positive rate.06-14-2012
20120149039DIAGNOSTIC APPARATUS FOR ORGANIC SAMPLE ANALYSIS - A diagnostic apparatus for organic-sample analyses including a fluid sucking and ejecting device to enable suction and inner storage or ejection to the outside of the fluid, a feeding needle that can be secured to the sucking device including an inner channel for passage of the fluids and to be inserted into containers for intaking or ejecting a given amount of the fluid, an actuating device, including a carriage, to spatially move the carriage along three axes, the carriage being susceptible of connection with the sucking and ejecting device, a first replacement station to house a plurality of feeding needles of the disposable type and suitable to enable automatic fastening and removal of one of the disposable feeding needles to and from the sucking device connected to the carriage, and a second replacement station to allow automatic fastening and removal of a precision feeding needle to and from the carriage.06-14-2012
20110151489MONITORING SKIN METABOLISM PRODUCTS FOR EVALUATING BURN INJURY - The present invention relates to methods and kits for evaluating the severity of a burn injury, which are based on the detection in a clinical fluid sample of skin metabolism products, such as collagen peptides which are released upon collagen degradation or synthesis.06-23-2011
20110151486METHODS AND SYSTEMS TO PREVENT GAS BUBBLES FROM INTERFERING WITH FLOW OF FLUID THROUGH A MEMBRANE REGION - Methods and systems to remove gas bubbles from liquids and to improve uniform fluid flow through a region of a membrane in a microfluidic device, including to reduce, remove, and/or prevent gas bubbles on a surface of a porous membrane. An example membrane bubble trap system may include a fluid channel connected to a bubble pathway that surrounds an opening sealed with a membrane. The bubble pathway may be configured to collect bubbles in fluid that passes through the membrane through buoyancy forces and through a directional feature of a curved surface placed above the membrane.06-23-2011
20110033877Method for Evaluation or Selection of Adiponectin Secretion Regulator - Provided is a method for conveniently and rapidly evaluating or selecting an adiponectin secretion regulator.02-10-2011
20100304411Endogenous Morphine or a Naturally Occurring Metabolite Thereof as a Marker for Infection - The invention relates to a method for detecting infection in a patient comprising measuring the concentration of endogenous morphine or a naturally occurring metabolite thereof in a biological sample obtained from said patient.12-02-2010
20100297679IDENTIFICATION AND QUANTIFICATION OF BIOMARKERS FOR EVALUATING THE RISK OF PRETERM BIRTH - Described herein are methods for evaluating the risk of preterm birth in pregnant subjects. The methods involve detecting and quantifying one or more biomarkers associated with preterm birth in a biological sample from the subject. Also described herein are isolated biomarkers and kits useful in predicting the risk of preterm birth.11-25-2010
20100297680METHODS FOR ASSESSING THE RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE - The present invention relates to diagnostic tests, methods and kits that are useful to assess a subject's risk of developing a pathologic condition related in part to the presence of HDL oxidation product. Measuring the quantity of one or more HDL oxidation products present in the blood is useful in evaluating risk for developing or evaluating the severity of a disease or evaluating response to treatment for such a disease as, for instance, cardiovascular disease.11-25-2010
20100297678BIOMARKERS FOR MULTIPLE SCLEROSIS - The present invention relates to the diagnosis of neurological disorders, more specifically to the diagnosis of multiple sclerosis. A biomarker panel is provided which can be used to detect if a subject has multiple sclerosis. Also described are methods of identification of such biomarkers.11-25-2010
20090023164COMPOSITIONS AND METHODS FOR THE DETECTION OF HIV-1/HIV-2 INFECTION - This invention relates to compositions and methods or the detection of immunodeficiency virus infection, especially immunodeficiency virus-1 (HIV-1) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies.01-22-2009
20090023165Methods for Early Diagnosis of Kidney Disease - The invention provides reagents and methods for diagnosing kidney disease in a human or animal.01-22-2009
20110151488DETECTION AND MONITORING OF LIVER DAMAGE - A method of detecting liver damage in a subject comprises measuring the level of caspase-3 generated cytokeratin-18 fragments in the bodily sample. The level of measuring the level of caspase-3 generated cytokeratin-18 fragments is then correlated with liver disease progression.06-23-2011
20090004678METHOD FOR SCREENING FERTILITY AND NEW COMPOUNDS OR MOLECULES, USING CRT OR ERP57 TRANSLOCATION - A screening method for testing the immunogenicity of new molecules and compounds and for testing fertility and sterility conditions. The method includes inducing a translocation of a calreticulin protein and/or an ERP57 protein, to a cellular membrane in order to determine the immunogenicity of the new molecules and compounds, or the fertility or sterility conditions. The method includes also the using of recombinant CRT and/or ERP57 to treat sterility.01-01-2009
20120171702QUANTITATIVE AND SELF-CALIBRATING CHEMICAL ANALYSIS USING PAPER-BASED MICROFLUIDIC SYSTEMS - A method of determining the concentration of a test fluid sample using a paper-based microfluidic system having a plurality of hydrophilic testing zones, including: a) depositing said test fluid sample on at least one said testing zone; b) depositing a plurality of standard fluid samples or reactives of differing known concentrations on other said testing zones; c) introducing an indicator solution to each said test zone to thereby react with the deposited fluid sample and result in a colour intensity change which is a function of the fluid sample concentration; and d) comparing the differences in colour intensity between the test fluid sample and the standard fluid samples or reactives to thereby determine the concentration of said test fluid sample.07-05-2012
20110151487Compositions And Methods For The Treatment Of Cancer - Disclosed herein are methods and compositions for the treatment of cancer. In particular, the present invention discloses inhibitors of the Fanconi anemia pathway and methods using same. Such inhibitors are useful in inhibiting DNA damage repair and can be useful, for example, in the treatment of cancer.06-23-2011
20090317843METHOD FOR MEASURING PLASMA LEVELS OF LONG PENTRAXIN PTX3 - The present invention relates to a method for measuring PTX3 in a biological fluid, particularly in human or animal plasma. Particularly, the present invention relates to a method for measuring PTX3 levels in a human or animal derived plasma sample, comprising a stage of the treatment of said plasma sample with a red blood cell agglutinating agent and a subsequent stage of determining the plasma levels of PTX3.12-24-2009
20090317841Methods and Materials for the Detection of Leishmania Infection - The present invention provides rapid diagnostic assays for the detection of 12-24-2009
20090275059Marker proteins for diagnosing liver disease and method of diagnosing liver disease using the same - Using the protein chip technology, biological samples such as sera are subjected to proteome analysis. Thus, a protein which is a human fibrinogen α-E chain decomposition product and has a molecular weight of 5,900, a protein which is an apolipoprotein AII decomposition product and has a molecular weight of 7,800, and a protein which is an apolipoprotein AI decomposition product and has a molecular weight of 28,000, each showing an increase or a decrease with the habit of drinking, are newly found out. By detecting or quantifying these proteins, a liver disease in a subject such as one having a problem of drinking can be diagnosed at the early stage.11-05-2009
20090258378STRESS-INDUCED PHOSPHOPROTEIN 1 AS A BIOMARKER FOR THE DETECTION OF HUMAN OVARIAN CANCERS AND ENDOMETRIOSIS - Disclosed herein is a method for the detection, preliminary screening or monitoring of a gynecological disease selected form ovarian cancers and endometriosis, in which STIP1 is used as a biomarker for the gynecological disease.10-15-2009
20090208987Method and Composition for Stabilizing Liquid Reagents - The invention relates to methods and compositions for removing a dissociated species from a fluid medium solution during and after it has detached from a solid-phase immersed in said medium, thereby allowing the concentration of free species to remain close to zero, and for improving the signal to noise ratio in assays. This is achieved by employing a substrate, such as a scavenging solid-phase, having an attached binding partner or partners (“scavenger”) for the specifically binding species and which is present during storage. This substrate may also contain regions for binding signal generating components attached to the solid-phase. This substrate binds any free species bleeding off the solid phase, increasing the reliability and sensitivity of assays. A subset of the substrates in the invention additionally forms cross-linked networks of solid-phase particles that further increase the sensitivity of assays.08-20-2009
20110256560METHODS AND COMPOSITIONS FOR THE DETECTION OF OVARIAN CANCER - Provided is a method of screening for, diagnosing or detecting ovarian cancer in a subject comprising (a) determining a level of mdogen-2 in a test sample from the subject, and (b) comparing the level of mdogen-2 in the test sample with a control, where detecting an increase in the level of mdogen-2 in the test sample compared to the control is indicative of ovarian cancer in the subject.10-20-2011
20090170136DETERMINING FELINE proBNP - Methods and compositions are disclosed for determining feline proBNP or fragments thereof in a sample. In one method, feline proBNP or fragments thereof are determined by providing a feline sample, contacting the sample with at least one antibody that binds an epitope in the region from amino acids 68 to 80 of feline proBNP, and determining the presence of the feline proBNP or fragments thereof present in the sample. Antibodies that bind feline proBNP and kits comprising such antibodies are also disclosed.07-02-2009
20110212472Asbestos Exposure, Pleural Mesothelioma and Osteopontin Levels - The present invention provides diagnostic and disease progression or recurrence prediction methods based on osteopontin levels in a biological sample.09-01-2011
20080268481Sensitive Magnetic Catch Assay By Building a Strong Binding Couple - The invention relates to a sensor device for detecting a target in a sample suspected of comprising the target, which device is suitable for use in an assay such as a sandwich assay. The invention further relates to a method for detecting a target in a sample. The device comprises a sensor surface, which is functionalised with one moiety of a strong binding couple, which moiety preferably shows little or no cross reactivity with the target molecule.10-30-2008
20120064549Lenalidomide and Thalidomide Immunoassays - Novel conjugates and immunogens derived from lenalidomide and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of thalidomide and lenalidomide in biological fluids.03-15-2012
20080206793Ischemic Biomarkers and their Use to Predict Adverse Neurological Events from Surgery - Methods are provided for predicting the occurrence of adverse neurological events from surgery. Such adverse events include, for example, stroke, delirium and transient ischemic attach (TIA). The methods are based on the discovery that levels of circulating cerebral NMDA receptor peptides and antibodies can be used to identify patients who are likely to suffer from an adverse neurological event. Also provided are diagnostic procedures for practicing the predictive methods of the current invention, and interventional strategies for reducing the risk of adverse neurological events from surgery (FIG. 08-28-2008
20100304408USE OF THE ALPHA CHAIN OF BRAIN SPECTRIN AND FRAGMENTS THEREOF, FOR DIAGNOSING CEREBRAL DISEASES - The present invention pertains to a method for in vitro prognosticating and/or diagnosing cerebral cerebral malaria, wherein said method comprises a step of detecting non-erythroid spectrin or fragments thereof, and/or antibodies directed against non-erythroid spectrin, in a biological sample. Reagents and kits for performing this method are also disclosed.12-02-2010
20100323375AGENT AND METHOD FOR DIAGNOSIS ON THE OCCURRENCE OF ALZHEIMER'S DISEASE OR THE TENDENCY TO DEVELOP ALZHEIMER'S DISEASE - Disclosed are: an agent, an apparatus and a method for the diagnosis of a disease associated with the abnormality in γ-secretase; a method for providing information for the diagnosis of a disease associated with the abnormality in γ-secretase; a method for monitoring the condition or the degree of progression of a disease associated with the abnormality in γ-secretase; and a method for determining the therapeutic effect of a therapeutic agent on a disease associated with the abnormality in γ-secretase. More specifically disclosed are: a diagnostic agent for a disease associated with the abnormality in γ-secretase, which comprises an antibody capable of recognizing a digestion product of an alcadein with α-secretase or γ-secretase or a fragment of the antibody; and others.12-23-2010
20120276560BIOMARKERS FOR ASSESSING SIALIC ACID DEFICIENCIES - The present invention relates to methods of diagnosing, monitoring and assessing conditions of sialic acid deficiency such as Hereditary Inclusion Body Myopathy (HIBM) and to methods of predicting/determining responsiveness to treatment.11-01-2012
20120276559Thrombospondin Fragments and Uses Thereof In Clinical Assays for Cancer and Generation of Antibodies and Other Binding Agents - The invention relates to thrombospondin fragments found in plasma, their use or use of portions thereof in diagnostic methods, as method calibrators, method indicators, and as immunogens, and as analytes for methods with substantial clinical utility; and their detection in plasma or other bodily fluids for purpose of diagnostic methods, especially for cancer.11-01-2012
20120202228Antibody Profiles Characteristic of Tuberculosis State - Serum antibody assays capable of distinguishing cases of inactive TB from cases of active TB include a combination at least three 08-09-2012
20120202227Babesia microti Genomic Clones Containing Novel Antigens Useful in the Diagnosis of Babesiosis - Disclosed are the cloning and expression of novel antigens in 08-09-2012
20120135428NOVEL MARKERS FOR CHRONIC KIDNEY DISEASE - The present invention relates to a method for determining the progression of chronic kidney disease in a subject suspected of having chronic kidney disease, comprising of determining the expression levels of at least one marker selected from (a) FGF23; and (b) adiponectin in a biological sample. Furthermore, the present invention relates to a use of a specific detection molecule for FGF23 or adiponectin for the preparation of a diagnostic composition for the detection of chronic kidney disease or the progression of chronic kidney diseases in a subject suspected to suffer from said disease. In particular, the present invention also provides for use of FGF23 and/or of adiponectin as an in vitro marker for the presence, absence or progression of a chronic kidney disease and kits comprising a specific detection molecule for FGF23 or a specific detection molecule for adiponectin for use in the method of the present invention.05-31-2012
20110053191METHOD FOR RISK REDUCTION IN GLYCEMIC CONTROL - Disclosed is a method for identifying a subject being susceptible to a therapy for intensive glycemic control, the subject suffering from diabetes and being in need for a therapy for intensive glycemic control, based on determining the amount of PLGF (placental growth factor) in a sample of the subject and comparing the thus determined amount to a reference amount. In a preferred embodiment, the method further includes determining at least one further marker selected from the group consisting of a cardiac troponin and a natriuretic peptide and comparing the determined amount(s) to a reference amount (amounts). Moreover, disclosed is a method for predicting the risk of an acute cardiovascular event in a subject who suffers from diabetes and is on intensive glycemic control. Further disclosed is a kit and a device adapted to carry out the method of the present invention.03-03-2011
20110053190Use of CFH or ApoH as a Biochemical Diagnostic Marker for Complete Remission in Acute Myeloid Leukemia - The present invention relates to a diagnostic method for acute myeloid leukemia, in particular, a method for using CFH or ApoH in patient sera as biochemical diagnostic markers to determine complete remission in acute myeloid leukemia. In accordance with this invention, CFH and ApoH are identified as a novel biochemical marker for understanding the biological mechanism and responsiveness to disease in AML patients after induction chemotherapy, and can be used as a biochemical marker for evaluating the prognosis of disease in patients after induction chemotherapy.03-03-2011
20110053189Type IV secretion system proteins in sero-detection of Anaplasma phagocytophium - Disclosed are two (2) proteins in the Type IV Secretion System (TIVSS) in 03-03-2011
20110053188ENDOTOXIN DETECTION METHOD - The invention relates to a method for detecting endotoxins in a sample.03-03-2011
20110027810CHIMERIC RECOMBINANT ANTIGENS OF TOXOPLASMA GONDII - The invention described herein relates to a method for combining antigen fragments of 02-03-2011
20110027813Compositions for Binding to Assay Substrata and Methods of Using - Compositions and methods for binding to assay substrata in a stable and protective manner, thereby enhancing assay performance, are provided. The compositions comprise lyotropic materials (for example, lyotropic liquid and/or liquid crystalline materials) and may contain macromolecular standards, markers or capture compounds. The compositions are capable of binding to assay substrata such as that of chips that are employed for MALDI and SELDI mass spectroscopy analyses and plates that are used for ELISA type assays.02-03-2011
20100285509Melanoma-Associated Endogenous Retrovirus (MERV) Derived Peptide Sequences And Their Therapeutic/Diagnostic Use - The present invention provides antigenic polypeptides derived from the melanoma-associated endogenous retrovirus (MERV). These antigens are useful compounds for the detection of cancerous cells and melanoma-diagnosis as well as melanoma-prognosis. Furthermore these antigenic polypeptides of the present invention form the basis for anti-cancer vaccines.11-11-2010
20100285510MARKER FOR INFLAMMATORY CONDITIONS - Use of pregnancy-associated plasma protein-A as a marker for inflammatory conditions, and in particular, for acute coronary syndromes is described.11-11-2010
20100285508USE OF THE PROTEIN EM6 AS A PERFORMANCE MARKER FOR GERMINATION OF SEED LOTS AND APPLICATIONS THEREOF - The invention relates to the determination of the level, maintenance and/or performance of germination of a seed lot, by quantification of the protein EM6, belonging to the group of Late Embryogenesis Abundant (LEA) proteins. The present invention further relates to antibodies permitting the quantification of the protein EM6.11-11-2010
20110256561LIVER DISEASE MARKER, METHOD AND APPARATUS FOR MEASURING THE SAME, AND METHOD FOR ASSAYING PHARMACEUTICAL PREPARATION - A normal person (i.e. a control) and liver diseases such as drug induced liver injury, an asymptomatic hepatitis B carrier, an asymptomatic hepatitis C carrier, chronic hepatitis B, chronic hepatitis C, liver cancer, a nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and simple steatosis (SS) are identified by measuring the concentrations of γ-Glu-X (X represents an amino acid or an amine) peptides or the levels of AST or ALT in blood and carrying out, for example, a multiple logistic regression based on the measured value.10-20-2011
20120202226 METHOD AND SYSTEM FOR THE DETECTION OF CANCER - Disclosed are a method and kit of diagnosis of cancer in a body sample of a subject, comprising contacting the sample with at least two different suitable antigens to form at least two different complexes with antibodies present in the sample, determining the actual levels of each of said antigen-antibody complexes in said sample and establishing the ratio between the levels of the different complexes in said subject; and comparing the ratio to a predetermined ratio between antigen-antibody complexes levels formed between the same at least two antigens and samples from healthy subjects, whereby if said ratio determined in step higher or lower than a predetermined cutoff point pre-established for healthy subjects, said subject is diagnosed with cancer. The method and kit can be used for diagnosing various types of cancer, including breast, ovary, lung, prostate and colon cancer.08-09-2012
20110117584Detection of Chronic Kidney Disease Patients or Coronary Artery Disease Using Bone Morphogenic Protein-4 - The invention is a method of detecting CAD in a CKD diagnosed human patient or CKD in a CAD diagnosed human patient, or detection of the presence of both CKD and CAD by assaying a plasma or serum sample of a human patient for elevated levels of BMP-4.05-19-2011
20110117583METHOD FOR DETECTING THE EXISTENCE OF RENAL CALCULI AND/OR INFLAMMATION OF THE EXCRETORY URINARY TRACTS - A non-invasive method for detecting disease of the excretory urinary tract and presence of renal calculi is provided. According to the method, the presence or concentration of one or more TFF peptides from among TFF1, TFF2, and TFF3 is determined in a urine sample, the presence or concentration being indicative of urinary tract disease or presence of renal calculi.05-19-2011
20110256559Method for Detecting Soluble Amyloid Precursor Protein (APP) Alpha and/or Soluble APP Beta - The present invention relates to a method for detection or quantification of sAPPα and/or sAPPβ in a sample and their use for diagnosing and/or monitoring a neurodegenerative disease in a subject in need thereof and kit for use in said method.10-20-2011
20110136155PEPTIDES AND METHODS FOR THE DETECTION OF LYME DISEASE ANTIBODIES - The invention provides compositions (e.g., peptide compositions) useful for the detection of antibodies that bind to 06-09-2011
20110136154VOLTAGE-GATED METAL-ENHANCED FLUORESCENCE, CHEMILUMINESCENCE OR BIOLUMINESCENCE METHODS AND SYSTEMS - In the present invention, it is demonstrated for the first time, the influence of electrical current on the ability of surface plasmons to amplify fluorescence signatures. An applied direct current across silver island films (SiFs) of low electrical resistance perturbs the fluorescence enhancement of close-proximity fluorophores. For a given applied current, surface plasmons in “just-continuous” low resistance films are sparsely available for fluorophore dipole coupling and hence the enhanced fluorescence is gated as a function of the applied current.06-09-2011
20110136153Use of VEGF-D in the Diagnosis of Lymphangioleiomyomatosis (LAM) Disease - Described herein are methods of diagnosing lymphangioleiomyomatosis (LAM) that permits differentiating LAM from another lung disorder. Methods of treatment are also provided.06-09-2011
20100261206Peptide fragments reacting specifically with antibodies against highly pathogenic newcastle disease virus and uses thereof - We disclose synthetic peptide fragments comprising amino acid sequences of specific antigen sites of pathogenic Newcastle disease virus in birds, and more particularly synthetic peptide fragments that comprise polybasic amino acid sequences at the cleavage site of the F protein of pathogenic Newcastle disease virus and that induce humoral immune responses in hosts while reacting only with antibodies to pathogenic Newcastle disease virus and are useful to differentiate infected individuals from vaccinated individuals.10-14-2010
20100323373METHOD FOR THE ASSESSMENT OF THE INHIBITORY ACTIVITY OF ANTIBODIES AGAINST INSULIN-LIKE GROWTH FACTOR I RECEPTOR - A method for the assessment of the inhibitory activity of an antibody for inhibiting the binding of IGF-1 and/or IGF-2 to IGF-1R in a lysed PBL sample of a mammal which has been treated with said antibody, characterized in that the IGF-1R protein level of said PBLs is measured as a measure for the inhibitory activity of said antibody.12-23-2010
20110081668BIOMARKERS ASSOCIATED WITH NEPHROPATHY - Use of urine biomarkers for diagnosing nephropathy, monitoring nephropathy progress, and assessing efficacy of a nephropathy treatment. These urine biomarkers include leukocyte-associated Ig-like receptor-2, alpha-1 acid glycoprotein, their fragments, and combinations thereof.04-07-2011
20090197287SYSTEMS AND METHODS FOR CHARACTERIZING KIDNEY DISEASE - The present invention relates to methods of diagnosing, predicting and monitoring kidney disorders. In particular, the present invention relates to the diagnosis, prediction and monitoring of kidney disorders by detection of cytokines, cytokine-related compounds and chemokines in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat kidney disorders.08-06-2009
20100167318Fluidic Structures Including Meandering and Wide Channels - The present invention relates generally to microfluidic structures, and more specifically, to microfluidic structures and methods including meandering and wide channels. Microfluidic systems can provide an advantageous environment for performing various reactions and analyses due to a reduction in sample and reagent quantities that are required, a reduction in the size of the operating system, and a decrease in reaction time compared to conventional systems. Unfortunately, the small size of microfluidic channels can sometimes result in difficulty in detecting a species without magnifying optics (such as a microscope or a photomultiplier). A series of tightly packed microchannels, i.e., a meandering region, or a wide channel having a dimension on the order of millimeters, can serve as a solution to this problem by creating a wide measurement area. Although this invention mainly describes the use of meandering and wide channels in heterogeneous immunoassays on a microfluidic chip, this invention could be used for amplifying optical signals for other types of reactions and/or assays.07-01-2010
20100159487Assay system - An assay apparatus comprising: i) an assay cartridge (06-24-2010
20100159489PROMOTER - The current invention reports a promoter having the nucleic acid sequence of SEQ ID NO: 02, or SEQ ID NO: 03, or SEQ ID NO: 04, or SEQ ID NO: 06, which is a 5′ shortened SV40 promoter with reduced promoter strength especially useful for the limited expression of heterologous polypeptides or selectable markers.06-24-2010
20100196933Recombinant Polypeptides for Diagnosing Infection with Trypanosoma Cruzi - Recombinant polypeptides are disclosed that are useful for diagnosing American trypanosomiasis, or Chagas disease, a disease caused by the infectious agent 08-05-2010
20100196936METHOD AND KIT FOR DETECTING CANCER - A method for detecting cancer is disclosed. The method includes the steps of: (1) obtaining a test sample of body fluid from a subject; (2) measuring a calsyntenin-1 (CLSTN-1) level in the test sample of body fluid in vitro; and determining if the CLSTN-1 level in the test sample of body fluid is significantly higher than a normal CLSTN-1 level in a sample of body fluid from a healthy population of the same species as the subject, and if yes, indicating that the subject under test has cancer. Methods for monitoring therapeutic efficacy of a therapy or a medicament for treating a cancer patient and for identifying efficacy of a medicament in treatment of cancer are disclosed, and a kit for use in the aforesaid methods is also provided.08-05-2010
20100120074Methods and Kits for Detection of Cancer Metastasis - The invention provides a method of detecting metastasis of cancers in the body fluids from a mammal, the method comprising the steps of: (a) providing the body fluids from the mammal; and (b) the measurement of the CAS protein level or CAS polypeptide level in the body fluids to screen or diagnose the metastatic cancers.05-13-2010
20100047829ACTIVATED HER3 AS A MARKER FOR PREDICTING THERAPEUTIC EFFICACY - The present invention provides methods for the determination of the activation level of Receptor Tyrosine kinases, e.g. phosporylated HER3, for the selection of patients for disease treatment. Methods are also provided for the evaluation of the biological and pharmacodynamic effects of an active substance and/or its efficacy in disease treatment, utilizing a tissue sample from a test subject, for example tumor material or normal tissue such as skin or hair follicle. Further, methods for the treatment of HER receptor-associated diseases are disclosed.02-25-2010
20120178111METHODS AND COMPOSITIONS FOR THE DETECTION OF LUNG CANCERS - A method of screening for, diagnosing or detecting lung cancer in a subject, the method comprising: a) determining a level of a biomarker or a plurality of biomarkers in a sample from the subject, wherein the biomarker(s) is/are selected from the biomarkers listed in Table 8, and b) comparing the level of each biomarker in the sample with a control; wherein an increased level of any one of the biomarkers compared to the control is indicative that the subject has lung cancer Biomarkers were identified by shot-gun proteomics analysis of lung cancer cell-lines H1688, H520, H460 and H23. These lines are of differing histo-types, and were grown on serum-free media.07-12-2012
20120178107HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha - Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. These antibodies have high affinity for hTNFα (e.g., K07-12-2012
20090197286Methods and Kit for Diagnosing T1DM - A method of diagnosing Type 1 Diabetes Mellitus (T1DM) in a subject in need thereof is provided. The method comprising determining a presence and/or a level of antibodies in a biological sample of the subject, wherein the presence or level above a predetermined threshold is indicative of T1DM, thereby diagnosing T1DM in the subject. Also provided are a kit for diagnosing T1DM and a method of monitoring anti diabetic treatment.08-06-2009
20090176258TEST FOR THE DETECTION OF PATHOLOGICAL PRIONS - The am of the invention is to create a method for detecting pathological prions which is highly sensitive, can be carried out quickly and at a low cost, and allows prions to be detected at an early stage of a disease. Said aim is achieved by the fact that immobilized capture antibodies bind the pathological and non-pathological form of the prion protein contained in a sample whereupon the bound non-pathological form is specifically divided by means of plasmin. The undivided, pathological form of the prion protein, which is bound by the immobilized capture antibodies, can then be easily detected with the aid of detection antibodies. The inventive method is used for detecting pathological prions.07-09-2009
20090176257Methods and Biomarkers for Diagnosing and Monitoring Psychotic Disorders - The invention relates to methods of diagnosing or monitoring a psychotic disorder in a subject comprising providing a test biological sample from the subject, performing spectral analysis on said test biological sample to provide one or more spectra, and, comparing the one or more spectra with one or more control spectra. The invention also relates to methods for diagnosing or monitoring psychotic disorders such as schizophrenic or bipolar disorders, comprising measuring the level of one or more biomarkers present in a biological sample taken from a test subject, said biomarkers being selected from the group consisting of transthyretin, ApoA1: VLDL, LDL and aromatic species such as plasma proteins. The invention also relates to sensors, biosensors, multi-analyte panels, arrays, assays and kits for performing methods of the invention.07-09-2009
20110189705Immunoassay - The invention provides a highly sensitive immunoassay for detection of a biological species. The immunoassay comprises exposing an electrode to an analyte liquid putatively containing the biological species so as to couple the biological species, if present in the analyte liquid, to a binding antibody on the electrode. The electrode comprises a binding antibody and an anchor group, each being coupled to an electrically conductive substrate, said binding antibody being capable of binding to the biological species and said anchor group being capable of binding to a redox polymer. The electrode is then exposed to an antibody-enzyme liquid comprising an antibody-enzyme species, said antibody-enzyme species comprising a detection antibody capable of binding to the biological species, said detection antibody being coupled to a redox enzyme, whereby, if the analyte liquid comprises the biological species, the redox enzyme couples to the electrode by means of the coupling of both the detection antibody and the binding antibody to the biological species. The electrode is then exposed to a polymer solution comprising the redox polymer and to an enzyme substrate, whereby if the redox enzyme is coupled to the anchor group on the electrode the redox polymer is reduced and couples to the anchor group on the electrode. A voltage is then applied between the electrode and a reference electrode and the electrode is exposed to an oxidisable species, whereby a magnitude of an electric current between said electrode and a reference electrode is indicative of the presence or absence of the biological species.08-04-2011
20100190190FOOD SENSITIVITY TESTING IN ANIMALS - Diagnosing an immunologic food sensitivity or intolerance in companion animals comprises collecting a sample; screening the sample to detect the presence of an antibody to a particular food ingredient or composition. The sample can be serum, saliva or other bodily fluid to detect the presence of an IgA, IgM or IgG antibody or immune complex to a particular food ingredient or composition. The food ingredient for which sensitivity or intolerance is tested is contained in at least one of a preprocessed food composition, balanced diet or recipe. Offending ingredient(s) in a preprocessed food composition, balanced diet or recipe is determined. An assessment is made as to whether it is possible to use a different preprocessed food composition, balanced diet or recipe, or whether a special diet needs to be formulated without the offending ingredient(s).07-29-2010
20120309033METHOD FOR DETECTING AN ANTIGEN - The present invention relates to a method for detecting an antigen with use of an antibody and an enzyme. Specifically, the present invention provides a method for detecting an antigen without use of a labeled-antibody. the method comprises immersing particles in a first buffer solution which is predicted to contain the antigen; wherein an antibody and a multi-copper oxidase CueO are immobilized on each surface of the particles, and the antibody reacts specifically with the antigen. The method further comprises the following steps recovering the obtained particles; mixing the particles recovered, an oxidation-reduction indicator (reductant), and a second buffer solution so as to prepare a reaction solution; measuring an activity degree of the multi-copper oxidase CueO contained in the reaction solution; determining that the first buffer solution contains the antigen based on the above activity degree.12-06-2012
20120309032Animal Model Having a Chimeric Human Liver and Suceptible to Human Hepatitis C Virus Infection - The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.12-06-2012
20110189707Goodpasture Antigen Binding Protein and its Detection - The present invention provides native Goodpasture antigen binding protein isoforms, monoclonal antibodies directed against such proteins, and methods for their use.08-04-2011
20110189706PROCESS FOR THE MEASUREMENT OF THE POTENCY OF GLATIRAMER ACETATE - The subject invention provides a process for measuring the relative potency of a test batch of glatiramer acetate. In addition, the subject invention provides a process for preparing a batch of glatiramer acetate as acceptable for pharmaceutical use.08-04-2011
20110189704NON-SPECIFIC REACTION INHIBITOR - Disclosed is a non-specific reaction inhibitor for use in an immunological measurement, comprising a complex of an antibody or a fragment of the antibody capable of specifically binding to a non-specific reaction factor, and a polymer. The non-specific reaction inhibitor can inhibit a non-specific reaction which may interfere with the accurate detection or quantification of a trace substance in an immunological measurement method.08-04-2011
20110262939METHODS AND ASSAYS FOR CLASSIFYING FOODSTUFF AND/OR BEVERAGE AND/OR DIET AND/OR NUTRITION REGIMEN AND/OR MEDICAMENT IN VIEW OF AN EFFECT ON THE CARDIOVASCULAR SYSTEM - Subject of the present invention is an in vitro-method for classifying a foodstuff and/or beverage and/or diet and/or nutrition regimen and/or medicament in view of an effect on the cardiovascular system of a subject, comprising determining the relative level of one or more cardiovascular markers.10-27-2011
20100028919METHOD FOR THE EARLY DETECTION OF RENAL INJURY - A method and kit for detecting the immediate or early onset of renal disease and injury, including renal tubular cell injury, utilizing NGAL as an immediate or early on-set biomarker in a sample of blood serum. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctuate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.02-04-2010
20100028918GLUTAMINYL CYCLASE AS A DIAGNOSTIC/PROGNOSTIC INDICATOR FOR NEURODEGENERATIVE DISEASES - A method for predicting, diagnosing and prognosticating a neurodegenerative disease, such as Alzheimer's disease (AD), Mild Cognitive Impairment (MCI) and neurodegeneration in Down's syndrome (NDS) using glutaminyl cyclase (QC) as a diagnostic/prognostic indicator. The use of antibodies binding to QC and kits for performing said diagnostic method are also provided.02-04-2010
20100028917A NEUROGLOBIN ENZYME-LINKED IMMUNOSORBENT ASSAY KIT AND THE USE OF IT - The invention discloses a Neuroglobin enzyme-linked immunosorbent assay kit and the use of it. The Neuroglobin enzyme-linked immunosorbent assay kit provided by the invention includes Neuroglobin polyclonal antibody, Neuroglobin monoclonal antibody and enzyme labeled antibody. Neuroglobin monoclonal antibody is produced through culturing hybridoma cells prepared by cell conjugation after inoculating mice with Neuroglobin antigen, whereas Neuroglobin polyclonal antibody is produced from animal antiserum after inoculating with Neuroglobin antigen.02-04-2010
20100021946METHOD FOR PREPARING STANDARD SERUM MIXTURE FOR DETERMINING ALLERGEN ACTIVITY AND THE USE THEREOF - A method for preparing standardized serum mixture for determining allergen potency which comprises: 1) providing multiple serum samples from patients moderately hypersensitive to said allergen; 2) determining the relative content of sIgE against said allergen in each serum sample, obtaining the mean value of the relative content of sIgE of said multiple serum samples, and obtaining deviation value of the relative content of sIgE of each serum with respect to said mean value; 3) removing at least 5% of serum samples that have the largest and smallest deviation values respectively, and mixing the residual sera in the same volume. A serum mixture prepared by the method as well as the use of such serum mixture are also described.01-28-2010
20100021945DETERMINATION OF CHANGES IN CONCENTRATION - The invention relates to the field of macrocyclic host systems and fluorescent dyes. In particular, the invention relates to apparatuses and methods for determining a change in the concentration of an analyte, in particular as a result of a catalysed reaction, preferably an enzymatically catalysed reaction and preferably in an aqueous solution (>50% by weight water).01-28-2010
20100112605Biomarker for the Medicine and the Biology of the Reproduction - The present invention relates to a new biomarker for the medicine and the biology of reproduction, in particular for in vitro fertilization (IVF) outcome. It relates to methods for predicting IVF outcome and for selecting the subject for IVF.05-06-2010
20110059472REAGENTS AND METHODS FOR DETECTING INFLUENZA VIRUS PROTEINS - Antibodies that specifically bind to a peptide having an amino acid sequence as found at the N-terminus of the HA2 fusion peptide of the influenza A virus may be raised by inoculating a mammal with a conjugate of the peptide. In one embodiment, the conjugate comprises the peptide linked to a spacer (e.g. 6-aminocaproic acid) and a carrier protein (e.g. KLH). The antibodies may be used as a universal reagent for detecting HA proteins of influenza viruses. The antibodies are useful as versatile reagents for laboratory research and vaccine potency determination, especially in the event of pandemic influenza outbreaks.03-10-2011
20110097751GLP-1 RECEPTOR AGONIST BIOASSAYS - Provided herein are cell-based bioassays for measuring GLP-I receptor agonist activity of test compounds, such as GLP-I receptor agonist compounds. Exemplary GLP-I receptor agonist compounds include exendins, exendin analogs, GLP-1(7-37), and GLP-1(7-37) analogs. The bioassays are useful for quantitatively determining cAMP generated in samples containing GLP-I receptor agonist compounds (e.g., exenatide) and 6-23 (clone 6) cells having GLP-I receptors, whereby the amount of cAMP generated can be correlated to the GLP-I receptor agonist activity of the GLP-I receptor agonist compounds (e.g., exenatide). Suitable cell-based bioassays include enzyme-linked immunosorbent assays and homogeneous time-resolved fluorescence assays.04-28-2011
20100291602CLINICAL DIAGNOSIS OF HEPATIC FIBROSIS USING A NOVEL PANEL OF LOW ABUNDANT HUMAN PLASMA PROTEIN BIOMARKERS - The inventors have proposed a novel panel of human plasma protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis. A 2D-PAGE based proteomics study was used to identify potential fibrosis biomarkers. Plasma from patients with hepatic cirrhosis induced by infection with the hepatitis C virus (HCV) were analysed. Several proteins associated with liver scarring and potentially also related to viral infection were identified. These proteins include 14-3-3 protein zeta/delta, adiponectin, afamin, alpha-1-antitrypsin, alpha-2-HS-glycoprotein, apolipoprotein C-III, apolipoprotein E, C4b-binding protein beta chain, intact/cleaved complement C3dg, corticosteroid-binding globulin, fibrinogen gamma chain, beta haptoglobin at pH 5.46-5.49, haptoglobin-related protein, hemopexin, immunoglobulin J chain, leucine-rich alpha-2-glycoprotein, lipid transfer inhibitor protein, retinol-binding protein 4, serum paraoxonase/arylesterase 1, sex hormone-binding globulin and zinc-alpha-2-glycoprotein. These biomarkers can be used in conjunction with polypeptides in WO/2008/031051. The concentrations of these novel biomarkers can be determined using an immunoassay where the concentrations would reflect the extent of fibrosis. A fibrosis scoring scale for each of the novel biomarkers is proposed. The additive result from the scores of all the novel biomarkers would give a more reliable indication of the degree of fibrosis rather than examining individual biomarkers.11-18-2010
20090275062METHOD OF TACROLIMUS EXTRACTION AND QUANTIFICATION USING AQUEOUS DETERGENTS - The present invention relates to a method of extracting tacrolimus in a test blood sample to use in a tacrolimus quantification assay. The method of the present invention extracts tacrolimus in non-precipitating, non-denaturing aqueous environment, avoiding cumbersome manual pretreatment procedures or the use of organic solvents. The method of the present invention permits full automation of tacrolimus quantification assays.11-05-2009
20080280310Testing for Blood Group Immunological Reaction Without the Use of Anti-Human Globulin - A method testing for blood antigens (known as forward blood grouping) is presented wherein known antibodies are attached to a solid surface and the red blood cell sample for immunological reaction is centrifuged to physically overcome the natural repellent force between two red cells (know in the industry as the zeta potential) and to allow for the antigen antibody reaction to occur more rapidly. A reverse blood grouping procedure utilizes synthetic or purified antigens, which are attached directly attached directly to a solid surface. The surface is then contacted with the patient's serum and then centrifuged to allow the antigen antibody reaction to occur. The cells are then washed and a second labeled antibody of known concentration is added as an indicator. This is a method of performing a major crossmatch that does not utilize anti-human immunoglobin. In an alternative major crossmatch procedure, a binder is used to attach red blood cell membranes from a blood donor and the serum from a recipient is allowed to undergo an immune reaction with these membranes on the solid surface. Antibody screening and antibody identification are carried out by attaching known antigen carrying cells to a solid surface. The solid surface is contacted with the unknown solution which will undergo an immune reaction to the extent that antibodies specific to the previously adhered antigens are present and will bind. Red blood cells or synthetic labeled particles are used as the indicator mechanism.11-13-2008
20100055723Galectin-3-Binding Protein as a Biomarker of Cardiovascular Disease - The present invention provides compositions and methods for using biomarkers to diagnose and monitor cardiovascular associated diseases and disorders. More specifically, the present invention provides Galectin-3-binding protein as a biomarker for disease.03-04-2010
20100240077METHODS OF ASSESSING CROHN'S DISEASE PATIENT PHENOTYPE BY I2 SEROLOGIC RESPONSE - The invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease in a subject having Crohn's disease by determining the presence or absence of IgA anti-I2 antibodies in the subject, where the presence of the IgA anti-I2 antibodies indicates that the subject has a clinical subtype of Crohn's disease. In one embodiment, a method of the invention is practiced by further determining the presence or absence in the subject of a NOD2 variant, anti-09-23-2010
20090291461METHOD OF SELECTIVELY ASSAYING ADIPONECTIN MULTIMERS - Kits and methods for selectively assaying a target adiponectin multimer in a biological sample. Such methods accurately evaluate the relationship between a disease and adiponectin through selective assay of adiponectin multimers and provide information that cannot be obtained through measurement of the total amount of adiponectin alone. A method for selectively assaying a target adiponectin multimer in a biological sample comprising distinguishing target adiponectin multimer from the other adiponectin multimers by using a protease and/or an antibody.11-26-2009
20110045508Urinary CA125 Peptides as Biomarkers of Ovarian Cancer - The present invention is directed to diagnostic methods based upon the detection of peptides derived from the degradation of CA125. In particular, it is concerned with assays of urine samples collected from women for the purpose of determining whether they are at increased risk for having ovarian cancer, have decreased their risk as the result of clinical or non-clinical procedures, to monitor the efficacy of a treatment method, or to determine whether cancer has recurred or advanced.02-24-2011
20100129838METHODS FOR PREDICTION OF INFLAMMATORY BOWEL DISEASE (IBD) USING SEROLOGIC MARKERS - The present invention provides methods, systems, and code for accurately classifying whether a sample from a pediatric individual is associated with inflammatory bowel disease (IBD) or a clinical subtype thereof. In particular, the present invention is useful for classifying a sample from a pediatric individual as an IBD sample using a statistical algorithm and/or empirical data. The present invention is also useful for differentiating between a clinical subtype of IBD such as Crohn's disease (CD) and ulcerative colitis (UC) using a statistical algorithm and/or empirical data. Thus, the present invention provides an accurate diagnostic prediction of IBD or a clinical subtype thereof and prognostic information useful for guiding treatment decisions.05-27-2010
20110008808BIOMARKERS - The invention provides binding agents and assays for ghrelin signal peptide. The agents and assays are useful in methods for predicting, diagnosing, assessing or monitoring acute cardiac disorders, glucose handling disorders and diabetes in a subject. Also provided are nucleotides, polypeptides, and kits useful in the methods of the invention.01-13-2011
20090004680DETERMINING AND REDUCING IMMUNORESISTANCE TO BOTULINUM TOXIN THERAPY USING BOTULINUM TOXIN A PEPTIDES - The present invention provides BoNT/A peptide compositions, tolerogizing compositions, BoNT/A immune response inducing compositions and antibody compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of preventing or reducing immunoresistance to botulinum toxin therapy in an individual, methods of vaccinating an individual against botulinum toxin, methods of preparing anti-BoNT/A antibodies, methods of treating botulinum toxicity in an individual and methods of reducing anti-botulinum toxin antibodies in an individual.01-01-2009
20120040378Meprobromate Immunoassay - Carisoprodol is a centrally-acting prescription drug of known abuse. Upon ingestion it is rapidly metabolised to meprobamate, also a prescription drug with abuse potential. Current immunoassays are specific for carisoprodol and therefore have a short window of detection and, furthermore, are ineffective at detecting meprobamate. The current invention, underpinned by an antibody specific for meprobamate, overcomes these deficiencies.02-16-2012
20120040376LUNG CANCER DIAGNOSTIC POLYPEPTIDE, METHOD FOR DETECTING LUNG CANCER, AND METHOD FOR EVALUATING THERAPEUTIC EFFECT - A novel biomarker for use in lung cancer diagnosis is provided.02-16-2012
20110008804ANGIOPOIETIN-1 AND -2 BIOMARKERS FOR INFECTIOUS DISEASES THAT COMPROMISE ENDOTHELIAL INTEGRITY - The invention relates to a method of identifying a subject having, or at risk of developing, an infectious disease state wherein endothelial integrity is compromised comprising: (a) determining a test ANG-1 level in a sample from a subject; and (b) comparing the test ANG-1 level to a control level wherein lower test ANG-1 level compared to the control level is indicative of the subject developing said infectious disease state.01-13-2011
20080305505Method For Dissolution Testing of Pharmaceutical Products - The present invention relates to the field of dissolution measurement and, more particularly to methods for reproducible dissolution testing of pharmaceutical products such as allergen vaccines.12-11-2008
20080274483Method for Diagnosing Renal Disorder, Hemolytic Uremic Syndrome and Enterohemorrhagic Infectious Disease Caused by Escherichia Coli - Methods for diagnosing renal disorder, hemolytic uremic syndrome and enterohemorrhagic 11-06-2008
20100055724METHODS OF DETECTING AUTOANTIBODIES FOR DIAGNOSING AND CHARACTERIZING DISORDERS - Methods for detecting and/or quantitating levels of autoantibodies in subjects are provided. Methods for diagnosing and/or characterizing a disorder associated with autoantibody production are further provided. In some embodiments, the disorder diagnosed and/or characterized can be a cancer or an infertility disorder.03-04-2010
20110065133O-ring Systems and Methods for Quantification of Multiplex Biomarkers in Multiple Samples - Kits and methods of using O-rings having apertures are provided herein. O-rings are useful for incubating with a sample fluid potentially having one or more biomarkers, in order to detect the presence of the biomarkers. O-rings can be readily organized in a trackable manner prior to and during incubation with the sample fluid. O-rings can also be readily transferred and organized into one or more trackable arrays for detecting the presence of bound biomarkers and measuring the signaling product generated by bound detect molecule-linked enzymes present in a homogeneous solution with a spectrophotometer.03-17-2011
20110306068Method For Detecting And Removing Endotoxin - The present invention relates to bacteriophage tail proteins and the derivatives and fragments thereof that are capable of binding endotoxins in the absence of bivalent positive ions, especially Ca12-15-2011
20110306069Corin As A Marker For Heart Failure - The invention is a method of assessing whether an individual is afflicted with congestive heart failure (CHF) comprising comparing the level of corin or portion thereof in the individual to the level of corin or portion thereof in a control, wherein a decrease in the level of corin or portion thereof in the individual compared to the level of corin or portion thereof in the control indicates that the individual is afflicted with CHF. The methods described herein can be also be used to determine the severity of CHF in an individual, whether an individual's treatment for CHF is effective and whether an individual is at risk of developing CHF.12-15-2011
20130011863Follistatin-Like Protein-1 as a Biomarker for Sepsis - The present invention relates to methods and kits for diagnosing systemic inflammatory response syndrome or sepsis using levels of FSTL-1.01-10-2013
20110306067Antibody Profiles Characteristic of Tuberculosis State - Serum antibody assays capable of distinguishing cases of inactive TB from cases of active TB include a combination at least three 12-15-2011
20100267061DETECTING PHOSPHOLIPIDOSIS AND DIAGNOSING LYSOSOMAL STORAGE DISORDERS - Disclosed are methods for evaluating the potential or activity of a test compound to induce phospholipidosis in a target subject, for managing patient treatment, and for diagnosing a lysosomal storage disorder in a human subject.10-21-2010
20080318257Polynucelotides encoding novel variants of the TRP channel family member, LTRPC3 - The present invention provides novel polynucleotides encoding LTRPC3g, LTRPC3h, LTRPC3i, LTRPC3j, LTRPC3k, or LTRPC3l polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel LTRPC3g, LTRPC3h, LTRPC3i, LTRPC3j, LTRPC3k, or LTRPC3l polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.12-25-2008
20090286266Method of Determining The Sex of Birds, Reptiles and Mammals Using Steroid Hormones - The present invention consists in the design of an ELISA test, specific to determine through fecal feces, urine or plasma of birds, reptiles and mammals, the levels of concentration of the hormone testosterone as an indicator of masculine sex in these species for a better handling of the reproduction and the production of birds, reptiles and mammals. The procedure can be applied for practical purposes in any commercial operation that involves these species. With this method a greater efficiency and economic return is obtained, which reports improvement and greater benefits to the producers.11-19-2009
20110033876METHOD FOR DIAGNOSING PULMONARY ARTERY HYPERTENSION - The invention relates to an in vitro method for detecting pulmonary arterial hypertension (PAHT), or the risk of developing PAHT, which includes determining the presence and/or amount of anti-tenascin C antibodies in a biological sample from a patient.02-10-2011
20120149041IDENTIFICATION AND QUANTIFICATION OF BIOMARKERS FOR EVALUATING THE RISK OF PRETERM BIRTH - Described herein are methods for evaluating the risk of preterm birth in pregnant subjects. The methods involve detecting and quantifying a first biomarker and a second biomarker associated with preterm birth in a biological sample from the subject. Also described herein are isolated biomarkers and kits useful in predicting the risk of preterm birth.06-14-2012
20120301904MULTIPROTEIN ASSEMBLIES - The present invention provides compositions and methods of use in investigations of the formation of mulitprotein assemblies implicated in disease. Also provided are assays for screening candidate compounds of potential utility in preventing and/or treating such diseases by preventing the assembly of or disrupting the function of multiprotein assemblies.11-29-2012
20120301903Microfluidic Devices and Methods of Manufacture and Use - Series of bio-detection elements, shown as short hollow transparent reaction vessels (11-29-2012
20120301901GEMCITABINE IMMUNOASSAY - The present invention comprises novel analogs of gemcitabine and novel gemcitabine immunogens leased out of, i.e., derived from, the 5′-hydroxy position of gemcitabine. The invention also comprises unique monoclonal antibodies generated using gemcitabine linked immunogens as well as unique conjugates and tracers which antibodies, conjugates, and tracers are useful in immunoassays for the quantification and monitoring of gemcitabine in biological fluids.11-29-2012
20090111130METHOD OF EXAMINING PREGNANCY TOXEMIA - It is intended to provide a method of detecting the onset of pregnancy toxemia whereby the onset risk of pregnancy toxemia can be adequately evaluated. Namely, a method of detecting the onset of pregnancy toxemia in a pregnant mammal which comprises the measurement step of measuring the concentration of angiopoietin-2 in a body fluid, the comparison step of comparing the angiopoietin-2 concentration obtained in the above measurement step with a normal level, and the judgment step of judging the presence or absence of the onset risk of pregnancy toxemia based on the results of the above comparison step. In the judgment step, it may be considered that the patient has a risk of the onset of pregnancy toxemia in the case where the angiopoietin-2 concentration obtained in the measurement step is lower than the normal level.04-30-2009
20110318764METHOD FOR DETECTING MUSCLE DEGENERATIVE DISEASES, AND METHOD FOR DETERMINING THERAPEUTIC EFFICACY ON THE DISEASES - Muscle degenerative diseases can be detected in the early stage and the therapeutic efficacy of a therapeutic agent and/or a therapy method for the diseases can be determined by measuring 11,15-dioxo-9α-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid (referred to as “Tetranor-PGDM”, hereinbelow) in a sample isolated from a subject.12-29-2011
20110318762Graft-Versus-Host Disease Predicting Marker and Use Thereof - A test method that provides data useful in predicting the probability of onset of acute graft-versus-host disease (GVHD) is described along with a kit for performing the method, and a pharmaceutical preparation and a molecular targeted therapy for treating or preventing GVHD. The test method includes measuring the blood DNAM-1 concentration of a patient of hematopoietic stem cell transplantation from bone marrow or the like over a period after the transplantation to provide data concerning the transition of the concentration to an abnormally high level deviating from the normal range, whereby the probability of the development of acute graft-versus-host disease is predicted, the risk of the development is estimated, or therapeutic effects after the development are evaluated. Concerning the molecular targeted therapy and pharmaceutical preparation used therefor wherein blood DNAM-1 of a GVHD patient or a graft recipient that is a possible patient is used as a target molecule, GVHD is treated or prevented by administering an anti-DNAM-1 antibody that is a neutralizing antibody.12-29-2011
20110318761METHODS AND KITS FOR PREDICTING A RESPONSE TO AN ERYTHROPOIETIC AGENT - Methods for predicting a response to an erythropoietic agent in a subject include providing a biological sample from the subject, and determining an amount in the sample of at least one peptide selected from the group consisting of SEQ ID NOS: 1-17. If there is a measurable difference in the amount of the at least one peptide in the sample, when compared to a control level of the same peptide, the subject is then predicted to have a good response or a poor response to the erythropoietic agent. Kits for predicting a response to an erythropoietic agent are further provided and include one or more antibodies, or fragments thereof, that specifically recognize a peptide of SEQ ID NOS: 1-17.12-29-2011
20110318759METHOD FOR ASSAYING KERATAN SULFATE, ASSAY KIT THEREFOR AND METHOD FOR DETECTING JOINT DISEASE BY USING THE SAME - The inventions provides a method for immunologically determining a keratan sulfate level which method includes bringing an anti-keratan sulfate monoclonal antibody into contact with a biological sample, the anti-keratan sulfate monoclonal antibody exhibiting a relative reaction specificity between keratan sulfate-I and keratan sulfate-II represented by IC5012-29-2011
20110318758HUMAN MONOCLONAL ANTIBODIES AND METHODS FOR PRODUCING THE SAME - The present invention provides for methods of producing human monoclonal antibodies against a wide variety of antigens including bacterial and viral antigens, as well as tumor antigens, and various autoantigens. Also provided are the antibodies themselves, nucleic acids encoding such antibodies, cells producing such antibodies, and methods of using such antibodies for diagnostic assays and passive immunity against disease states such as infection and cancer.12-29-2011
20110318760METHOD FOR THE IN VITRO DIAGNOSIS OF AN AUTOIMMUNE RESPONSE ASSOCIATED WITH THE EXISTENCE OF AN ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES-ASSOCIATED VASCULITIS BY DETECTION OF ANTIBODIES DIRECTED AGAINST THE PENTRAXIN 3 ANTIGEN - A method for the in vitro diagnosis of an autoimmune immune response in an individual by detection, in a biological fluid from said individual, of antibodies directed against the pentraxin 3 (PTX3) antigen, characterized in that the presence of antibodies directed against the PTX3 antigen (anti-PTX3 antibodies) are determined in a biological fluid from the individual, and kits for implementing the method.12-29-2011
20120045781PATHOLOGY BIOMARKER ASSAY - Methods of diagnosis or of quantitation of pathological conditions comprise conducting an immunoassay to measure neo-epitope containing protein fragments naturally present in a biofluid sample, and associating an elevation of said measure in said patient above a normal level with the presence or extent of pathology. The immunoassay is conducted by a method comprising: contacting protein fragments naturally present in said sample with an immunological binding partner reactive with a neo-epitope formed by cleavage of a protein by a proteinase and measuring the extent of binding of peptide fragments to said immunological binding partner to measure therein protein fragments comprising said neo-epitope. Neo-epitopes from, collagen type I, collagen type III, collagen type IV, collagen type V, collagen type VI, elastin, biglycan, decorin, lumican, versican, C-reactive protein, ApoE and laminins are described.02-23-2012
20120045780SIGNAL BIOMARKERS - Diagnostics relating to C-type natriuretic and erythropoietin signal peptides and fragments, and kits, uses and applications therefor.02-23-2012
20120045779METHOD FOR DIAGNOSING ENDOMETRIOSIS AND DIAGNOSTIC KIT FOR ENDOMETRIOSIS - It is an object of the present invention to provide: a method for determining endometriosis, in which a blood sample from a subject can be used, and which is capable of determining endometriosis with higher sensitivity and higher precision than those of a conventional method using only a conventional endometriosis marker such as CA125; and a diagnostic kit for carrying out the method of the present invention. The method for determining endometriosis according to the present invention comprises: a step of analyzing an expression of at least one selected from among an anti-syntaxin autoantibody, an anti-PDIK1L autoantibody and an anti-enolase autoantibody; and a step of determining the presence or absence of the onset of endometriosis based on results of said expression analysis.02-23-2012
20120045778ELISA FOR HAPTOGLOBIN-MATRIX METALLOPROTEINASE 9 COMPLEX AS A DIAGNOSTIC TEST FOR CONDITIONS INCLUDING ACUTE INFLAMMATION - A method for detecting a haptoglobin-matrix metalloproteinase 9 (Hp-MMP9) complex in a biological sample. The sample includes incubating the biological sample with a capture reagent immobilized on a solid support to bind Hp-MMP9 to the capture reagent. The capture reagent includes a monoclonal antibody that binds MMP9. The method detects Hp-MMP9 bound to the immobilized capture reagent by contacting the bound Hp-MMP9 with a detectable antibody that binds to Hp.02-23-2012
20120003671METHODS FOR ANTIBODY ENGINEERING - The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications.01-05-2012
20120003674Chloral Hydrate Detection - The invention relates to an immunoassay method and kit for the indirect detection of chloral hydrate. The invention is underpinned by a novel immunogen that produces an antibody that is specific for the chloral hydrate metabolite trichloroethanol glucuronide. Detection and quantification of trichloroethanol glucuronide has important applications in clinical toxicology, drug facilitated crime, water testing and solvent exposure.01-05-2012
20120003673Screening method, composition containing substance selected by the screening method, and binding substance - Disclosed is a screening method which can select a substance having an influence on the binding between thioredoxin and MIF. The screening method is characterized in that a test substance capable of enhancing the binding between a polypeptide belonging to the thioredoxin family and a macrophage migration inhibitory factor is selected through the steps of mixing at least one binding substance selected from the substances (1) to (4) shown below with the test substance, allowing the binding substance to bind to the macrophage migration inhibitory factor, and confirming the binding between the binding substance and the macrophage migration inhibitory factor: (1) a polypeptide belonging to the thioredoxin family; (2) a protein which comprises an amino acid sequence produced by deleting, substituting or adding one or several amino acid residues in an amino acid sequence for a polypeptide belonging to the thioredoxin family and has the same activity as that of a polypeptide belonging to the thioredoxin family; (3) a gene encoding the polypeptide (1); and (4) a gene encoding the protein (2).01-05-2012
20120003672IN VITRO-METHOD FOR THE DIAGNOSIS, PROGNOSIS, MONITORING AND THERAPY FOLLOW-UP OF DISORDERS ASSOCIATED WITH THE METABOLIC SYNDROME, A CARDIOVASCULAR DISEASE AND/OR INSULIN RESISTANCE - The present invention relates to an in vitro-method for diagnosis, prognosis and/or monitoring/therapy follow-up of a disorder of the metabolic system and/or cardiovascular system and/or insulin resistance in a subject, comprising the determination of the relative level of one or more cardiovascular markers in a sample of a subject and the use of the determined relative level of said one or more cardiovascular peptides for the diagnosis, prognosis and/or monitoring/therapy follow-up of a disorder of the metabolic system and/or cardiovascular system and/or insulin resistance in said subject.01-05-2012
20120064547DIAGNOSTIC ANTIBODY ASSAY - Novel diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.03-15-2012
20090017478HIGH-THROUGHPUT ENZYME-LINKED IMMUNO ABSORBENT ASSAY (ELISA) FOR DETERMINATION OF RHO-KINASE (ROK) ACTIVITY - The invention is referring to an assay for measuring the activity of a ROK (Rho Kinase) protein by means of a biotinylated peptide.01-15-2009
20090311725POLYPEPTIDE PRODUCING CELLS - The current invention describes a nucleic acid comprising in a 5′ to 3′ direction a) a first nucleic acid encoding a heterologous polypeptide without an in frame stop codon, b) a second nucleic acid beginning with a 5′ splice donor site and terminated by a 3′ splice acceptor site comprising an in frame translational stop codon and a polyadenylation signal, and c) a nucleic acid encoding i) at least a fragment of a transmembrane domain, or ii) a signal peptide for a GPI-anchor.12-17-2009
20100291598PRION ELISA - Assays for detecting PrP11-18-2010
20090170137DETERMINING CANINE proBNP - Methods and compositions are disclosed for determining canine proBNP or fragments thereof in a sample. In one method, canine proBNP or fragments thereof are determined by providing a canine sample, contacting the sample with at least one antibody that binds an epitope in the region from amino acids 1 to 22 of canine proBNP, and determining the presence of the canine proBNP or fragments thereof present in the sample. Antibodies that bind canine proBNP and kits comprising such antibodies are also disclosed.07-02-2009
20120208213Detection of Synthetic Cannabinoids - The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and CP families. Unique antibodies derived from novel immunogens enable said methods and kits.08-16-2012
20120009605NEW ASSAYS FOR PREIMPLANTATION FACTOR AND PREIMPLANTATION FACTOR PEPTIDES - The present invention relates to assay methods used for detecting the presence of PIF, and to PIF peptides identified using this assay. In particular, the present invention relates to flow cytometry assays for detecting PIF. It is based, at least in part, on the observation that flow cytometry using fluorescently labeled anti-lymphocyte and anti-platelet antibodies demonstrated an increase in rosette formation in the presence of PIF. It is further based on the observation that flow cytometry demonstrated that monoclonal antibody binding to CD2 decreased in the presence of PIF. The present invention further relates to PIF peptides which, when added to Jurkat cell cultures, have been observed to either (i) decrease binding of anti-CD2 antibody to Jurkat cells; (ii) increase expression of CD2 in Jurkat cells; or (iii) decrease Jurkat cell viability. In additional embodiments, the present invention provides for ELISA assays which detect PIF by determining the effect of a test sample on the binding of anti-CD2 antibody to a CD2 substrate.01-12-2012
20120009604USE OF GRF1 PROTEIN FOR SCREENING MOLECULES - The invention concerns the use of whole or part of the GRF1 protein, or of cells expressing whole or part of the GRF1 protein, in methods for detecting compounds for preventing and/or treating pathologies or disorders of the central nervous system involving neuronal death, such as apoptosis, or related to leptin metabolism. The pathologies of the central nervous system are in particular cerebral ischemia, Parkinson's disease or Alzheimer's disease.01-12-2012
20120009603METHOD FOR INCREASING AND REGULATING LIGHT EMISSION FROM A CHEMILUMINESCENT REACTION - Method for increasing and regulating the emission of light from a chemiluminescent reaction including luminol, a peroxidase enzyme, an oxidant and an electron mediator (primary enhancer) through the use of an acylation catalyst (secondary enhancer) belonging to the class of N-azoles., i.e., a class of five-membered nitrogen heteroaromatic ring compounds containing at least one other atom of nitrogen. N-azoles, which are especially useful as secondary enhancers are imidazole, 1-methylimidazole, 1,2,3-triazole and 1,2,4-triazole. The invention also describes the use in diagnostic assays of chemiluminescent substrates containing said N-azoles, as secondary enhancers.01-12-2012
20120015385DOXORUBICIN IMMUNOASSAY - Novel conjugates of doxorubicin and novel doxorubicin immunogens derived from the 13 and 14 positions of doxorubicin and antibodies generated by these doxorubicin linked immunogens all of which are useful in immunoassays for the quantification and monitoring of doxorubicin in biological fluids.01-19-2012
20120015386IP-10 BASED IMMUNOLOGICAL MONITORING - The present invention relates to an immunological method and, more particularly, a method for measuring cell-mediated immune reactivity (CMI) in mammals based on the production of IP-10. The invention further discloses an assay and a kit for measuring CMI to an antigen using whole blood or other suitable biological samples. The methods of the present invention are useful in therapeutic and diagnostic protocols for human, livestock and veterinary and wild life applications, thus the invention further relates to a method for diagnosing an infection in a mammal.01-19-2012
20120015384Interleukin-1 Alpha Antibodies and Methods of Use - Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.01-19-2012
20120015383NOVEL DIAGNOSTIC MARKER FOR TYPE 1 DIABETES MELLITUS - The present invention provides, as a novel diagnosis marker for type 1 diabetes mellitus, a type 1 diabetes mellitus diagnostic composition comprising alanyl-tRNA synthetase, glycyl-tRNA synthetase, asparaginyl-tRNA synthetase, or tryptophanyl-tRNA synthetase, a diagnostic kit comprising the same, and a diagnostic method using the same. The composition, the kit, and the method, according to the present invention, may be used for early diagnosis and confirmed diagnosis of type 1 diabetes mellitus because type 1 diabetes mellitus can be easily diagnosed from a patient sample.01-19-2012
20120015380ANTI-POLYETHYLENE GLYCOL ANTIBODY EXPRESSING CELL QUANTIFY ANY FREE POLYETHYLENE GLYCOL AND POLYETHYLENE GLYCOL-DERIVATIZED MOLECULES - In this invention, anti-PEG antibodies or anti-methoxyl-PEG (anti-CH01-19-2012
20120015382DROPLET-BASED SELECTION - The present invention generally relates to fluidic droplets, and techniques for screening or sorting such fluidic droplets. In some embodiments, the fluidic droplets may contain cells (e.g., hybridoma cells) that can secrete various species, such as antibodies, for example. In one aspect, a plurality of fluidic droplets containing cells is screened to determine proteins, antibodies, polypeptides, peptides, nucleic acids, or the like. For example, cells able to secrete species such as antibodies may be selected according to certain embodiments of the invention. Examples of such cells include, for instance, immortal cells such as hybridomas, or non-immortal cells such as B-cells. For instance, blood cells may be encapsulated within a plurality of fluidic droplets, and the cells able to produce antibodies may be determined. In some cases, expression or secretion levels may be determined using signaling entities, for example, determinable microparticles present within the fluidic droplet. Other aspects of the invention relate to kits involving such fluidic droplets, methods of promoting the making or use of such fluidic droplets, and the like.01-19-2012
20110081667BIOMARKERS ASSOCIATED WITH NEPHROPATHY - Use of urine biomarkers for diagnosing nephropathy, monitoring nephropathy progress, and assessing efficacy of a nephropathy treatment. These urine biomarkers include leukocyte-associated Ig-like receptor-2, alpha-1 acid glycoprotein, their fragments, and combinations thereof.04-07-2011
20120208214RAPID SACCHARIDE BIOMARKER ASSAY - The present invention includes compositions, methods, kits and diagnostics for biosugar profiling of biological samples from a patient suspected of having a disease associated with changes in the biosugar profile. The biosugar profile from the patient sample is compared to a healthy biosugar profile from the same type of biological sample to evaluate disease potential and progression.08-16-2012
20110165598METHODS AND COMPOSITIONS FOR TREATING ALZHEIMER'S DISEASE - Aspects of the invention relate to methods and compositions for treating Alzheimer's disease (AD). In some embodiments, the invention provides methods for screening and identifying compounds that selectively inhibit the targeting of the insulin-Akt signaling pathway by Aβ oligomers.07-07-2011
20110165600DIAGNOSIS METHOD AND DIAGNOSIS KIT FOR DERMATOMYOSITIS - An object of the present invention is to identify an antigen corresponding to anti-CADM-140 antibody, produce a recombinant protein, and establish an assay system by ELISA or the like. The present invention provides a kit for diagnosing dermatomyositis containing an MDA5 protein shown in SEQ ID NO: 4 or a fragment thereof that is recognized by anti-CADM-140 antibody.07-07-2011
20110165599MONOCLONAL ANTIBODY THERAPY FOR PANCREAS CANCER - The present invention relates to the use of binding equivalents of monoclonal antibody 31.1, including chimerized and/or humanized versions thereof, antibody fragments as well as competitively binding and co-specific antibodies and antibody fragments, in the treatment of pancreatic cancer.07-07-2011
20120058498Compositions and Methods for Characterizing Arthritic Conditions - The present invention relates to autoantibodies against 14-3-3 proteins or circulating immune complexes thereof and the detection of such for the diagnosis and prognosis of an arthritic condition.03-08-2012
20120058497DIAGNOSTIC REAGENT FOR CROHN'S DISEASE - The present invention provides a reagent and a method of safely, conveniently, and specifically diagnosing Crohn's disease. Provided are a diagnostic method for Crohn's disease in a subject, including measuring antibodies against one kind or more of dietary components selected from the group consisting of grapefruit, alfalfa, avocado, cabbage, green pepper, lettuce, onion, potato (white), spinach, tomato, oat, pecan, yeast, cane sugar, celery, buckwheat, corn, rice and soy, and a diagnostic reagent or kit for Crohn's disease, containing the above-mentioned preparation of a dietary component.03-08-2012
20120058496PHYSIOLOGICALLY ACTIVE SUBSTANCE COLLECTING DEVICE AND BIOLOGICAL INFORMATION ACQUISITION METHOD - A physiologically active substance collecting device, includes: a collecting section brought into contact with a body surface of a living organism to acquire a physiologically active substance from the body surface; and a liquid sending means for sending a solvent to the collecting section, the collecting section having an aperture at which the solvent flown by being sent from the liquid sending means contacts the body surface.03-08-2012
20120156704IN VITRO METHOD FOR DETECTING GP91PHOX AS A MARKER OF OXIDATIVE STRESS - The invention relates to an in vitro method for detecting the activation of NADPH oxidase by measuring gp9106-21-2012
20120156703USE OF MIMECAN IN THE ASSESSMENT OF HEART FAILURE - The disclosure relates to assessing heart failure in vitro by measuring the concentration of the marker mimecan in a sample, and optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration of mimecan and the one or more other marker(s) to reference concentrations of this (or these) marker(s) as established in a reference population. The one or more markers may be selected from the group comprising a natriuretic peptide marker, a cardiac troponin marker, and a marker of inflammation. Also disclosed are the use of mimecan as a marker protein in the assessment of heart failure, a marker combination comprising mimecan, and a kit for measuring mimecan.06-21-2012
20090136971MULTIPLEX LIQUID TISSUE METHOD FOR INCREASED PROTEOMIC COVERAGE FROM HISTOPATHOLOGICALLY PROCESSED BIOLOGICAL SAMPLES, TISSUES, AND CELLS - The invention provides methods for multiplex analysis of biological samples of formalin-fixed tissue samples. The invention provides for a method to achieve a multiplexed, multi-staged plurality of Liquid Tissue preparations simultaneously from a single histopathologically processed biological sample, where the protocol for each Liquid Tissue preparation imparts a distinctive set of biochemical effects on biomolecules procured from histopathologically processed biological samples and which when each of the preparations is analyzed can render additive and complementary data about the same histopathologically processed biological sample.05-28-2009
20120208216NON-CROSS-REACTIVE ANTI IGG ANTIBODIES - Herein are reported the cell lines DSM ACC3006, DSM ACC3007, and DSM ACC3008, as well as the antibodies obtained from the cell lines and the use of an antibody obtained from the cell lines in an immunoassay. Also are reported antibodies binding to human or chimpanzee IgG and not binding to canine and marmoset IgG and antibodies specifically binding to an IgG08-16-2012
20120064548NOVEL GENES, COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF CERVICAL CANCER - The invention relates to newly discovered nucleic acid molecules and proteins associated with cervical cancer including pre-malignant conditions such as dysplasia. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human cervical cancers are provided.03-15-2012
20120156702CMYBP-C AND MLC2 AS DIAGNOSTIC MARKERS OF CARDIAC INJURY - The invention relates to markers for acute myocardial infarction (AMI), particularly markers that may be used in the rapid and accurate diagnosis of AMI or reinfarction. A method of diagnosing cardiac injury comprising identifying an elevated concentration of cardiac myosin binding protein C (cMyBP-C) or a fragment thereof or myosin regulatory light chain 2 (MLC2) or a fragment thereof in a sample obtained from a subject.06-21-2012
20120156701METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect C-X-C motif chemokines-1, -2, and -3 as diagnostic and prognostic biomarker assays in renal injuries.06-21-2012
20120156700DETECTION AND QUANTITATION OF URINE GELSOLIN - The invention relates generally to gelsolin binding agents (e.g., antibodies) which can bind to gelsolin polypeptides. Gelsolin binding agents of the invention are useful, alone or in combination, to detect a gelsolin polypeptide in a test sample. In particular, the gelsolin binding agents are useful in assays of urine samples to diagnose a gelsolin-related medical condition. Kits to detect gelsolin in biological samples are also provided by the present disclosure.06-21-2012
20120070854HNRNP A3 Related Peptides and Use Thereof for Diagnosis of Rheumatoid Arthritis - The invention relates to a peptide and retro or retro-inverso peptide thereof, with a length of ≦25 amino acid residues, characterized in that the peptide comprises at least one citrulline residue, and exhibits a sequence identity over the whole sequence of the peptide of ≧70% compared to human hnRNP A3 protein (SEQ ID No. 1) and uses thereof.03-22-2012
20110091913DRUG SAFETY TEST USING PENTRAXIN-3 (PTX-3) - The invention relates to an in vitro method for assessing the immunogenicity of a compound of interest comprising the steps of: a) providing a whole blood sample, wherein said blood was exposed to said compound of interest, b) measuring the level of pentraxin-3 in said sample, and c) comparing the measured level of pentraxin-3 with a control.04-21-2011
20110091912HIGH MOLECULAR WEIGHT NGAL AS A BIOMARKER FOR CHRONIC KIDNEY DISEASE - A high molecular weight form of Ngal is provided which can be used to diagnose chronic kidney disease. High molecular weight Ngal is about 75 kDa to about 350 kDa, and comprises non-Ngal proteins, such as polymeric immunoglobulin receptor, alpha-2-macroglobulin and immunoglobulin heavy chain. Methods are disclosed for assessing high molecular weight Ngal in a diagnostic sample from a subject.04-21-2011
20110091911ANTIBODIES, SYSTEMS AND METHODS FOR DETERMINING RELATIVE HEMOLYTIC INDEX - Disclosed herein are antibodies, systems and methods for assessing the risk of hemolysis following a blood transfusion with crossmatch incompatible blood. The disclosure provides a method for determining the relative hemolytic index and therefore the risk of post-transfusion hemolysis for said patient.04-21-2011
20110091910NOVEL ASSAY - A novel method for detection of Aβ peptides, in particular in plasma, and to the use of Aβ peptides for diagnosis of Alzheimer's disease.04-21-2011
20120208215Biomarkers for Pre-Diabetes, Cardiovascular Diseases, and Other Metabolic-Syndrome Related Disorders and Methods Using the Same - Biomarkers relating to insulin resistance, pre-diabetes, type-2 diabetes, metabolic syndrome, atherosclerosis, and cardiomyopathy are provided, as well as methods for using such biomarkers as biomarkers for insulin resistance, pre-diabetes, type-2 diabetes, metabolic syndrome, atherosclerosis, and cardiomyopathy. In addition, methods for modulating the respective disorders or conditions of a subject are also provided. Also provided are suites of small molecule entities as biomarkers for insulin resistance, pre-diabetes, type-2 diabetes, metabolic syndrome, atherosclerosis, and cardiomyopathy.08-16-2012
20130011864PHOTOLUMINESCENT NANOPARTICLE, PREPARATION, AND APPLICATION THEREOF - Luminescent nanoparticles, preparation, and application thereof are disclosed. The luminescent nanoparticle consists of matrix, which is a macromolecular compound containing carboxyl group, and a rare-earth luminescent dye dispersed in the matrix. The preparation method of the luminescent nanoparticle comprises: dissolving the rare-earth complex luminescent dye and the macromolecular compound in organic solvent miscible with water, adding the solution into water, and forming the luminescent nanoparticle by coprecipitation-selfassembly process. The prepared luminescent nanoparticle has excellent long-wave excitational luminescent properties and good stability, and can be used in coupling the surface carboxyl group of a biomolecule. The biological probes based on such luminescent nanoparticles have wide application prospects on the aspects of high-sensitivity luminescent immunoassay, biological imaging and the like.01-10-2013
20120231482METHOD, KIT OR DIAGNOSTIC FOR THE DETECTION OF REAGENTS WHICH INDUCE ALTERED CONTRACTILITY - A method of screening for compounds that enhance or depress contractile function, based on measuring the formation of heterodimers of contractile fibers (e.g. Tm and actin, myosin heavy and myosin light chains), for example through disulfide bond formation. Diagnostic and prognostic methods and kits are also provided.09-13-2012
20110065134SYNTHETIC PEPTIDES IMMUNO-REACTIVE WITH RHEUMATOID ARTHRITIS AUTO-ANTIBODIES - Embodiments of the present invention relate to a three dimensional matrix of selected, synthetic peptide mimic sequences that are preferentially recognized by auto-antibodies, specifically by autoimmune antibodies, to be detected in patients afflicted with rheumatic arthritis, enabling enhanced sensitivity and specificity in detection of these antibodies in pre-symptomatic patients, in patients showing symptoms as well as patients confirmed positive for rheumatoid arthritis.03-17-2011
20120231480MATERIALS AND METHODS FOR THE DIFFERENTIAL DIAGNOSIS OF PACREATIC LESIONS - Levels of VEGF-A, VEGF-C and PGE09-13-2012
20120231479COMBINATION METHODS OF DIAGNOSING CANCER IN A PATIENT - The present disclosure relates to methods for determining the presence, activity, and/or concentrations of certain cancer biomarkers and their use in determining the presence of cancer.09-13-2012
20110104723BIOMARKERS - The invention provides binding agents and assays for insulin signal peptide. The agents and assays are useful in methods for predicting, diagnosing, assessing or monitoring acute cardiac disorders, glucose handling disorders and diabetes in a subject. Also provided are nucleotides, polypeptides, and kits useful in the methods of the invention.05-05-2011
20110104722METHOD FOR IDENTIFYING A SUBJECT AT RISK OF DEVELOPING HEART FAILURE BY DETERMINING THE LEVEL OF GALECTIN-3 OR THROMBOSPONDIN-2 - The present invention relates to a method for identifying a subject at risk of developing hypertensive end organ damage, such as and in particular heart failure, comprising: a) obtaining a biological sample of said subject; b) determining the level of at least one non-myocytal marker in said sample; c) comparing the level of said marker to a standard level; and d) determining whether the level of the marker is indicative of a risk for developing hypertensive end organ damage. The non-myocytical marker preferably is galectin-3 or thrombospondin-2.05-05-2011
20110104725Method of Effecting Coagulation in a Droplet - The invention provides techniques for coagulating blood on a droplet actuator. The invention also provides methods of manipulating the coagulated blood including a variety of droplet operations that may be conducted using the coagulated blood. Further, the invention provides a variety of assays that make use of the coagulated blood or various blood samples as input.05-05-2011
20120135426Method for quantifying phosphokinase activity on proteins - The invention involves a method for measuring phosphorylation of proteins at specific sites and, as such, is an indicator of the protein kinase activity of enzymes capable of phosphorylating those sites. The method involves the in vitro or in vivo phosphorylation of a target protein at a specific serine, threonine or tyrosine residue, subjecting that protein (non-phosphorylated) to reaction mixture containing all reagents, including phosphokinase which allow the creation of a phosphorylated form of protein. The phosphorylated protein is measured by contacting it with an antibody specific for the phosphorylation site(s). The invention includes antibodies useful in practicing the methods of the invention. The invention particularly relates to all proteins modified by phosphorylation and dephosphorylation as illustrated by Tau, Rb and EGFR proteins and antibodies specific for the site of phosphorylation of the Tau, Rb or EGFR proteins.05-31-2012
20120122126ANTI-PSK ANTIBODY - An antibody which recognizes PSK is provided.05-17-2012
20100093006HIGH AFFINITY ANTI-N1,N12-DIACETYLSPERMINE MONOCLONAL ANTIBODY - The present invention provides an anti-diacetylspermine specific monoclonal antibody which satisfies a specific measuring condition in an immunoreaction system between a solid-phased diacetylspermine and the anti-diacetylspermine specific monoclonal antibody, wherein the immunoreaction system comprises a sample diacetylspermine or sample N04-15-2010
20100093005IDENTIFYING DUCT CANCERS - This document relates to methods and materials involved in identifying mammals that are likely to have duct cancer. For example, this document provides methods and materials related to using the presence of a variant form of the secretin receptor in a mammal's blood to identify the mammal (e.g., human) as being likely to have duct cancer.04-15-2010
20120122123DETECTION OF ANTHRAX PATHOGENICITY FACTORS - One major problem in diagnosis methods presently available for anthrax is that these methods require several days to produce a result. The only existing treatment for anthrax requires administration soon after infection at a time when patients are exhibiting only mild flu-like symptoms. Thus, a patient may be days beyond the time when treatment would be effective by the time a diagnosis is made. The present invention reduces diagnosis time to as little as four hours providing same day identification of anthrax radically increasing the odds of delivering proper treatment and patient recovery. The rapid identification of anthrax lethal factor activity exhibited by the instant invention is also amenable to in vivo screening protocols for the discovery and development of anthrax vaccines and lethal factor inhibitors. The instant invention isolates and concentrates lethal factor and lethal toxin from nearly any biological sample. By capitalizing on the endopeptidase activity of lethal factor the present invention amplifies output signals producing reliable detection of picomolar concentrations of lethal factor. The instant invention involves novel purification and detection techniques and substrates for rapid, reproducible, and quantitative measurements of anthrax lethal factor in biological samples.05-17-2012
20120122127Cleavage Sensitive Antibodies and Methods of use thereof - We disclose cleavage-sensitive antibodies with epitopes spanning the scissile bond of the toxins molecular target protein, enabling toxin-associated proteolysis to be measured in a variety of assay formats.05-17-2012
20120122125ANTI-T. CRUZI ANTIBODIES AND METHODS OF USE - The present disclosure is directed to reagents and methods of using the reagents to detect epitopes of 05-17-2012
20120122124NEW BACTERIOPHAGE ADHESION PROTEINS - The present invention relates to bacteriophage adhesion proteins binding to the O-antigen of gram negative bacteria, lacking the ability of binding to a bacteriophage and of hydrolysing lipopolysaccharides. The invention further relates to nucleic acid molecules comprising a sequence encoding the proteins according to the present invention. In addition, the present invention relates to a method for generating bacteriophage adhesion proteins according to the present invention. The invention further relates to the use of said proteins and methods of detection, purification and enrichment of bacteria.05-17-2012
20100255515ELISA FOR VEGF - The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA methods and kits for VEGF as an antigen are provided to detect types of VEGF levels in biological samples from animal models and human patients and can be used as a diagnostic/prognostic index.10-07-2010
20100248269DETECTION OF FIBRIN AND FIBRINOGEN DEGRADATION PRODUCTS AND ASSOCIATED METHODS OF PRODUCTION AND USE FOR THE DETECTION AND MONITORING OF CANCER - Disclosed herein are methods, systems and kits for the detection of, or monitoring the progression of, cancer by simultaneously detecting the presence of six fibrin and fibrinogen degradation products (FDP) in a biological sample in a single assay system.09-30-2010
20100248271Fibrinogen Alpha and Hemoglobin Polypeptides as Cancer Markers - The present invention provides methods of detecting cancer using biomarkers.09-30-2010
20100248270Novel Nucleotide and Amino Acid Sequences, and Assays and Methods of Use Thereof for Diagnosis of Cardiac Disease - Novel markers for cardiac disease that are both sensitive and accurate. These markers are differentially and/or specifically expressed in cardiac tissue, as opposed to other types of tissues, optionally and preferably including muscle tissue. The measurement of these markers, alone or in combination, in patient samples provides information that the diagnostician can correlate with a probable diagnosis of cardiac disease, including pathology and/or damage, including acute and/or chronic damage. The markers of the present invention, alone or in combination, show a high degree of differential detection between cardiac disease states and non-cardiac disease states.09-30-2010
20120214180NT-pro ANP and SFlt-1 FOR THE DIFFERENTIATION BETWEEN CIRCULATORY AND ISCHEMIC EVENTS - The present disclosure relates to the field of laboratory diagnostics. The present disclosure provides means and methods for differentiating between an acute circulatory event and an ischemic event, as the cause underlying an acute medical event of a patient.08-23-2012
20110183364ANALYTICAL METHOD FOR THE DETECTION OF LATENT HEPATITIS C, USE THEREOF AND CORRESPONDING DIAGNOSIS KIT - The invention relates to an improved analytical method for the detection of latent hepatitis C, to the use thereof and to the corresponding diagnosis kit. The analytical method is based on the immunoassay technique and the most suitable operating conditions for detecting latent hepatitis C have been determined. The invention also relates to a diagnosis kit complementary to the method. The invention is suitable for use in medicine, biomedical research and in the field of analytical techniques.07-28-2011
20110183362COMPOSITIONS AND METHODS FOR MEASURING LEVELS OF BIOACTIVE HUMAN HEPCIDIN - The invention provides compositions and methods for measuring human serum hepcidin levels. The invention provides methods for the oxidative refolding of a hepcidin polypeptide to a form that is mature, bioactive and folded as in the native configuration and molecular mass; a method for measuring the level of native, bioactive hepcidin in a vertebrate animal.07-28-2011
20120164667METHOD FOR TEST ON DIABETIC NEPHROPATHY - Provided is a test method for the detection of diabetic nephropathy at an early stage as compared to a conventional method. Specifically provided are: a test method for diabetic nephropathy, including detecting urinary podocalyxin; the test method, further including assessing diabetic nephropathy at least Stage I; a test reagent for use in the test method; and a test reagent kit for use in the test method. The present invention is based on a finding that urinary podocalyxin reflects the development and condition of diabetic nephropathy with high sensitivity at an early stage as compared to urinary albumin.06-28-2012
20120129198NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS - Assay systems and specialized antibodies for the detection and quantitation of troponin I and troponin T in body fluids as an indicator of myocardial infarction. Since troponin I and T exist in various conformations in the blood, the ratios of the monomeric troponin I an T and the binary and ternary complexes, as well as which form of troponin present in the blood, may be related to the metabolic state of the heart. Disclosed is a system to determine the presence of a troponin form or a group of troponin forms in a sample of whole blood, serum or plasma.05-24-2012
20120129197Immunomodulation of Functional T Cell Assays for Diagnosis of Infectious or Autoimmune Disorders - Improved assays for detecting the presence of a specific cell-mediated immune response in an individual are provided, where a sample comprising T cells and other cells of the immune system, usually a blood sample or derivative thereof, is contacted with test antigen(s) of interest in the presence of a pattern recognition receptor (PRR) agonist. The sample is incubated for a period of time sufficient to activate effector T cells; and release of immune effector molecule(s) is then detected. In some embodiments, the PRR is an agonist of a toll-like receptor (TLR) expressed by mature antigen presenting cells, including without limitation agonists TLR3 and TLR7, such as LPS, poly I:C, imiquimod, etc.05-24-2012
20120129196HIGHLY SENSITIVE MONOCLONAL ANTIBODY RESIDUAL DETECTION ASSAY - The present invention relates to compositions and highly sensitive methods for the detection of biotechnology product residual when monitoring product carry over and/or for cleaning verification in the manufacture of biotechnology products. In particular, the present invention is directed to immunoassays wherein one or more capture antibodies, or antigen binding fragments thereof, are used to detect residuals associated with the production of biotechnology products.05-24-2012
20120129195Method of quick laboratory diagnosis if illnesses based on the discovery of specific proteins and equipment for its implementation - A method of quick laboratory diagnosis of diseases, based on the discovery of specific protein targets characteristic to the disease in the reaction of their specific interaction with other protein reagents, distinct in that specific protein targets for the given disease are hydrolyzed with proteolytic enzymes and then the chemical structure of the oligopeptide formula created is modified in such a way that its charge is changed to the opposite. This method of quick laboratory diagnosis of illnesses based on the discovery of specific proteins, and the equipment for its implementation, may be applied for the discovery of viral and microbial antigens in various human biological fluids. The method may also be used for the detection of new and little-studied infectious diseases in connection with the ease of diagnostic preparation.05-24-2012
20120129199COMPOSITIONS, KITS AND METHODS FOR IN VITRO ANTIGEN PRESENTATION, ASSESSING VACCINE EFFICACY, AND ASSESSING IMMUNOTOXICITY OF BIOLOGICS AND DRUGS - Nanoparticle-based compositions, assays, kits, methods and platforms for delivering an antigen (peptides, proteins) or a nucleic acid encoding an antigen to professional APCs (PAPCs) result in the generation of autologous APCs that present a natural peptide repertoire of the antigen for use in assessing the efficacy of a vaccine (e.g., a cytotoxic T lymphocyte (CTL) response to a particular antigen) or other therapy or intervention (cell-based therapy, adjuvant therapy, etc.). The compositions, kits, assays and methods also can be used for delivering a drug or biologic or portion thereof to APCs for assessing the immunogenicity of drugs and biologics. The composition, kits, assays and methods involve the combined use of MHC targeting, universal DR binding peptides (e.g., PADRE, HA) with charged (e.g., positively-charged) highly branched polymeric dendrimers (e.g., PAMAM and other dendrimers) as vehicles for the targeted delivery of nucleic acids, peptides, biologics, drugs, or polypeptides to APCs, giving rise to a new nanoparticle-based method for assessing the immune response (CTL response) to a vaccination or other therapy or intervention, or for assessing the immunogenicity of a biologic or drug. Targeted delivery of nucleic acids, peptides, biologics, drugs, or polypeptides to APCs for effective expression and processing generates more physiologically relevant target antigens for evaluation of cell-mediated immune responses to vaccination, for example, and provides a low-cost approach for rapid generation of reagents and development of assay systems for more accurate profiling of immunological responses to infection, immunization, and other therapies or interventions. Immunoevaluation kits using targeted nanoparticle-based antigen delivery are described herein.05-24-2012
20120164668ULTRASOUND ASSISTED IMMUNOASSAY - The invention relates to methods, devices and systems for an enhanced, ultrasound assisted immunoassay (such as a Western blot immunoassay). In particular, there are provided methods, devices and system for the automated and enhanced processing of a membrane having proteins associated therewith, wherein the processing includes the use of ultrasonic energy.06-28-2012
20100209948BIOMARKERS ASSOCIATED WITH NEPHROPATHY - Use of urine biomarkers for diagnosing nephropathy, monitoring nephropathy progress, and assessing efficacy of a nephropathy treatment. These urine biomarkers include leukocyte-associated Ig-like receptor-2, alpha-1 acid glycoprotein, their fragments, and combinations thereof.08-19-2010
20100209947Free human serum IgE immunoenzymetric assay and methods of use - The present invention relates to the development of novel of free blood fluid IgE Immunoenzymetric assay that is specifically designed to evaluate the blood fluid of patients on therapeutic agents designed to reduce free serum IgE levels, such as Omalizumab. The assay displays the robustness required for clinical analysis of serum containing such agents as Omalizumab.08-19-2010
20120214181ASSAY FOR PCSK9 INHIBITORS - The present invention provides methods for identifying modulators of PCSK9, for example, using a variety of assay formats. Inhibitors of PCSK9 can be used for example, to treat diseases such as hyperlipidemia and related disorders.08-23-2012
20120214183METHODS FOR EVALUATING RISK OF MOTHER'S MILK OR FOOD INDUCING AN ONSET OF ATOPIC DERMATITIS, AND MOTHER'S MILK OR FOOD WITH REDUCED RISK OF INDUCING AN ONSET OF ATOPIC DERMATITIS - An entity of a Th2 adjuvant activity in mother's milk has been revealed as coenzyme A by HPLC and mass spectrometry. The followings have been found out that: a risk of developing atopic dermatitis can be evaluated by targeting coenzyme A; and any one of a food and mother's milk with a reduced risk of developing atopic dermatitis can be prepared by removing or inactivating coenzyme A.08-23-2012
20120214178Mesenchymal Stem Cells Expressing TNF-alpha Receptors - Mesenchymal stern cells which express TNF-α receptor Type I in an amount of at least 13 pg/1008-23-2012
20120214177METHODS AND COMPOSITIONS FOR DIAGNOSIS OF UROSEPSIS AND URINARY TRACT INFECTION - Methods for diagnosis of and distinguishing between, urosepsis, sepsis, and urinary tract infections (UTIs) are disclosed The diagnostic methods are based on determining the level of NGAL protein in a bodily fluid sample, such as urine sample.08-23-2012
20120135430COMPLEMENT ASSAYS AND USES THEREOF - The present invention provides methods for assessing complement activation and methods for assessing the ability of an agent or condition of interest to modulate complement activation. The present invention provides methods for assessing whether a subject has or is at increased risk of developing a complement-mediated disorder, e.g., age-related macular degeneration (AMD). Also provided are kits containing materials useful for performing the methods.05-31-2012
20120135429PRO-GRP AS A SURROGATE MARKER TO PREDICT AND MONITOR RESPONSE TO BCL-2 INHIBITOR THERAPY - A method for classifying cancer patients as eligible to receive cancer therapy with a Bcl-2 inhibitor comprising determination of the presence or absence in a patient tissue sample of levels of pro-GRP, as a surrogate marker for the presence of chromosomal copy number gain at chromosomal locus 18q21-q22. The classification of cancer patients based upon pro-GRP levels as a surrogate for the presence or absence of 18q21-q22 gain allows selection of patients to receive chemotherapy with a Bcl-2 family inhibitor, either as monotherapy or as part of combination therapy, and to monitor patient response to such therapy using a peripheral blood sample.05-31-2012
20120135433PROGNOSIS DIAGNOSIS METHOD AND PROGNOSIS DIAGNOSIS KIT FOR SEPSIS OR MULTIPLE ORGAN FAILURE - Disclosed are: a prognosis diagnosis method which can diagnose the prognosis of a patient suffering from sepsis or sepsis-related multiple organ failure in a simple manner and with high accuracy and a prognosis diagnosis kit for use in the prognosis diagnosis method. The prognosis diagnosis method comprises: a first detection step of detecting a liver fatty acid-binding protein contained in urine collected from a subject with a specific antibody; a second detection step of treating the urine with a Redox reagent such as hemin and detecting a liver fatty acid-binding protein contained in the treated urine with the specific antibody; and a comparison step of comparing a detection value obtained in the first step with a detection value obtained in the second step. It is determined that the larger the detection value obtained in the second step compared to that in the first step, the worse the prognosis.05-31-2012
20120135432DIAGNOSTIC METHOD FOR DETERMINING THE SUSCEPTIBILITY TO DELIVERY AND REAGENT KIT FOR USE THEREOF - The invention relates to a diagnostic method for detecting susceptibility to delivery, and to a test kit for this purpose. A low, but higher than baseline level concentration of Insulin-like Growth Factor Binding Protein 1 (IGFBP-1), which is due to leakage from decidual cells, is detected by an immunological assay in a vaginal secretion sample.05-31-2012
20120135427METHODS FOR DETERMINING MATERNAL HEALTH RISKS - The present description relates to a method for determining the risk of a pregnant woman developing a hypertensive disorder, more specifically gestational hyper-tension or late onset preeclampsia. The present description provides methods useful for determining risk that a pregnant individual will develop a hypertensive disorder or condition of pregnancy, such as gestational hypertension, early preeclampsia, late preeclampsia and related disorders. Several useful combinations of biochemical markers and related clinical population studies are described herein. Additionally, it is proposed herein that certain sets of biochemical markers can be used to determine risk of multiple hypertensive disorders in a single screen. The biochemical markers are PlGF, Activin A and optionally P-Selectin.05-31-2012
20120135425ELISA for Haptoglobin-Matrix Metalloproteinase 9 Complex as a Diagnostic Test for Conditions Including Acute Inflammation - A method for detecting a haptoglobin-matrix metalloproteinase 9 (Hp-MMP 9) complex in a biological sample. The sample includes incubating the biological sample with a capture reagent immobilized on a solid support to bind Hp-MMP 9 to the capture reagent. The capture reagent includes a monoclonal antibody that binds MMP9. The method detects Hp-MMP 9 bound to the immobilized capture reagent by contacting the bound Hp-MMP 9 with a detectable antibody that binds to Hp.05-31-2012
20120214179METHODS FOR DETECTING PRE-DIABETES AND DIABETES USING DIFFERENTIAL PROTEIN GLYCOSYLATION - Methods for identifying individuals who are not yet diabetic (pre-diabetic), but who are at significant risk of developing diabetes, such as type 2 diabetes, are disclosed herein. Methods are also provided for the identification of diabetic subjects. Also disclosed are methods for identifying individuals with diabetic complications. The methods include the identification of an overall glycosylation profile of proteins in a biological fluid, such as saliva, urine, or serum. In some examples, the methods include determining the amount of one or more protein in a biological fluid or determining the glycosylation pattern of one or more proteins in a biological fluid.08-23-2012
20120214182SYSTEM FOR DETERMINING UNPROCESSED AND PARTIALLY PROCESSED NEUROTOXIN TYPE A - The present invention is concerned with tools for the quality control and safety during manufacture of neurotoxins. In particular, it relates to a method for the determination of the amount of partially processed and/or unprocessed Botulinum neurotoxin A polypeptide (BoNT/A) in a solution comprising processed and partially processed and/or unprocessed BoNT/A comprising the steps of contacting a sample of the solution with a capture antibody which specifically binds to the partially processed and unprocessed BoNT/A under conditions which allow for binding of the antibody to the partially processed and unprocessed BoNT/A, whereby a complex is formed, and determining the amount of the formed complex, whereby the amount of the complex is indicative for the amount of the partially processed and/or unprocessed BoNT/A in the solution. Moreover, the present invention contemplates a device and a kit for carrying out the method.08-23-2012
20100173334CANCER EVALUATION METHOD USING HAPTOGLOBIN BETA-CHAIN DEFINED BY ANTIBODY RM2 - The object of the present invention is to identify a molecule that is specifically recognized by antibody RM2 in tissue or serum of a cancer patient, and provide a method for diagnosing cancer in a simple manner with high specificity using the molecule as an indicator. The present method comprises evaluating a risk or grade of malignancy of genitourinary cancer in a subject using the level of the haptoglobin β chain to which antibody RM2 specifically binds or a fragment thereof in tissue or body fluid isolated from the subject as an indicator.07-08-2010
20120171703IMIDAZO[1,2-ALPHA]PYRAZIN-3(7H)-ONE DERIVATIVES BEARING A NEW ELECTRON-RICH STRUCTURE - The present invention relates to compound of formula I: and their use as chemiluminescent and/or bioluminescent reagents.07-05-2012
20120252040KIT FOR DIAGNOSING PROSTATE CANCER AND DIAGNOSIS METHOD - The present invention relates to a kit and method for diagnosing prostate cancer, which use an antibody to prostate-specific antigen (PSA) to detect PSA in human urine. More specifically, the invention relates to a kit for diagnosing prostate cancer, which comprises an antibody to PSA and uses human urine as a sample, and to a method for diagnosing prostate cancer, which comprises brining a human urine sample into contact with an antibody to PSA in order to detect PSA in the sample.10-04-2012
20120219976REDUCING THE RISK OF HUMAN ANTI-HUMAN ANTIBODIES THROUGH V GENE MANIPULATION - The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included.08-30-2012
20120219974DISTINGUISHING ASSAY - The current invention comprises a method for determining of an antibody against a drug antibody in a sample using an immunoassay comprising a capture drug antibody and a tracer drug antibody, wherein the method comprises providing i) a capture drug antibody, which is the drug antibody conjugated to a solid phase, ii) a tracer drug antibody, which is the drug antibody conjugated to a detectable label, contacting the capture drug antibody separately with i) the sample, ii) the sample, to which the drug antibody in monomeric form has been added, iii) the sample, to which the drug antibody in oligomeric form has been added, and determining an antibody against the drug antibody in the sample by a positive immunoassay in i) and a negative immunoassay in ii) and iii).08-30-2012
20120219973IMMUNOREGULATION IN CANCER, CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES - The present invention primarily relates to a method for analyzing the amount of immunoregulatory integrin binding factors and/or patient endogenous antibodies which are directed against such factors, the factors having the capacity to modulate the immune functions in a. subject suffering from cancer or inflammatory or autoimmune diseases, by utilizing binding reagents to determine these factors and/or the patient endogenous antibodies which are directed against such factors, whereby the prognosis and/or the therapeutic efficacy of any treatment of a subject suffering from cancer or inflammatory or autoimmune diseases can be determined and/or monitored. The invention further relates to the use of therapeutically active compounds for eliminating, inhibiting or enhancing such binding factors for the manufacture of pharmaceuticals to be used in the treatment of cancer, inflammatory conditions or autoimmune diseases.08-30-2012
20120219972DIAGNOSIS AND TREATMENT OF EHRLICHIOSIS - The present invention provides an isolated 08-30-2012
20090104634ONE-STEP IMMUNOASSAYS EXHIBITING INCREASED SENSITIVITY AND SPECIFICITY - The present disclosure relates to immunoassays for detecting or quantifying at least one analyte of interest in a test sample which exhibits improved sensitivity and specificity compared to the immunoassay formats known in the art.04-23-2009
20120178110SCREENING OF PROTEIN CANDIDATES - Successful application of an engineered protein as therapeutics or in other industries would require the protein to have good expression level, good biophysical properties and often desired affinity to its target. The present invention provides a method of screening large numbers of protein candidates (PCs) in all three aspects simultaneously. PCs are fused to a protein anchor, which is captured by the target/antigen. The captured PCs are evaluated for their expression levels, biophysical properties and affinities using conventional methods.07-12-2012
20120178108IMMUNODETECTABILITY - In the present disclosure, there is provided a method for improving the immunodetectability of at least one protein in an optionally diluted sample of blood, serum or plasma, comprising a step of heating the sample to a temperature of 64-85° C. prior to a contact between the sample and at least one affinity ligand for detection and/or quantification of the at least one protein.07-12-2012
20120178109DIAGNOSIS OF A PARASITIC DISEASE SUCH AS LEISHMANIASIS USING RIBOSOMAL PROTEIN EXTRACT (RPE) - The invention relates to a diagnosis method for 07-12-2012
20120178106ANTIGEN BINDING MOLECULES THAT BIND EGFR, VECTORS ENCODING SAME, AND USES THEREOF - The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.07-12-2012
20120178105DETECTION OF GLOBOTRIAOSYLCERAMIDE (GLC) IN HUMAN URINE SAMPLES USING AN ANTIBODY SANDWICH - Applicant has developed an assay for the detection of GL3 in human samples using a sandwich based immunoassay in which utilizes a pair of GL3 specific monoclonal antibodies, one for capture and one for detection, to create an antibody “sandwich” around the GL3 ligand. To further increase sensitivity, Applicant has modified traditional sandwich based assays by complexing the capture antibody with GL3 before adding the sample or detector antibody, providing an inhibition based assay.07-12-2012
20100273194IMMUNOREACTIVE EHRLICHIA P120/P140 EPITOPES AND USES THEREOF - Provided herein are immunoreactive peptides which can selectively bind 10-28-2010
20100273193Triacetone Triperoxide and Diacetone Diperoxide Derivatives, Method for the Preparation and Use Thereof - This disclosure is drawn to a triacetone triperoxide derivative in accordance with the general formula (I) and a diacetone diperoxide derivative in accordance with the general formula (II)10-28-2010
20100273192METHOD FOR DETECTION OF DISEASE HAVING INSULIN-RESISTANT CONDITIONS - Disclosed is a simple method for detecting a pathological condition of an insulin-resistant disease, particularly type-2 diabetes. The method comprises quantifying the ganglioside GM3 in a blood sample separated from a living body. More specifically, the method comprises the following steps (a) to (c): (a) separating a plasma or serum from the blood collected from a human; (b) quantifying the ganglioside GM3 in the plasma or serum; and (c) comparing the quantified ganglioside GM3 level to the mean ganglioside GM3 level determined in blood samples from healthy volunteers.10-28-2010
20110097752COPD Diagnosis - The present invention relates to a method for diagnosing chronic obstructive pulmonary disease (COPD) in a human subject or the risk of a human subject to develop COPD comprising the steps of: —providing a sample from a human subject, —determining the amount of caspase-cleaved cytokeratin-18 (ccCK-18), histones, heat shock protein 27 (HSP27), heat shock protein 70 (HSP70) and/or heat shock protein 90 alpha (HSP90 alpha) in said sample, —diagnosing COPD when the amount of ccCK-18, histones, HSP27, HSP70 and/or HSP90 alpha is increased compared to the amount of ccCK-18, histones, HSP27, HSP70 and/or HSP90 alpha in healthy human subjects, or—diagnosing the risk to develop COPD when the amount of ccCK-18, histones and/or HSP70 is reduced compared to the amount of ccCK-18, histones and/or HSP70 in healthy human subjects.04-28-2011
20100009393FACTOR H POLYMORPHISMS IN THE DIAGNOSIS AND THERAPY OF INFLAMMATORY DISEASES SUCH AS AGE-RELATED MACULAR DEGENERATION - The invention relates to antibodies, including monoclonal and polyclonal, or fragments thereof, which discriminate between the histidine and tyrosine isoforms of Complement Factor H and to their use in diagnostic methods and therapeutic treatments relating to Complement Factor H mediated diseases.01-14-2010
20100009392USE OF MELANOMA INHIBITORY ACTIVITY (MIA) PROTEIN AS AN EARLY INDICATOR FOR THERAPEUTIC RESPONSE IN MELANOMA - The present invention provides a method for determining a response of a mammalian subject having melanoma tumor cells to treatment with a melanoma inhibitory agent. In one aspect, the method comprises (a) determining a first concentration of melanoma inhibitory activity protein (MIA) in a first biological sample taken from the mammalian subject before treatment with the melanoma inhibitory agent; (b) determining a second concentration of MIA in a second biological sample from the mammalian subject taken after treatment with the melanoma inhibitory agent; and (c) comparing the first and second concentrations of MIA, wherein a decrease in the second concentration of MIA measured in the second biological sample as compared to the first concentration of MIA measured in the first biological sample indicates a positive response to the treatment with the melanoma inhibitory agent.01-14-2010
20100009391METHOD FOR EXTRACTING GLUTEN FROM PROCESSED AND UNPROCESSED FOODS BY MEANS OF HEAT BASED ON THE USE OF IONIC AND NON-IONIC DETERGENTS - The present invention relates the analysis of foods for celiac patients. In particular, the invention includes: a method for extracting gluten from foods, which is compatible with an enzyme-linked immunosorbent assay (ELISA) and with the Western Blot technique; compositions suitable for implementing this method; kits that comprise these compositions; a method for the quantification of the gluten present in a food.01-14-2010
20090061466ANTI-DRUG ANTIBODY ASSAY - The invention provides a method for the immunological determination of an antibody against a drug antibody in a sample using a double antigen bridging immunoassay comprising a capture drug antibody and a tracer drug antibody, characterized in that the capture drug antibody is a mixture of said drug antibody conjugated to the solid phase at least two different antibody sites and the tracer drug antibody is a mixture of said drug antibody conjugated to the detectable label at least two different antibody sites.03-05-2009
20090061465COMPOSITION FOR ANALYZING DIABETES MELLITUS AND/OR RETINAL VASCULAR DISEASE AND ANALYZING METHOD THEREOF - Disclosed are composition for diagnosing a diabetes mellitus and a retinal vascular disease, a kit for diagnosing the retinal vascular disease including the protein, a gene encoding the protein, and a method for analyzing an antibody prepared by the diabetes mellitus and/or the retinal vascular disease using the same.03-05-2009
20100003707GLAUCOMA BIOMARKER - According the present invention, Brain Derived Neurotrophic Factor (BDNF) in the tears or blood is used as a biomarker for early detection and assessing the progression of POAG. A reduced level of BDNF compared to normal range can be the sign of POAG. Lower levels of BDNF represent more advanced cases of POAG. The invention includes both the method and the analytic kit for performing the method.01-07-2010
20100291601CARBOHYDRATE BINDING MODULE AND USE THEREOF - The present invention relates to an antibody mimetic of carbohydrate binding module (CBM) which specifically binds to an epitope on HIV glycoprotein. The present invention also relates to a method of detecting HIV glycoprotein.11-18-2010
20100291600Immunoassay - The present invention provides an immunoassay method for detecting or determining the amount of salvinorin A, salvinorin B and/or analogues thereof in an in vitro sample, an antibody for salvinorin A, salvinorin B and/or analogues thereof and a kit for detecting the presence of or determining the amount of salvinorin A, salvinorin B and its analogues thereof in a sample.11-18-2010
20100291599LARGE AREA SCANNING APPARATUS FOR ANALYTE QUANTIFICATION BY SURFACE ENHANCED RAMAN SPECTROSCOPY AND METHOD OF USE - Raman spectra of protein immunoblots or enzyme linked immunosorbant assay procedures are acquired with a scanning Raman spectrometer. The sensitivity of the measurement is increased by conjugating secondary antibodies used in the Western blot and ELISA methods to surface enhanced Raman Scattering (SERS) labels. The resulting blot or well plate is analyzed with a Raman system that has forms a pixel map of the sample. More specifically, the Raman system generates an effectively line-shaped illumination pattern and scans the sample in the direction perpendicular to the line while the signal is accumulating on the detector. Each pixel is therefore a rectangle defined by the length of the illumination and the distance traveled by the sample within the duration of signal accumulation on the detector. The pixels are sequentially acquired to generate a map of the sample.11-18-2010
20120264144METHOD FOR BINDING A RECOMBINANT POLYPEPTIDE TO A CARRIER - The present invention refers to a method for binding a recombinant polypeptide to a carrier, wherein a layer is bound to a carrier, and the layer comprises a recombinant polypeptide on the surface distal to the carrier.10-18-2012
20120225441PROTEIN MARKERS FOR DETECTING LIVER CANCER AND METHOD FOR IDENTIFYING THE MARKERS THEREOF - The present invention relates to the diagnosis of liver cancer. It discloses the use of protein ERBB3 and protein IGFBP2 in the diagnosis of liver cancer. It relates to a method for diagnosis of liver cancer from a liquid sample, derived from an individual by measuring ERBB3 protein and IGFBP2 protein in the sample. Measurement of ERBB3 protein and IGFBP2 protein can, e.g., be used in the early detection or diagnosis of liver cancer.09-06-2012
20120225442New Markers for the Diagnosis of Celiac Disease - The invention relates to new peptides and to their use in the diagnosis of celiac disease.09-06-2012
20120225440HEPATOCELLULAR CARCINOMA PROTEIN MARKER, AND METHOD FOR DETECTION OF HEPATOCELLULAR CARCINOMA USING THE SAME - A method of detecting hepatocellular carcinoma includes using an isolated protein including an amino acid sequence represented by SEQ ID NO: 1.09-06-2012
20120083008Methods for obtaining molecules with reduced immunogenicity - The invention provides a method for reducing immunogenicity of a peptide, protein or protein complex in an individual comprising introducing at least one cross-link between two amino acids in the peptide, protein or protein complex that is stable or irreversible in vivo, wherein the at least one cross-link reduces the immunogenicity of the peptide, protein or protein complex in the individual compared to an identical peptide, protein or protein complex not so cross-linked.04-05-2012
20120258478METHOD OF COLLECTING SPECIMEN AND METHOD OF DIAGNOSING SUBJECT TO DETECT UPPER DIGESTIVE SYSTEM DISEASE - A method of collecting a specimen of the present invention detects upper digestive system disease. The method of collecting a specimen includes: a step of administering a stimulant of pancreatic juice secretion or a stimulant of bile secretion to a subject; a step of positioning sampling equipment in the duodenum of the subject into which duodenal juice is secreted, the sampling equipment being used to collect and store the duodenal juice; a step of starting collection of the duodenal juice by the sampling equipment within five minutes from the administration of the stimulant of pancreatic juice secretion or the stimulant of bile secretion; and a step of stopping collection of the duodenal juice such that collection time for the duodenal juice is within five minutes from the start of collection.10-11-2012
20120190050CANCER BIOMARKER AND THE USE THEREOF - Gastric cancer is one of the leading causes of cancer-related death worldwide. To date no specific marker is available for gastric cancer screening. The expression profile of 37 proteins was identified to be consistently different between the plasma of normal and gastric cancer subjects. The expression of complement component C9 protein was validated to be significantly higher in the plasma of gastric cancer compared to normal subjects. This was independent of the gastritis and 07-26-2012
20120329078METHOD OF DIAGNOSING CANCER USING G-CSF PROTEIN HAVING A DELETION OF AN AMINO ACID SEQUENCE CORRESPONDING TO EXON 3 AS A DIAGNOSTIC CANCER MARKER - Disclosed are a method, a composition, a microarray, an antibody and a kit for diagnosis and prognosis of cancer, based on detection of deletion of the exon 3 region of G-CSF gene or levels of a mutated G-CSF protein having a deletion of an amino acid sequence corresponding to the exon 3 region, wherein the deletion of the exon 3 region of the G-CSF gene is used as a cancer biomarker.12-27-2012
20090017479LY6H GENE - The invention provides a brain-specific gene useful in treating Alzheimer's disease, for instance, which comprises a nucleotide sequence cording for the amino acid sequence shown in SEQ ID NO:1 and fragments thereof; an expression vector comprising the gene; a host cell comprising the expression vector; an expression product of the gene; an antibody against the product; a therapeutic and prophylactic composition for neurodegenerative disease; and the like.01-15-2009
20110124019METHOD OF USING CARBONIC ANHYDRASE TO DETECT HEMOLYSIS - A method and a test for using carbonic anhydrase (CA), particularly CA-I or CA-II, as a biomarker of hemolysis. The method and test detect hemolysis by determining a percentage erythrocyte hemolysis in a specimen or sample of blood based upon quantification of carbonic anhydrase present in the extracellular portion of the blood. The method and test serve to optimize therapeutic efficacy for treatments of hemolysis. Plasma carbonic anhydrase is used to determine the percentage hemolysis in plasma. Furthermore, CA is quantified with specificity to the isozyme present in the plasma.05-26-2011
20110124018DETECTION OF PATHOGENIC POLYPEPTIDES USING AN EPITOPE PROTECTION ASSAY - The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide target epitope with a blocking agent. After denaturation of the polypeptide, a detecting agent is used to detect protein with target epitope that was inaccessible during contact with the blocking agent.05-26-2011
20120231481METHODS OF EVALUATING BAFF - The present disclosure provides compositions and methods relating to the evaluation of BAFF in a biological sample from a subject.09-13-2012
20130171671METHODS FOR MODELING PROTEIN STABILITY - The present invention relates to a method for determining the highest temperature that is suitable for performing accelerated protein stability studies, as well as to a method for modeling real-time protein stability from accelerated stability data generated at said temperature.07-04-2013
20120264145Assay for Soluble CD200 - The disclosure relates to methods for identifying a subject having elevated CD200 levels and/or comprising cells overexpressing CD200, the method comprising the step of assaying a biological fluid from the subject to determine a level of soluble CD200, wherein a level above control indicates the subject has elevated CD200 levels. Diagnostic methods, methods of monitoring prognosis and methods of medical treatment relating to CD200 associated medical conditions are also provided. The disclosure also provides assays and kits useful in the diagnosis of a medical condition associated with elevated CD200 and/or comprising cells overexpressing CD200.10-18-2012
20120264143CYTOKINE-LIKE PROTEINS - A full-length cDNA corresponding to an EST (AA418955), which does not show any homology to other proteins in the database but has a weak homology to G-CSF, has been successfully isolated by synthesizing primers based on the EST sequence, and effecting PCR-cloning from a human fetal spleen library. Sequencing of the thus-isolated cDNA and analysis of its structure revealed that the cDNA has typical characteristics of a factor belonging to the IL-6/G-CSF/MGF family. It is also found out that the culture supernatant of said sequence-transfected CHO cells shows a proliferation supporting activity towards bone marrow cells in the coexistence of kit ligand.10-18-2012
20100227342DIAGNOSIS OF PREECLAMPSIA - The present invention provides methods and compositions related to the detection and/or monitoring of the levels of angiogenic factors, specifically VEGF, PlGF and sFlt-1, in urine samples obtained from pregnant women and the effects of such levels on the risk of developing complications of pregnancy, including hypertensive disorders such as preeclampsia, in the first, second, and/or third trimester of pregnancy. The present invention also provides kits for identifying and screening patients at risk of developing a complication of pregnancy, such as preeclampsia.09-09-2010
20110045511METHODS OF MONITORING THE MODULATION OF THE KINASE ACTIVITY OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USES OF SAID METHOD - The present invention relates generally to methods of in vitro diagnostics, in particular the use of a compound selected from the group consisting of fibroblast growth factor 23 (FGF23), inorganic phosphorus (P), the product of inorganic phosphorus and total calcium (P×tCa), osteopontin (OPN) and parathyroid hormone (PTH) as biomarker. Said biomarkers can be used to monitor the modulation of fibroblast growth factor receptor (FGFR) kinase activity, in particular its inhibition, and/or the occurrence of secondary effects of FGFR inhibition. The invention further provides methods and kits relating to these uses.02-24-2011
20110045509Method For Determining The Type of an Inflammatory-Rheumatic Disease in Synovial Fluid - Disclosed is an in vitro method for determining the type of an inflammatory-rheumatic disease, wherein the presence or absence of the protein Hdj2 in synovial fluid is determined at an early stage of the disease.02-24-2011
20110045507FSTL-1 AS A BIOMAKER OF INFLAMMATION - The invention provides methods and kits for diagnosing severity of particular types of inflammatory diseases, such as rheumatic diseases, by assessing protein levels of follistatin-like protein 1 (FSTL-1). The level of FSTL-1 protein present in the serum or synovial fluid of individuals suspected of having certain inflammatory disease (e.g, rheumatoid arthritis) is positively correlated with the severity of the disease.02-24-2011
20110045505INTEGRATED SEPARATION AND DETECTION CARTRIDGE WITH MEANS AND METHOD FOR INCREASING SIGNAL TO NOISE RATIO - The present invention relates to a device and a method for quantitative detecting of the presence or absence of a target analyte in a liquid sample having a volume of less than 200 μl, the device comprising a reaction chamber in the form of a capillary channel, a first part comprising a sample inlet for the introduction of a sample containing an analyte, and a discharge outlet for the discharge of waste products; a second part comprising means for detection of the target analyte, and a solution inlet for introduction of washing solutions and reaction mixtures; and means for transferring an immobilized analyte from the first part to the second part of the chamber and vice versa, where the first and second parts are separated such that other liquid sample material may not enter the second part of the chamber and such that light may not be transferred from the first part of the chamber to the detector part of the second part of the chamber.02-24-2011
20110045504Prognostic Prediction Method for Acute Coronary Syndrome - Problem is to provide a diagnostic marker for prognostic prediction of acute coronary syndrome. Means to solve the Problem is to make it possible to predict the risk of recurrence of acute coronary syndrome by measuring the concentration of soluble LOX-1 in the blood.02-24-2011
20100136588Methods and Devices for Diagnosis of Appendicitis - A method is provided for determining the severity of appendicitis in a patient that includes testing a blood, serum or plasma sample from the patient for the quantity of MRP8/14 in the sample and comparing it with the quantity of MRP8/14 present in standard samples correlated with an appendicitis severity scoring system. A histologically-based appendicitis severity scoring system is also provided. Immunoassays and kits for performing the appendicitis assays of this invention are also provided, as are standard samples and data correlating MRP8/14 quantities present in patient samples to histologically-based appendicitis severity grades. The methods and immunoassay devices and kits of this invention are useful for managing the treatment of patients presenting with appendicitis symptoms.06-03-2010
20120322087METHOD FOR EXAMINING ACUTE RENAL DISORDER - Provided is a test method for acute kidney injury, including detecting urinary podocalyxin. According to the test method, a subject to be tested who has a higher value for the urinary podocalyxin than a reference value can be assessed to have acute kidney injury. Further, as compared to a conventional method, the test method allows acute kidney injury to be assessed accurately and non-invasively, which allows a physical burden on a patient to be reduced. Thus, the test method is useful.12-20-2012
20120322088METHODS FOR THE DIAGNOSIS, RISK ASSESSMENT, AND MONITORING OF AUTISM SPECTRUM DISORDERS - Methods for the diagnosis, risk assessment, and monitoring of Autism Spectrum Disorder (ASD) are disclosed. More specifically the present invention relates to the measurement of small molecules (metabolites) in human plasma that are found to have different abundances between persons with a clinical manifestation of ASD and subjects not expressing symptoms of ASD. Further, this invention relates to the monitoring of putative therapeutic strategies designed to ameliorate the biochemical abnormalities associated with ASD.12-20-2012
20100203559Immuno-Based Botulinum Toxin Serotype A Activity Assays - The present specification discloses SNAP-25 compositions, methods of making α-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P08-12-2010
20100203558METHOD AND IMMUNE ABSORBENTS FOR THE SPECIFIC DETECTION AND ABSORPTION OF CELIAC DISEASE-AND HERPETIFORM DERMATITIS-ASSOCIATED ANTIBODIES - The present invention relates to fusion peptides that are derived from components of gliadin, to a method and reagents for the serological diagnosis of celiac disease or dermatitis herpetiformis by way of assaying antibodies that are directed against modified gliadin. The invention also relates to methods and pharmaceutical compositions for treating said diseases by specific immunoabsorption of these antibodies.08-12-2010
20110236915ZAP-70 EXPRESSION AS A MARKER FOR CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) - It has been surprisingly found that ZAP-70 expression, both at the protein and mRNA levels, is indicative of clinical subgroups of CLL/SLL patients. In particular, high ZAP-70 expression is indicative of Ig-unmutated CLL/SLL. Methods are provided for discriminating between clinical subgroups of CLL/SLL, by determining whether subjects overexpress ZAP-70 mRNA mRNA or protein.09-29-2011
20110236913COMPOSTION AND KIT FOR DIAGNOSING IMMUNOGLOBULIN A NEPHROPATHY AND TGBM NEPHROPATHY - Disclosed is the development of a protein used as a biomarker for diagnosing IgA nephropathy and TGBM (thin-glomerular-basement-membrane) using urine through a target proteomics method. The disclosed development relates to a diagnosis biomarker protein and a kit for diagnosing IgA nephropathy and TGBM and predicting progress of the nephropathy in advance using the protein. The protein level is increased or decreased in urine from a patient with IgA nephropathy or TGBM nephropathy compared to urine from a normal patient. According to the disclosed development, the degree of the disease can be grasped by detecting IgA nephropathy and TGBM, enabling early diagnosis and confirming progress from the patient's urine. In addition, a monoclonal antibody produced based on the diagnosis biomarker protein can be used for an immunoassay kit (ELISA, antibody coated tube test, lateral-flow test, potable biosensor). As well, the monoclonal antibody is used in early diagnosis and progress detection of IgA nephropathy and development of a novel drug for the purpose of treatment.09-29-2011
20110236912SYSTEMS AND METHODS FOR CHARACTERIZING LUPUS ERYTHEMATOSUS - The present invention provides systems and methods for characterizing biological markers in the urine of systemic lupus erythematosus (SLE) subjects. In particular, the present invention relates to the detection of cytokines and chemokines in urine of SLE subjects for determining nephritic disease states and kidney damage in SLE subjects and the efficacy of agents and interventions used to treat lupus nephritis.09-29-2011
20100233740USE OF URINARY NGAL TO DISTINGUISH KIDNEY DISEASE AND PREDICT MORTALITY IN SUBJECTS WITH CIRRHOSIS - In one embodiment, the present invention is directed to methods for diagnosis of acute kidney injury (AKI) and hepatorenal syndrome (HRS) in cirrhosis patients, and to methods for distinguishing between AKI and/or HRS and/or other kidney diseases in cirrhosis subjects. In another embodiment, the present invention is directed to prognostic methods for predicting disease-specific mortality in cirrhosis patients. In some aspects, the diagnostic and prognostic methods of the invention are based on determining whether a bodily fluid sample, such as a urine sample, contains an amount of NGAL protein that exceeds or is less than a certain threshold level, or that falls within a certain range.09-16-2010
20100233739USE OF URINARY NGAL TO DIAGNOSE UNILATERAL AND BILATERAL URINARY OBSTRUCTION - In one embodiment, the present invention is directed to methods for diagnosis of urinary tract obstruction (UTO), and to methods for distinguishing between unilateral and bilateral UTO. In some aspects, the diagnostic methods of the invention are based on determining whether a bodily fluid sample, such as a urine sample, contains an amount of NGAL protein that exceeds or is less than a certain threshold level, or that falls within a certain range. The present invention also provides diagnostic kits for the diagnosis of UTO and for distinguishing between unilateral and bilateral UTO.09-16-2010
20100233738URINE PRETREATMENT AGENT FOR URINARY PROTEIN QUANTITATION, URINE PRETREATMENT METHOD, AND URINARY PROTEIN QUANTITATION METHOD - The present invention is intended to develop a urine pretreatment agent, a urine pretreatment method, and a urinary protein quantitation method which reduce or cancel the influences of urine pH variations, cancel the influences of precipitates of urinary inorganic salts, and solubilize membrane proteins. The present invention provides: a urine pretreatment agent for urinary protein quantitation, comprising a buffer, a chelating agent, and a surfactant; a urine pretreatment method comprising a step of mixing 10 to 1000 parts by mass of the urine pretreatment agent of the present invention with 100 parts by mass of urine; and a urinary protein quantitation method comprising steps of: mixing 10 to 1000 parts by mass of the urine pretreatment agent of the present invention with 100 parts by mass of urine; and then measuring the protein concentration.09-16-2010
20100233737MARKER SPECIFIC TO AN OXIDATIVE DEGRADATION OF TISSUES CONTAINING TYPE III COLLAGEN, MEANS AND METHODS AND KITS FOR THE DIAGNOSIS, MONITORING OR PROGNOSIS OF PATHOLOGIES TARGETED BY THIS MARKER - Novel peptide marker, specific to the oxidative degradation of tissues containing type III collagen, preferably to nitrosylation of the type III collagen. This marker is defined of at least one peptide sequence of 5 to 25 amino acids (AAs) including a sub-sequence QYDSYD in which at least one of the Ys is nitrosylated and Q corresponds not only to glutamine but also to pyroglutamic acid. This marker is simple, sensitive and reliable and expedites the clinical information for obtaining oxidative degradation of tissues containing type III collagen (O.D.T.Coll III) pathologies. This marker allows better monitoring, prognosis and treatment of the O.D.T.Coll III pathologies. This invention concerns also elements of detection of the marker, methods and kits which allow, on one hand, the early, reliable, efficient and economical diagnosis of the pathologies targeted and, on the other hand, improved monitoring and prognosis of the O.D.T.Coll III pathologies.09-16-2010
20120276561MARKER PROTEIN FOR TYPE-2 DIABETES - The present invention provides a marker protein for the early detection of type II diabetes, antibodies directed to the marker protein and their use in a diagnostic method for type II diabetes and in drug development.11-01-2012
20120088259Post-Translation Modified Cardiac Troponin T As A Biomarker Of A Risk For Heart Failure - The present invention relates to methods and kits for the prediction of risk for heart failure using post-translation modified forms of cardiac troponin T as a biomarker.04-12-2012
20120088258INTEGRATED DEVICE FOR SURFACE-CONTACT SAMPLING, EXTRACTION AND ELECTROCHEMICAL MEASUREMENTS - The invention relates to a device and method for non-invasive detection of an analyte in a fluid sample. In one embodiment, the device comprises: a collection chamber containing an absorbent hydrogel material; a fluidic channel connected to the collection chamber; a sensing chamber connected to the fluidic channel, wherein the device is comprised of a compressible housing that allows transfer of fluid collected by the collection chamber to be transferred to be extracted and withdrawn to the sensing chamber upon compression of the device, wherein the sensing chamber contains a material that specifically detects the analyte and wherein the sensing chamber is operably linked to a processor containing a potentiostat that allows detection of the analyte using electrochemical sensing.04-12-2012
20120088257METHOD FOR DIAGNOSING VASCULITIS - The invention relates to a method for the in vitro detection of vasculitis or the risk of developing vasculitis, including determining the presence and/or the amount of anti-endothelial cell antibodies (AECA) or anti-vascular smooth muscle cell (VSMC) antibodies in a biological sample from a patient.04-12-2012
20120088256Anaplasma translocated substrate-1 (ATS-1) and sero-detection of anaplasma phagocytophilum - Disclosed is the use of isolated Ats-1 protein in 04-12-2012
20120088255HER-2 BINDING ANTAGONISTS - There is disclosed a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an isolated polypeptide having from about 50 to 79 amino acids taken from the sequence of SEQ ID NO:1, wherein the polypeptide binds to the extracellular domain ECD of HER-2 at an affinity of at least 1004-12-2012
20110287454METHODS FOR MONOCLONAL ANTIBODY PRODUCTION - This invention provides improved methods for production of monoclonal antibodies against a protein of interest. The present methods are based on immunization of an animal with a fusion protein between a protein of interest and a Th2 cytokine such as IL-4, IL-5, IL-13 and IL-31.11-24-2011
20110294147SEROLOGICAL SCREENING FOR HHV-8 INFECTION USING ANTIGEN MIXTURES - The invention provides compositions, methods, and kits for the diagnosis or detection of active, latent, or prior infection with human herpesvirus 8 in a subject sample.12-01-2011
20120329077METHODS AND COMPOSITIONS FOR CATEGORIZING PATIENTS - The disclosure provides, among other things, molecular markers for categorizing the neoplastic state of a patient, methods for using the molecular markers in diagnostic tests, nucleic acid and amino acid sequences related to the molecular markers, reagents for detection of molecular markers, and methods for identifying candidate molecular markers in highly parallel gene expression data.12-27-2012
20090203053METHODS AND MATERIALS FOR AMPLIFICATION OF A SIGNAL IN AN IMMUNOASSAY - Ultrafine particles are provided having a core region that has a signal amplifying molecule and a shell region that surrounds the core region. The shell region has at least one antibody affixed to its surface that is specific for at least one antigen. Alternatively, the ultrafine particles may entrap the signal amplifying molecule within its matrix and may also have antibodies affixed to its surface for molecular recognition. Ultrafine particles are also provided having a matrix component that includes a signal amplifying molecule and at least one antibody specific for the antigen or biomaterial. The ultrafine particles of the present disclosure may be used in assays for the detection, including quantification, of one or more antigens present in a biological sample.08-13-2009
20120288882TYPE IV SECRETION SYSTEM PROTEINS IN SERO-DETECTION OF ANAPLASMA PHAGOCYTOPHILUM - Disclosed are two (2) proteins in the Type IV Secretion System (TIVSS) in 11-15-2012
20120288879METHODS FOR DEVELOPING AND ASSESSING THERAPEUTIC AGENTS - Assays are provided that can effectively assess tumor response to one or more therapeutic agents. Preferred assays of the invention include assessment of posttranslation modification and expression of target proteins.11-15-2012
20120288880METHODS AND COMPOSITIONS FOR DIAGNOSIS OR PROGNOSIS OF CARDIOVASCULAR DISEASE - The invention provides methods of screening a mammalian subject to determine if the subject is at risk to develop or is suffering from, cardiovascular disease. In one embodiment, the method comprises detecting a measurable feature of at least two biomarkers in an EMT subfraction, or in a complex containing apoA-I or apoA-III isolated from a biological sample obtained from the subject, wherein the at least two biomarkers are selected from the group consisting of apoA-I, apoA-II, apoB-100, Lp(a), apoC-I, and apoC-III, combinations or portions and/or derivatives thereof, and comparing the measurable features of the at least two biomarkers from the biological sample to a reference standard, wherein a difference in the measurable features of the at least two biomarkers from the biological sample and the reference standard is indicative of the presence or risk of cardiovascular disease in the subject.11-15-2012
20120100562METHODS AND COMPOSITIONS FOR MODULATING THE WNT PATHWAY - The invention provides methods and compositions for modulating the Wnt signaling pathway, in particular by interfering with binding of Dkk1 or SOST with LRP5 and/or LRP6.04-26-2012
20100151504DIAGNOSIS AND RISK CLASSIFICATION OF ACUTE CORONARY SYNDROME BY MEANS OF CT-PROET-1 IN COMBINATION WITH NT-PROBNP - The invention relates to a method for diagnosis and/or risk classification for acute coronary syndrome (ACS), in particular for acute myocardial infarct (AMI) and angina pectoris (AP) and/or a post-myocardial infarct, wherein a determination of the C-terminal pro-endothelin (CT-proET-1) or fragments and partial peptides therefrom, is carried out in combination with NT-proBNP.06-17-2010
20100159486BIOMARKERS FOR NEUROLOGICAL CONDITIONS - Low molecular weight (LMW) peptides have been discovered that are indicative of neurological conditions, such as Alzheimer's Disease (AD), cognitive impairment and brain microhemmorhages. Evaluating patient samples for the presence of such LMW peptides is an effective means of detecting neurological conditions and monitoring the progression of the disease. The LMW peptides are particularly useful in detecting neurological conditions during the early stages without invasive procedures.06-24-2010
20100167320Compositions and Methods for Detecting and Quantifying Toxic Substances in Disease States - The present invention relates to compositions comprising synthetic aggregated peptides (SAPs). The present invention also relates to the use of these SAPs as standards in methods for quantifying substances in a sample. The present invention also relates to methods of detecting, diagnosing and monitoring the progression of an abnormal condition in a subject with the methods comprising determining levels of an aggregated biomarker in a subject by measuring levels of the aggregated biomarker in the subject and correlating these levels to a standard curve, where the standard curve is established using a SAP peptide as the standard.07-01-2010
20100167322METHOD OF DETECTING CEREBRAL STROKE OR ASYMPTOMATIC CEREBRAL INFARCTION USING ACROLEIN, INTERLEUKIN-6 AND CRP CONTENTS, POLYAMINE OXIDASE ACTIVITY OR POLYAMINE OXIDASE PROTEIN CONTENT AND SUBJECT'S AGE AS INDICATORS - A method of detecting cerebral stroke or asymptomatic cerebral infarction is disclosed. The method comprises measuring the contents of aldehyde compounds formed from polyamines, interleukin-6 and C-reactive proteins, the polyamine oxidase activity or the polyamine oxidase protein content in a biological sample obtained from a subject and using the measurement data thus obtained and the age of the subject as indications. Also disclosed is a kit for conducting this detection method; and a system for detecting cerebral stroke or asymptomatic cerebral infarction which comprises this kit.07-01-2010
20100167323METHOD FOR STABILIZATION OF PROTEINS IN SOLUTION - The present invention relates to a method for stabilization of analytes in solutions of solubilized body samples. The method comprises the steps of solubilizing the body samples obtained from a subject in a suitable sample medium and stabilizing said body sample contained within the sample medium by heating said sample medium for a certain period of time. A further aspect of the invention is a method of a denaturing immunoassay of proteins in solution. The method comprises the steps of bringing a sample containing proteins into contact with a denaturing agent and heating said sample in the presence of the denaturing agent to allow the protein to be denatured.07-01-2010
20130011868NOVEL PLATELET ACTIVATION MARKER AND METHOD FOR DETERMINATION THEREOF - The present invention provides a convenient and highly sensitive method of determining sGPVI present in plasma; this is accomplished by establishing a plurality of mouse hybridomas that produce antibody against GPVI and combining the antibodies produced therefrom. Provided thereby are a novel platelet activation marker, a reagent and method for determining this novel platelet activation marker, and novel applications of this marker in, for example, the diagnosis of diseases associated with platelet activation/vascular endothelial injury.01-10-2013
20130011866ANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TO TWO OR MORE ANTIGEN MOLECULES REPEATEDLY - The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.01-10-2013
20130011867BLADDER CANCER BIOMARKER AND TEST METHOD USING THE SAME - A bladder cancer biomarker and a test method using the same are provided. The biomarker contains serum amyloid A-4 protein (SAA4), which exist in the urine specimen of a testee. The expression intensity of the biomarker can facilitate diagnosis of bladder cancer and evaluation of aggressiveness and malignancy of bladder cancer. Thereby, the physician can arrange an optimized treatment to achieve the best therapeutic effect.01-10-2013
20130011869NOVEL MONOCLONAL ANTIBODIES AND METHOD OF IMMUNOLOGICAL ANALYSIS OF D-DIMER - Provided are an antibody capable of specifically and accurately measuring digested products of stabilized fibrin (D-dimer), and a method and a reagent for measuring D-dimer using the antibody. The antibody specifically reacts with D-dimer, which is plasmin-digested products of stabilized fibrin, but does not react with fibrinogen or plasmin-digested products of fibrinogen, which include fragment X, fragment Y, fragment D1, and fragment E3, and does not react with dissociation products of DD/E monomer, which include fragment DD, fragment E1, and fragment E2.01-10-2013
20130011865MARKER FOR DETECTING GASTRIC CANCER AND METHOD FOR DETECTING GASTRIC CANCER - It is intended to provide a method for detecting gastric cancer, which is low invasive to a human test subject and has high detection sensitivity and accuracy. The present invention provides a method comprising measuring in vitro the amount of Cofilin 1 protein, a variant thereof, and/or a fragment thereof in a body fluid sample derived from a human test subject, and detecting the presence or absence of gastric cancer affecting the test subject on the basis of the amount, and a kit for gastric cancer diagnosis comprising an antibody capable of specifically binding to the protein.01-10-2013
20130017562Assay for Vascular CalcificationAANM Shanahan; Catherine M.AACI LondonAACO GBAAGP Shanahan; Catherine M. London GBAANM Kapustin; Alexander N.AACI LondonAACO GBAAGP Kapustin; Alexander N. London GB - An assay for identifying an individual having or at risk of developing vascular calcification, said assay comprising obtaining a blood sample from an individual and measuring the level of a vesicular compound in a matrix vesicle present in the blood sample from said individual; wherein an increased level of said compound indicates an individual at risk of developing vascular calcification.01-17-2013
20130017561Lateral Flow Device for Diagnosing Microbial Infections - Fungal infections are difficult to diagnose. The most common filamentous fungal infection, aspergillosis, carries with it a high mortality. Culture of the organism is difficult and obtaining samples, e.g., though a lung biopsy, sometimes causes morbidity. Biomarkers that indicate ‘early’ infection in it development are sought after. One such biomarker is detection of galactomannan (GM), a polysaccharide that is attached to hyphal cell walls and secreted during growth of the organism. Galactomannan is excreted in urine. Disclosed herein is a lateral flow assay comprising monoclonal antibodies that recognize specific residues of 01-17-2013
20110159528Methods and Materials for the Detection of Leishmania Infection - The present invention provides rapid diagnostic assays for the detection of 06-30-2011
20110159527METHODS AND KITS FOR DIAGNOSING NEURODEGENERATIVE DISEASE - Methods and diagnostic kits for determining whether a subject may develop a or for diagnosing a neurodegenerative disease. The method includes quantitating the amount of alpha-synuclein and total protein in a cerebrospinal fluid (CSF) sample obtained from the subject and calculating a ratio of alpha-synuclein to total protein content; comparing the ratio of alpha-synuclein to total protein content in the CSF sample with the alpha-synuclein to total protein content ratio in CSF samples obtained from healthy neurodegenerative disease-free subjects; and (c) determining from the comparison whether the subject has a likelihood to develop neurodegenerative disease or making a diagnosis of neurodegenerative disease in a subject. A difference in the ratio of alpha-synuclein to total protein content indicates that the subject has a likelihood to develop a neurodegenerative disease or has developed a neurodegenerative disease.06-30-2011
20110159526METHODS FOR PRDICTING PREGNANCY OUTCOME IN A SUBJECT BY HCG ASSAY - The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.06-30-2011
20080254490Salivary Protease Assays for Identifying Increased Risk of Preterm Delivery Induced by Premature Rupture of Fetal Membranes - Assay methods for identifying an increased risk of preterm delivery induced by premature rupture of the fetal membranes are provided. More specifically, the invention provides salivary protease assays indicative of amniochorion and fetal membrane concentrations of proteases involved in the degradation of the fetal membranes leading to rupture. An increase in salivary protease levels beyond normal or individual baseline provides an indication that protease levels in fetal membranes and/or the amniotic fluid are abnormally elevated. Abnormally elevated protease levels define an increased risk of a premature delivery caused by rupture of the fetal membranes. Thus, abnormally high levels of salivary protease levels indicates elevated risk of PROM, and provides an indication for therapeutic intervention to prevent PROM-induced preterm labor.10-16-2008
20080248508Methods of making a chitosan product having an ultra-low endotoxin concentration and the ultra-low endotoxin chitosan product derived therefrom and method of accurately determining inflammatory and anti-inflammatory cellular response to such materials - Chitosan is a natural product having wide range of applications in the food and cosmetic industries. Food and commodity grade chitosan are laden with pyrogens, such as endotoxins and proteins which limit its applicability in the biological and medical arenas, as minute amounts of endotoxins may induce adaptive and innate responses when contacted with mammalian tissue, pharmaceuticals and biomedical devices. Due to chitosan's ability to avidly bind endotoxin and other pyrogens, they are difficult to remove. The present invention is directed to methods for purifying chitosan from shells, food and commodity grade chitosan into ultra-pure, low endotoxin chitosan having biological and medical applicability. Additionally, the present invention is also directed to a method of determining the pyrogenicity of the ultra-pure low endotoxin chitosan.10-09-2008
20080248506Method of Monitoring Anti-Tumor Activity of an Hdac Inhibitor - The present invention relates to the method of determining the anti-tumor activity of a histone deacetylase inhibitor by measuring the phosphorylation of the histone variant H2AX or the level of cytokeratin-18 fragment aa 387-397.10-09-2008
20080241863Biomarkers for liver diseases and method for using the same - Biomarkers for liver diseases and method for using the same are provided. For detecting liver cirrhosis and liver cancer, the biomarkers are selected from any one of the amino acid sequences with SEQ ID NO:1 to SEQ ID NO:24 or derivatives or fragments or variants or the combination thereof or the antibodies against the amino acid sequences. Then the biomarkers are further developed into detection kits, such that by detecting the existence of autoantibodies or autoantigens in screened specimens, liver diseases are detected with higher accuracy and sensitivity.10-02-2008
20090142781Non-Liquid Phase Type Chemiluminescent Enzyme Immunoassay Method and Assay Kit - A chemiluminescent enzyme immunoassay method whereby a target substance such as a protein is assayed. This chemiluminescent enzyme immunoassay method comprises: the step of capturing an immune complex containing an enzyme-labeled antibody, which is labeled with an enzyme acting a chemiluminescent substrate, and the target substance on a support having no solution layer; the step of overlaying a support membrane containing the chemiluminescent substrate on the immune complex having been captured above; and the step of measuring the luminescence dose caused by the reaction between the enzyme-labeled antibody and the chemiluminescent substrate to thereby quantify the target substance. Since a highly sensitive chemiluminescent enzyme immunoassay is conducted by using a non-liquid phase type reaction system in the chemiluminescent enzyme immunoassay method as described above, multiple items can be assayed by using only a small amount of a specimen and, furthermore, the target substance can be assayed at a high sensitivity thereby without resorting to any troublesome procedures such as pipetting a reagent.06-04-2009
20080233601POLYMERIZABLE CHEMILUMINESCENT COMPOUNDS - Disclosed are compounds having the formula:09-25-2008
20080227127Human NK3-Related Prostate Specific Gene-1 - The present invention relates to a novel member of the NK family of homeobox genes. In particular, isolated nucleic acid molecules are provided encoding the human NK-3 prostate specific gene 1 (NKX3.1) protein. NKX3.1 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of NKX3.1 activity. Also provided are diagnostic methods for detecting prostate cancer and other cancers and therapeutic methods for prostate cancer and other cancers.09-18-2008
20080227126OPTICAL WAVEGUIDE TYPE ANTIBODY CHIP AND METHOD OF MEASURING ANTIGEN CONCENTRATION - An optical waveguide type antibody chip includes a transparent substrate, an incident-side optical element and an emitting-side optical element placed at a distance from each other on a primary face of the substrate, a water repellent resin film formed on the primary face of the substrate including an optical waveguide layer formed between the optical elements, the water repellent resin film includes a reaction hole having exposed the optical waveguide layer on its bottom and a frame-shaped trench surrounding the reaction hole, a rectangular frame-shaped cell wall which is fixed in the trench of the water repellent resin film and which forms a cell capable of infusion and discharge of a specimen solution together with the reaction hole, and an antibody immobilization layer formed on the bottom of the reaction hole, the surface of the antibody immobilization layer being masked with at least a buffer agent and a salt.09-18-2008
20080227125Secreted Polypeptide Species Reduced in Cardiovascular Disorders - The invention discloses human secreted polypeptides that circulate at a decreased level in the plasma of patients with cardiovascular disorders. The invention also provides methods of using compositions including the polypeptides, polynucleotides encoding them, and antibodies specific for these polypeptides, for diagnosis, prognosis, and for drug development.09-18-2008
20080220459Diagnosis of collagen IX destruction - A method for detecting or monitoring the presence of protein fragments, cleaved at novel cleaving sites near the N-terminal part of the collagen IX alpha 1 chain, close to the C-terminal part of the NC4 domain, and at the COL3 domain close to the NC3 domain. Neoepitope antibodies against the neoepitopes were created by the cleavages and an epitope in the cleaved N-terminal part of the NC4 domain unique to collagen IX. A diagnostic kit and antibodies useful in carrying out such methods are also presented09-11-2008
20090275061 METHOD TO MEASURE SERUM BIOMARKERS FOR THE DIAGNOSIS OF LIVER FIBROSIS - This invention discloses using SPR technology to simultaneously and quantitatively measure the concentrations of different liver fibrosis-associated serum biomarkers in a serum sample, which can be used for the diagnosis of liver fibrosis. It also discloses an efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of relevant antibodies used for the detection of liver fibrosis-associated serum biomarkers for the diagnosis of liver fibrosis.11-05-2009
20130177928NORMALIZATION OF PLATELET BIOMARKERS - Described herein are methods useful for normalizing any biomarker in platelets. This has application in any method in which one wishes to ascertain or compare the level of a biomarker, e.g., for diagnostic or prognostic methods relating to a biomarker of interest. Using such an approach can permit the assessment of disease status (e.g., angiogenic status) of an individual with less error than an expression value that is not normalized or that is normalized to total protein levels. Also provided are methods for selecting a normalizing protein for normalizing biomarkers in a sample, e.g., a platelet sample.07-11-2013
20130177931SOLUBLE HUMAN ST-2 ANTIBODIES AND ASSAYS - Provided herein are antibodies and antigen-binding antibody fragments that bind to human soluble Growth Stimulation-Expressed Gene 2 (ST2) protein, kits containing these antibodies and antibody fragments, and methods of using these antibodies and antibody fragments.07-11-2013
20130177932EX-VIVO METHOD FOR THE EARLY DIAGNOSIS OF MINIMAL HEPATIC ENCEPHALOPATHY BY MEANS OF THE DETERMINATION OF THE 3-NITROTYROSINE IN SERUM - An ex-vivo method for the early diagnosis of minimal hepatic encephalopathy by means of determining serum 3-nitrotyrosine relates to an ex-vivo method for the detection and early diagnosis of minimal hepatic encephalopathy (MHE) in patients with liver diseases, including cirrhosis, based on the presence of specific serum biomarkers, specifically by means of determining 3-nitrotyrosine (3-NT), which comprises obtaining serum or plasma obtained from the blood of patients and controls, and determining whether or not the measurement of the concentration of 3-nitrotyrosine obtained is greater than a specific level.07-11-2013
20130143244SOX9 AS A MARKER FOR AGGRESSIVE CANCER - The invention provides methods for determining whether a cancer is or is likely to become aggressive, by detecting the presence of the transcription factor SOX9 in the cytoplasm of cells of the cancer, provided the cancer is not solid pseudopapillary tumor or a melanoma.06-06-2013
20120252039PLASMA KALLIKREIN FRAGMENTS AS DIAGNOSTIC BIOMARKERS FOR LUNG CANCERS - Disclosed herein are diagnostic markers for lung cancer, isolated from serum glycoproteins. The disclosed diagnostic markers for lung cancer are specifically expressed only in the sera of lung cancer patients at high levels, and thus will be very useful for diagnosing lung cancer and estimating disease progression and treatment.10-04-2012
20090023166Method For the in Vitro Diagnosis of Autoimmune Immune Response by Detection of Antibodies Directed Against The Pentraxin 3 Antigen - A method for the in vitro diagnosis of an autoimmune immune response in an individual by detection, in a biological fluid from said individual, of antibodies directed against the pentraxin 3 (PTX3) antigen, characterized in that the presence of antibodies directed against the PTX3 antigen (anti-PTX3 antibodies) are determined in a biological fluid from the individual, and kits for implementing the method.01-22-2009
20110269158USE OF S-ERBB-3 AS A MARKER FOR CANCER - The present invention relates to a method aiding in the assessment of cancer. It discloses the use of s-ErbB-3 as a universal marker of different cancer types. Measurement of s-ErbB-3 can, e.g., be used in the early detection or diagnosis of cancer or in the surveillance of patients who undergo surgery.11-03-2011
20130171670DIAGNOSIS AND MONITORING OF INFLAMMATION, ISCHEMIA AND APPENDICITIS - The invention provides methods and kits for diagnosing and monitoring inflammation and/or ischemia in an animal. The methods comprise determining the quantity of a post-translationally modified protein, other than phosphorylated tau, present in a body fluid from an animal.07-04-2013
20130171669POROUS MEMBRANES HAVING A HYDROPHILIC COATING AND METHODS FOR THEIR PREPARATION AND USE - A modified porous membrane comprising a polymeric hydrophilic coating bonded to a porous membrane is described. The polymeric hydrophilic coatings grafted to the porous membranes comprise, for example, a PEG moiety such as a PEGMA, a PEGDA, or a TMPET, wherein the polymeric hydrophilic coating on the porous membrane decreases non-specific binding of unwanted material to the porous membrane and increases the signal to noise ratio in immunoassays, in vitro diagnostic tests, and point of care tests. Methods of making these modified porous membranes are also disclosed.07-04-2013
20130177929METHOD FOR THE THREE-DIMENSIONAL CO- CULTURE OF PODOCYTES AND ENDOTHELIAL CELLS AND RELATIVE IN VITRO CO- CULTURE SYSTEM - The present invention relates to a new three-dimensional co-culture method of podocytes and endothelial cells, and a relative co-culture system. Furthermore, the invention relates to the use of said co-culture system as an in vitro study model of pathologies affecting the kidneys, and in particular the renal glomerular filtration barrier.07-11-2013
20130177930Methods for measuring protein content - A process for measuring the amount of an antigen in a sample comprising the steps of binding the antigen to a solid phase, forming an antigen-antibody immunocomplex on the solid phase by applying a detection antibody that is specific for the antigen, liberating the detection antibody from the immunocomplex by applying a competing molecule that disrupts the immunocomplex by competing against the antigen for binding to the detection antibody, collecting the liberated detection antibody; and quantifying the liberated detection antibody to measure the amount of the antigen in the sample.07-11-2013
20130095507Method Of Identifying Risk For Thyroid Disorder - A method for identifying a patient that is at risk for developing a thyroid disorder that occurs subsequent to treatment with a regimen that depletes lymphocytes, comprising determining whether antibodies directed against thyroid peroxidase or thyroid microsomes are present in the patient, wherein if the antibodies are present in the patient then the patient is at increased risk for developing a thyroid disorder. A particular embodiment is a method for identifying a patient with multiple sclerosis that is at risk for developing a thyroid disorder that occurs subsequent to treatment with a regimen that depletes CD52-positive cells, comprising determining whether antibodies directed against thyroid peroxidase or thyroid microsomes are present in the patient, wherein if the antibodies are present in the patient then the patient is at risk for developing the thyroid disorder.04-18-2013
20130095506METHODS OF MAKING A DIAGNOSTIC DEVICE BY INTERWEAVING HYDROPHOBIC AND HYDROPHILIC FIBERS, AND DIAGNOSTIC DEVICE THEREFROM - In one aspect, the invention provides a method for making a hydrophilic-silk composition. The method includes providing at least one strand of silk fiber, treating the silk fiber with an alkaline solution to provide at least one strand of degummed silk fiber, and treating the degummed silk fiber with a treatment solution to provide a hydrophilic-silk composition. The degummed silk fiber or the hydrophilic-silk composition is further immobilized with at least one reagent to make a silk-based diagnostic composition. The invention provides a silk-based diagnostic composition made by the method of the invention, and a diagnostic device that comprises the silk-based diagnostic composition. In another aspect, the invention provides a method of making a diagnostic device. The method includes providing at least one strand of a diagnostic-fiber composition, providing at least one strand of a hydrophobic-fiber composition, inter-weaving the at least one strand of the diagnostic-fiber composition and the at least one strand of the hydrophobic-fiber composition. In one embodiment, the diagnostic-fiber composition and the hydrophobic-fiber composition are both based on silk.04-18-2013
20130115631Methods For Measuring High Molecular Weight Complexes Of Fibrinogen With Fibronectin And Fibulin-1 - A method of detecting MSDX Complex-1, the method introducing a first antibody to a sample to create an antibody-sample mixture, wherein the first antibody is specific for one of fibrinogen, fibronectin, or fibulin-1, the first antibody having a label molecule; providing a well coated with a second antibody, the second antibody is specific for one of fibrinogen, fibronectin, or fibulin-1; introducing the antibody-sample mixture to the well; and introducing a substrate to the antibody-sample mixture in the well, wherein the label molecule and the substrate interact to provide a signal, wherein when the signal is detected then MSDX Complex-1 is detected.05-09-2013
20130102014FLUORINATED RESORUFIN COMPOUNDS AND THEIR APPLICATION - The invention provides novel fluorinated resorufin compounds that are of use in a variety of assay formats. Also provided are methods of using the compounds and kits that include a compound of the invention and instructions detailing the use of the compound in one or more assay formats.04-25-2013
20130102013MATERIALS AND METHODS TO DETECT PYRIMIDINE-PYRIMIDINE DIMER FORMATION - Disclosed are methods and apparatuses pertaining to measuring DNA damage due to exposure to ultraviolet light, as measured by formation of pyrimidine-pyrimidine dimers in a polynucleotide. The apparatuses can be in the form of a patch which can be particularly useful in measuring the effectiveness of a sunscreen. The apparatuses can further include a reporter agent for instant determination of the pyrimidine-pyrimidine dimer formation.04-25-2013
20130115637Efficiency of Prion Conversion in vitro and Sensitivity of Prion Detection - The present invention relates to improved methods and kits for the amplification detection of pathogenic prion proteins in samples. In some aspects of the invention, the method comprises: i) contacting the sample with a source of PrP05-09-2013
20130115636HISTONE CITRULLINATED PEPTIDES AND USES THEREOF - The present invention refers to citrullinated synthetic peptides derived from the histone H4 protein and their use in the diagnosis of autoimmune diseases,particularly Rheumatoid Arthritis (RA).05-09-2013
20130115635EPITOPE TAG FOR AFFINITY-BASED APPLICATIONS - Described is an epitope tag useful in affinity-based applications. The invention further includes fusion proteins, methods for preparing fusion proteins, nucleic acid molecules encoding these fusion proteins and recombinant host cells that contain these nucleic acid molecules. The invention also relates to nanobodies and other affinity ligands specifically recognizing the epitope tag, and uses thereof in affinity-based applications.05-09-2013
20130115633Methods & Devices for Diagnosing Cardiac Disorders - A method for diagnosing a cardiac disorder by detecting levels of cardiac-specific membrane polypeptides in tissue samples.05-09-2013
20130115632HIGHLY SENSITIVE METHOD FOR ASSAYING TROPONIN I - A highly sensitive method of assaying an analyte present in a sample using protamine is provided, as well as an immunoassay reagent and biosensor that reduces non-specific binding by electrostatic interaction of protamine with fibrinogen present in the sample.05-09-2013
20130115634PEPTIDES AND METHODS FOR THE DETECTION OF LYME DISEASE ANTIBODIES - The invention provides compositions (e.g., peptide compositions) useful for the detection of antibodies that bind to 05-09-2013
20130130285Markers for Renal Disease - This invention provides reagents and methods for diagnosing renal disease. Differential levels of inosine metabolite, and proteins: apolipoprotein C-I, apolipoprotein C-II, fibrinogen alpha chain, or fibrinogen A-alpha chain, kininogen, Inter-Alpha Inhibitor H4 (ITIH4), keratin Type I cytoskeletol 10 cystatin A, cystatin B and other polypeptides and fragments thereof provide biomarkers of renal disease and are described herein.05-23-2013
20130130286METHODS FOR ASSESSING THE IMMUNE SYSTEM IN A PATIENT - Methods of determining the onset or susceptibility of an immunological disease are provided herein. Also provided are immunoassay techniques for carrying out such methods.05-23-2013
20130130284ENZYME-FIBER MATRIX COMPOSITE OF THREE-DIMENSIONAL NETWORK STRUCTURE, PREPARATION METHOD THEREOF, AND USE THEREOF - Disclosed is a composite of enzyme and fiber matrix with three-dimensional structure. The composite of enzyme and fiber matrix with three-dimensional structure includes a significantly large amount of an enzyme loaded in and immobilized in/onto a matrix when compared to conventional composites. In addition, the immobilized enzyme is prevented from leaching from the matrix when an external impact is applied to the composite of enzyme and fiber matrix with three-dimensional structure. Therefore, the stability of the composite of enzyme and fiber matrix with three-dimensional structure of the present invention is maintained even after a long period passes since a remarkably great amount of enzymes compared with a known composite can be supported and immobilized to a matrix, and the immobilized enzyme is not easily released by an external impact. In addition, it is possible to stably immobilize a great amount of enzymes even if a functional group covalently bonding to enzymes is hardly present on the surface of fiber. Therefore, it is possible to remarkably improve performance by using the composite of enzyme and fiber matrix with three-dimensional structure of the present invention in a biosensor, a bio-fuel cell and the like, compared with the case using a known matrix composite.05-23-2013
20130143239Melittin Peptide Conjugates And Methods Employing Same - Methods and reagents are disclosed for conducting assays for IgE specific for honey bee venom allergen. A reagent comprises a conjugate of a small molecule linked to a terminal glycine amino acid of a synthetic 26 amino acid melittin peptide. In the method a combination is provided that comprises a sample and the aforementioned reagent. The combination is subjected to conditions for binding of IgE specific for honey bee venom allergen to the reagent to form a complex. One or both of the presence and amount of the complex is detected and related to one or both of the presence and amount in the sample of IgE specific for honey bee venom allergen.06-06-2013
20130143240HOMOARGININE AS A BIOMARKER FOR THE RISK OF MORTALITY - The present invention relates to the field of laboratory diagnostics. Specifically, means and methods for determining the risk of mortality in a patient based on homoarginine and to reduce the risk of mortality by administration of homoarginine are disclosed. Moreover, the present invention relates to the use of homoarginine for the preparation of a medicament for the treatment of a patient having an increased risk of mortality caused by stroke or a cardiac cause. Furthermore, the present application relates to a pharmaceutical composition comprising homoarginine and a composition for foodstuff supplement comprising homoarginine.06-06-2013
20130143241IMMUNOASSAY FOR FREE VITAMIN D - Disclosed is the invention to conduct immuno-adsorption of free 25(OH) vitamin D from blood or blood components, notably serum or plasma, after which the absorbed material is measured. A fluoro-alkyl surfactant is used to enhance the solubility of Vitamin D and allow the measurement of free Vitamin D. The invention thus employs a binding protein to absorb the free 25(OH) vitamin D. Thereafter the binding protein comprising the 25-OH vitamin D is subjected to a competitive binding assay with a labeled vitamin D compound, preferably radiolabeled, fluorescent labeled, luminescent labeled, biotin labeled, gold labeled or enzyme labeled. Alternatively the immunocaptured 25-OH vitamin D can be quantitated by mass spectrometry.06-06-2013
20130143242MONOCLONAL ANTIBODY AGAINST GROUP 2 ALLERGEN OF DERMATOPHAGOIDES PTERONYSSIUNS, HYBRIDOMA CELL LINE PRODUCING THEREOF, STRIP, KIT AND METHOD USING SAID MONOCLONAL ANTIBODY FOR DUST MITE ASSAY - This present invention discloses a monoclonal antibody which specifically recognizes and binds to a epitope of group 2 allergen of 06-06-2013
20080206796Use of the Salivary Protein Cd14 as an Indicator of the Low Risk to Developing Dental Caries - It is generally accepted that salivary components are important for dental health, but till now no clear correlation has been found between one or more of said components and the onset of dental caries. The present invention relates to an assay method comprising analysing the presence and/or the content of the salivary soluble CD14 protein from a saliva sample of the individual subjected to examination; the absence of said protein from the salivary sample, or its presence in a reduced amount compared to a predetermined threshold value in caries-free individuals, is considered as a marker of susceptibility to developing caries and/or as a diagnostic element for the existence of ongoing carious lesions.08-28-2008
20110212473MMP ACTIVATION PEPTIDE DETECTION IN BIOLOGICAL SAMPLES - A method is provided along with related reagent kits for aiding the diagnosis of IPF or other interstitial lung diseases, as well as for potential monitoring of disease progression or therapeutic response to treatment.09-01-2011
20110212471METHOD FOR DIAGNOSING ATHEROSCLEROTIC PLAQUES BY MEASUREMENT OF CD36 - The present invention relates to diagnosis, classification and monitoring of atherosclerotic plaques in an individual using measurement of the concentration of CD36 in a body fluid and/or the plaque as such. The present invention also relates to diagnosing the burden of atherosclerotic plaques in an individual. Furthermore, the invention relates to a method for diagnosing stenosis caused by atherosclerotic plaques. Within the scope of the present invention are also methods for determining the treatment regime of an individual. Kits and oligonucleotides for use in the methods are claimed.09-01-2011
20130203087DIAGNOSTIC REAGENTS - There is provided a diagnostic reagent useful to determine whether an animal has a tuberculosis infection or has been exposed to a tuberculosis agent, for example a 08-08-2013
20130203088METHODS AND MEANS FOR DIAGNOSING SPONDYLARTHRITIS USING AUTOANTIBODY MARKERS - The present invention relates generally to methods for diagnosing the presence or the risk of development or the therapy control of spondyloarthritis (Spa), in particular, of ankylosing spondylitis (AS) and undifferentiated spondyloarthritis in a subject, in particular in mammals. In addition, the present invention relates to test kits for use in the diagnosis of the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis, in a subject. In particular, the present invention relates to a method for diagnosing the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis, in a subject analysing for the presence of autoantibodies against CD74 and/or IKBKB in a subject. The presence of autoantibodies against CD74 and/or IKBKB is indicative for the presence or the risk of development, or for the therapy control of Spa, like AS and undifferentiated spondyloarthritis. In particular, detection of the presence of autoantibodies against CD74 and/or IKBKB allows early diagnosis of Spa, in particular, AS and undifferentiated spondyloarthritis.08-08-2013
20130203086MICROFLUIDIC DEVICE FOR GENERATING NEURAL CELLS TO SIMULATE POST-STROKE CONDITIONS - This application provides devices for modeling ischemic stroke conditions. The devices can be used to culture neurons and to subject a first population of the neurons to low-oxygen conditions and a second population of neurons to normoxic conditions. The neurons are cultured on a porous barrier, and on the other side of the barrier run one or more fluid-filled channels. By flowing fluid with different oxygen levels through the channels, one can deliver desired oxygen concentrations to the cells nearest those channels.08-08-2013
20130203089Filtered Adapter for Pipettors - The present invention relates to an adapter containing a filter that can be used with pipetting devices, particularly robotic pipetting devices, to efficiently connect the pipetting device to pipette tips with minimal distortion of the pipette tip. The present invention also relates to a process and a system of using an adapter containing a filter that can be used with pipetting devices, particularly robotic pipetting devices, to assemble the adapter together with an unfiltered pipette tip on the site of application. The adapter and pipette tip are each stackable for saving space at the work station.08-08-2013
20130203090SYSTEMS AND METHODS FOR DETERMINING ANTIBODY-MEDIATED RISK INDEX - Disclosed herein are systems and methods for assessing the risk of risk of hemolytic disease of the fetus or neonate, neonatal alloimmune thrombocytopenic purpura, or transfusion-associated lung injury in a patient or transfusion recipient.08-08-2013
20130137121Method And Device For Assay Determination - A device and method for determining the assay result is disclosed. The device includes a photoelectric detection circuit and a processor, and an optical detection device which is set with a detection zone and a blank zone for measuring assay results, and the photoelectric detection circuit detects the light-reflection intensity signal, and feeds back the detected information to the processor, and the processor is preset with a threshold value changing with time, and determined value processed by the processor is compared with the preset threshold value to obtain the result of assay. The method for determining the assay result display the result when confirmed determined value is bigger than the preset threshold value or can not reach preset threshold value within a fixed time or detected signal can not be determined, wherein the threshold value changes with the time. The device and method for determining the assay result work more efficiently, measure more accurately and cost less than the prior art.05-30-2013
20130137123USE OF HMGB1 AS A BIOLOGICAL MARKER OF BOWEL INFLAMMATORY CONDITIONS, NON-INVASIVE METHOD FOR ITS DETECTION IN FECAL SAMPLES AND KIT THEREOF - A non-invasive method for measuring a bowel inflammatory condition in humans through the presence of HMGB1 protein in fecal extracts and the involvement of such protein in the pathogenesis of chronic inflammatory bowel diseases, more specifically of Crohn's Disease (CD) and of ulcerative colitis (UC), including an analysis protocol to detect the HMGB1 presence in feces through Western blot assay or ELISA assay using an appropriate antigen-antibody. The invention also includes the colorimetric kit for implementing such a method.05-30-2013
20130137120AMYLOID B MEASUREMENT METHOD - Disclosed herein is an Aβ measurement method capable of accurately measuring the concentration of Aβ in a sample even when the sample contains a very low level (about several pM) of Aβ. The amyloid β measurement method includes: a sample preparation step 05-30-2013
20130149720DETECTION OF SOLUBLE ADIPONECTIN RECEPTOR PEPTIDES AND USE IN DIAGNOSIS AND THERAPEUTICS - The present invention relates to soluble C-terminal fragments of the adiponectin receptor and their use in the diagnosis and management of disorders.06-13-2013
20130149721Methods for Inhibiting Amyloid Precursor Protein and Beta-Amyloid Production and Accumulation - Compositions and uses of mGluR06-13-2013
20130149722System and Method for Quantifying Fragile X Mental Retardiation 1 Protein in Tissue and Blood Samples - A system and method for the detection and quantification of fragile X mental retardation protein (FMRP) in human tissue and blood samples. The system includes several high avidity monoclonal antibodies that may be provided on Xmap microspheres to capture FMRP from a tissue or blood specimen. The resulting complex is reacted with a polyclonal anti-FMRP rabbit antibody and then mixed with an anti-rabbit IgG antibody conjugated to phycoerythrin. Fluorescence emitted from the resulting complex is a function of the amount of FMRP present in the specimen.06-13-2013
20130149723Method of controlling insect pests in cotton - An assay system is provided in which gossypol is used as a biological marker to detect evolved resistance of insects to Bt cotton. Detection of gossypol using a monoclonal antibody ELISA-based protocol enables at risk populations of insects to be evaluated for evolved resistance to Bt present in a genetically modified cotton.06-13-2013
20130149724SYSTEMS, DEVICES AND METHODS FOR MICROFLUIDIC CULTURING, MANIPULATION AND ANALYSIS OF TISSUES AND CELLS - Microfluidic devices for dissociating tissue, culturing, separating, manipulating, and assaying cells and methods for using the device are disclosed. Individual modules for tissue dissociation, cell, protein and particle separation, cell adhesion to functionalized, permissive micro- and nano-substrates, cell culturing, cell manipulation, cell and extracellular component assaying via metabolic and therapeutic compounds, compound titration, cell transfection, and micro-ELISA are described. Specialized micro- and nano-substrates and their methods of fabrication are also described. An integrated device is also disclosed. The devices and methods can be used for diagnostic applications, monitoring of disease progression, analysis of disease recurrence, compound discovery, compound validation, drug efficacy screening, and cell-based assays.06-13-2013
20110236914RECORDING ASSAY DEVICE - A method for assaying a sample involves an assessment device having an assay part and a detachable recording part, which are disposed on separable portions of a substrate. The sample to be assayed is received in a sample application well on the assay element, where it contacts a measuring element, generally after being mixed with an assay reagent. Assay information relating to the sample is transferred from the measuring element to data recording element on the recording part. After the information transfer, the assay part and the recording are separated, so that the assay part can no longer transfer information to the data recording element.09-29-2011
20130149725METHODS AND COMPOSITIONS FOR DIAGNOSIS OF UROSEPSIS AND URINARY TRACT INFECTION - The present invention is directed to methods for diagnosis of urosepsis, sepsis, and urinary tract infections (UTIs), and to methods for distinguishing between urosepsis, sepsis of other origins, and localized UTIs. In some aspects, the diagnostic methods of the invention are based on determining whether a bodily fluid sample, such as urine sample, contains an amount of NGAL protein that exceeds or is less than a certain threshold level, or that falls within a certain range. The present invention also provides diagnostic kits.06-13-2013
20110275100SERPIN B 13 AS A MARKER FOR SQUAMOUS CELL CARCINOMA OF THE LUNG - Disclosed is a method aiding in the assessment of squamous cell carcinoma (SCC). It involves the use of the protein serpin B13 as a marker of SCC. Furthermore, the disclosure relates to a method for assessing lung cancer in a tissue sample derived from a patient having non-small cell lung carcinoma (NSCLC) and for differentiating SCC from adenocarcinoma or large cell carcinoma of the lung.11-10-2011
20110275099DIAGNOSTIC METHOD FOR DISEASES BY SCREENING FOR HEPCIDIN IN HUMAN OR ANIMAL TISSUES, BLOOD OR BODY FLUIDS AND THERAPEUTIC USES THEREFOR - The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin protein, including prohepcidin and fragments thereof, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the amino acid sequence between and including amino acids 25 and 49 of a hepcidin precursor protein, and quantifying the hepcidin precursor level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of prohepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin.11-10-2011
20110275098Method for Evaluating The Immunogenicity of Proteins - The invention relates to a method for evaluating the immunogenicity of proteins in humans or animals, comprising analysing the CD4+ T lymphocyte response specific to the protein to be tested in individuals of the (human or animal) species in which the immunogenicity of said cell is analysed.11-10-2011
20120258477FECAL NEOPTERIN CONCENTRATION MEASUREMENT AS AN INDICATOR OF DISEASE ACTIVITY IN INFLAMMATORY BOWEL DISEASE - Disclosed are methods for determining disease activity in a patient having or at risk for developing inflammatory bowel disease (IBD) which include measuring neopterin concentration in a fecal sample from the patient.10-11-2012
20100317040METHODS AND KITS FOR DIAGNOSING CANCER - A method of diagnosing oral cancer or oral pharyngeal cancer in a subject in need thereof is provided. The method comprising determining a level or activity of at least one marker in a saliva sample of the subject, wherein a significant alteration in the level or the activity of the marker with respect to an unaffected saliva sample is indicative of the cancer, wherein the saliva marker is selected from the group consisting of Cyclin D1, phospho-Src, 8-oxoguanine DNA glycosylase (OGG1), Maspin, KI67 and translocator protein 18 kDa (TSPO).12-16-2010
20100317039MOLDING WITH EMBEDDED COUPLING PARTICLES FOR BIOMOLECULES - The invention relates to a molding, comprising a matrix in a material, selected from the group consisting of metal, ceramic and polymer synthetic material, and coupling particles embedded in the matrix, wherein a proportion of the surface of the molding in a geometrical form or in a regular pattern and/or an area of the molding is completely or the entire surface of the molding is mechanically treated.12-16-2010
20100317038GRANZYME A AND GRANZYME B DIAGNOSTICS - A method for identifying a subject being at risk for or having a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease is provided. The method may include determining the concentration of GrA and/or GrB in a blood or serum sample from said subject; and comparing the concentrations to the corresponding concentration in a control sample, wherein an elevated concentration of GrA and/or GrB may be indicative of a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease. The method may further include identifying concentrations of fibrinogen, elastin and/or fibrillin.12-16-2010
20130157294Methods and Compositions for the Diagnosis of Cancer Susceptibilities and Defective DNA Repair Mechanisms and Treatment Thereof - Methods and compositions for the diagnosis of cancer susceptibilities, defective DNA repair mechanisms and treatments thereof are provided. Among sequences provided here, the FANCD2 gene has been identified, and probes and primers are provided for screening patients in genetic-based tests and for diagnosing Fanconi Anemia and cancer. The FANCD2 gene can be targeted in vivo for preparing experimental mouse models for use in screening new therapeutic agents for treating conditions involving defective DNA repair. The FANCD2 polypeptide has been sequenced and has been shown to exist in two isoforms identified as FANCD2-S and the monoubiquinated FANCD-L form. Antibodies including polyclonal and monoclonal antibodies have been prepared that distinguish the two isoforms and have been used in diagnostic tests to determine whether a subject has an intact Fanconi Anemia/BRCA pathway.06-20-2013
20130157295XANTHURENIC ACID DERIVATIVE PHARMACEUTICAL COMPOSITIONS AND METHODS RELATED THERETO - The present invention relates to diuretic pharmaceutical compositions and methods and in particular to certain derivatives of the formula I:06-20-2013
20130157290SOLUBLE ST2 AS A MARKER FOR DISEASE - The present invention relates to materials and methods concerning the IL-1 receptor family protein ST2. Use of soluble ST2 as a marker for cardiovascular disease or disease outcome is provided, in particular as a marker of the risk of mortality.06-20-2013
20130157291DIAGNOSTIC MARKER FOR LUNG CANCER COMPRISING HPaR AS ACTIVE INGREDIENT - Disclosed is a diagnostic marker for lung cancer comprising HpαR as an active ingredient. Because blood, which is relatively easy to sample, is employed as a specimen, the diagnostic kit and marker for lung cancer is very simple and does not subject patients to a load compared to conventional methods that are directed to a biopsy. In addition, the kit and marker of the present invention is useful in the early diagnosis of lung cancer thanks to its high diagnostic sensitivity and selectivity.06-20-2013
20130157292COMPOSITION FOR THE DIAGNOSIS OF OVARIAN CANCER OR PNEUMONIA COMPRISING THIOREDOXIN 1 AS ACTIVE INGREDIENT AND USE THEREOF - Disclosed are a composition for the diagnosis of ovarian cancer and/or pneumonia, comprising thioredoxin 1 as an active ingredient, and the use thereof. Also, a diagnostic kit for ovarian and/or pneumonia and a diagnosis method are provided. Because blood, which is relatively easy to be sampled, is employed as a specimen, the diagnostic method is very simple and does not impose a load on patients compared to conventional methods that are directed to a biopsy. In addition, the method is useful in the early diagnosis of ovarian cancer thanks to the high diagnostic sensitivity and selectivity thereof. Thioredoxin 1 can be used as a diagnostic marker for pneumonia, which is characterized by a decreased serum level, with high selectivity for pneumonia, thereby readily discriminating pneumonia from cancer as well as diseases other than cancer.06-20-2013
20130157293PHARMACEUTICAL MANUFACTURING METHODS - The invention describes methods for manufacturing oligoadenylate synthetase (OAS) proteins for use as active pharmaceutical ingredients in pharmaceutical compositions. A manufacturing method is described that produces large quantities of concentrated, highly active OAS protein for use in pharmaceutical compositions for the treatment of a variety of diseases including viral infection. Methods for monitoring and validating the manufacturing process are also described.06-20-2013
20130183689METHOD FOR DETECTING AND REMOVING ENDOTOXIN - The present invention relates to bacteriophage tail proteins and the derivatives and fragments thereof that are capable of binding endotoxins in the absence of bivalent positive ions, especially Ca07-18-2013
20120282638METHOD FOR IMMUNOASSAY OF AUTOANTIBODY AGAINST KU86, KIT FOR USE IN SAME, AND METHOD FOR DETERMINATION OF PRIMARY HEPATOCELLULAR CARCINOMA USING SAME - An autoantibody against Ku86 can be measured by reacting the autoantibody contained in a sample with a Ku86 antigen (which serves as a reagent) to produce an immune complex of the autoantibody and the Ku86 antigen and measuring the immune complex using a labeled anti-human immunoglobulin antibody. The measurement of the autoantibody enables the determination of primary hepatocellular carcinoma.11-08-2012
20120282637POLYPEPTIDES FOR BINDING TO THE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS AS WELL AS COMPOSITIONS AND METHODS INVOLVING - The present invention relates to a polypeptide or polypeptide complex comprising at least the two amino acid sequences arranged to allow for specific binding to the “receptor for advanced glycation endproducts” (RAGE), one or more nucleic acid(s) coding for the polypeptide or polypeptide complex, a cell producing an antibody against RAGE, a pharmaceutical composition comprising at least one polypeptide or nucleic as defined above, optionally for treating a RAGE-related disease or disorder and a method of diagnosing a RAGE-related disease or disorder.11-08-2012
20120282636Diagnostic Device - The invention provides for rapid response analysis through lateral flow chromatographic assays of specific antigens present in human or animal fluids, or in agricultural, microbial or biological products, with an audio and visual result of the analysis and when needed, an electronic surge to provide heat for rapid results. A lateral flow device for conducting the analysis includes a plurality of components, and a method for making the device forms components of the device on an elongate, ribbon-like substrate of dielectric material, then folds the substrate into shorter lengths which are then secured together to establish a multiple-layered, self-sustaining structure.11-08-2012
20090170138DETERMINING CANINE proBNP - Methods and compositions are disclosed for determining canine proBNP or fragments thereof in a sample. In one method, canine proBNP or fragments thereof are determined by providing a canine sample, contacting the sample with at least one antibody that binds an epitope in the region from amino acids 32 to 48 of canine proBNP, and determining the presence of the canine proBNP or fragments thereof present in the sample. Antibodies that bind canine proBNP and kits comprising such antibodies are also disclosed.07-02-2009
20130183697Methods And Compositions For Detecting Fungi And Mycotoxins - The invention relates to a method of identifying a specific fungal species in patient tissue or body fluid. The method comprises the steps of extracting and recovering DNA of the fungal species from the patient tissue or body fluid, amplifying the DNA, hybridizing a probe to the DNA to specifically identify the fungal species, and specifically identifying the fungal species. The invention also relates to a method of identifying a mycotoxin in patient tissue or body fluid. The method comprises the steps of extracting and recovering the mycotoxin from the patient tissue or body fluid, contacting the mycotoxin with an antibody directed against the mycotoxin, and identifying the myocotoxin. Both of these methods can be used to determine if a patient is at risk for or has developed a disease state related to a fungal infection, and to develop an effective treatment regimen for the patient.07-18-2013
20130183696METHODS OF USE AND KIT FOR MEASUREMENT OF LIPOPOLYSACCHARIDE WITH A TIME RESOLVED FLUORESCENCE BASED ASSAY - The present invention relates to the methods of use for measurement of lipopolysaccharide (LPS) and methods of use for diagnosis of sepsis and LPS-related conditions. Specifically the present invention relates to a time resolved fluorescence (TRF) based assay for the measurement of LPS and methods of use for the measurement of LPS to diagnose sepsis, Gram-negative bacterial infections, and LPS-related conditions.07-18-2013
20130183695BIOMECHANICAL-BASED METHODS OF DIAGNOSING SCOLIOSIS - Methods for diagnosing a scoliosis (e.g., adolescent idiopathic scoliosis (AIS)) and/or a predisposition to developing a scoliosis based on the determination of the variation of osteopontin (OPN) levels induced by mechanical forces/stimuli are described.07-18-2013
20130183694Method For Analyzing A Sample - The invention relates to a method of analysing a sample, comprising the analysis of clinical-chemical parameters and the analysis of immunodiagnostic parameters in a fully automatic analysis apparatus, wherein the analysis apparatus comprises a pipetting apparatus, at least one holder for a reagent cartridge containing the components necessary for carrying out the analysis, a holding apparatus for a measurement cell, at least one measurement cell, with each reagent cartridge being associated with a measurement cell, a holding apparatus for a sample container containing sample, and a photometric or spectrometric measurement device. On the basis of a sample it is possible here for a plurality of different clinical-chemical and/or immunodiagnostic parameters to be determined, to which end a dedicated reagent cartridge is inserted into a holding apparatus of the analysis apparatus for each clinical-chemical or immunodiagnostic parameter to be determined.07-18-2013
20130183693METHOD AND KIT FOR DETECTING THE EARLY ONSET OF RENAL TUBULAR CELL INJURY - A method and kit for detecting the early onset of renal tubular cell injury, utilizing NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance of NGAL in the urine is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.07-18-2013
20130183692INTOLERANCE TESTING FOR INGREDIENTS IN NUTRIENTS, FLAVORINGS AND THERAPEUTICS - Diagnosing an ingredient sensitivity or intolerance in companion animals comprises collecting a sample; screening the sample to detect the presence of an antibody to a particular ingredient. The sample can be saliva or other bodily fluid to detect the presence of an IgA, or IgM antibody to a particular ingredient or composition. Firstly a saliva or blood spot or other non-serum bodily fluid sample is collected. Secondly a blood sample is collected and serum from the sample is screened to detect the semi-quantitative or quantitative presence of at least one of an IgA, or IgM antibody to a particular food ingredient or composition. Thirdly, a biologically active nutrient in relation to the animal is determined.07-18-2013
20130183691POLYPEPTIDE MARKER FOR DIAGNOSIS OF ARTERIOSCLEROSIS, METHOD FOR DETECTION OF ARTERIOSCLEROSIS BY USING THE MAKER OR THE LIKE, AND KIT FOR DIAGNOSIS OF ARTERIOSCLEROSIS - Disclosed are: a polypeptide marker for diagnosing arteriosclerosis; a gene marker for diagnosing arteriosclerosis; an antibody; a probe for detecting an arteriosclerosis marker gene; a DNA microarray or a DNA chip for detecting an arteriosclerosis marker gene; a method for detecting arteriosclerosis; and a kit for diagnosing arteriosclerosis; with which an arteriosclerotic lesion can be detected with much improved accuracy. Specifically disclosed are: a polypeptide marker for diagnosing arteriosclerosis, which comprises a polypeptide having an amino acid sequence set forth in any one of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35 of the Sequence Listing, or a partial amino acid sequence thereof; a gene which encodes the amino acid sequence; a probe for detecting the gene; a DNA microarray or a DNA chip comprising the probe; an antibody bindable to the polypeptide as an antigen; a kit comprising any one of the above-mentioned items; and a method for detecting arteriosclerosis by using any one of the above-mentioned items.07-18-2013
20130183690HIGH AFFINITY BINDING SITE OF HGFR AND METHODS FOR IDENTIFICATION OF ANTAGONISTS THEREOF - Use of a polynucleotide encoding or a polypeptide comprising at least the extra-cellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor.07-18-2013
20130183688TIM-3 LIGANDS AND METHODS THEREOF - The invention relates to isolated polypeptides and nucleic acids encoding polypeptides which comprise a tim-3 IgV domain and a tim-3 intracellular domain, wherein the polypeptides do not comprise a tim-3 mucin domain or a tim-3 transmembrane domain. In addition, the invention relates to methods of modulating immune responses in a subject, comprising administering to the subject a therapeutically effective amount of an agent that modulates tim-3 activity. Immune responses include, but are not limited to, immune tolerance, transplantation tolerance, Th1 responses and Th2 responses.07-18-2013
20130183687METHODS OF DIAGNOSING NON-ALCOHOLIC STEATOHEPATITIS (NASH) - Non-invasive methods for detecting non-alcoholic fatty liver disease (NAFLD) and identifying the presence or absence of non-alcoholic steatohepatitis (NASH) in a subject utilize one or more biomarkers. The methods can differentiate between subjects with NASH and those with simple steatosis. Kits containing one or more agents for measuring the level of the biomarkers can be utilized to perform the described methods.07-18-2013
20130122528COMPOSITIONS AND METHODS FOR ASSESSING APPENDICITIS - The invention relates to methods, devices and systems for assessing appendicitis in a subject. More particularly, this invention relates to methods, devices and systems for assessing appendicitis in a subject by evaluating multiple biomarkers in a sample from the subject and comparing the values of the biomarker to a reference value from a group having high or low risk for appendicitis, or combining the values of the biomarkers using a mathematical algorithm to produce a numerical test score, and comparing the test score to a reference value to assess appendicitis in the subject.05-16-2013
20110311999DIAGNOSTIC PREDICTION OF RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS - The present invention pertains to a diagnostic assay for the diagnosis of an autoimmune disease. The present invention provides an improved diagnostic assay for the diagnosis of an autoimmune disease, particularly rheumatoid arthritis (RA) and Systemic Lupus Erythematosus (SLE). In particular the invention pertains to a method of determining in a sample of a subject the presence of two or more antibodies comprising the step of determining whether an antibody is present in a sample that specifically recognizes a hnRNP-DL polypeptide or a fragment thereof or a splice variant thereof and the further step of determining whether at least one further antibody is present in the sample that specifically recognizes a at least one other hnRNP polypeptide which is not sequence homologue to said hnRNP-DL polypeptide or fragments thereof or splice variants thereof, and/or said CCP peptide and/or a polypeptide comprising at least the Fc-part of IgG, respectively. The invention also relates to polypeptides, protein sets and antibodies that may be used in such methods and assays and for therapeutic use in RA and SLE patients.12-22-2011
20110311998A+ Biomarker Assays - Disclosed herein assay methods which comprise detecting the presence, absence or amount of at least one antibody which specifically binds a first biomarker or an epitope thereof and at least one second biomarker in a sample which comprises a single reaction step whereby both a first capture reagent for the antibody and a second capture reagent for the second biomarker are together contacted with the sample, and detecting the presence, absence or amount of the antibody, and detecting the presence, absence or amount of the second biomarker. Also disclosed are assay methods for prostate cancer.12-22-2011
20110311997METHODS FOR ESTIMATING PRION CONCENTRATION IN FLUIDS AND TISSUE BY QUANTITATIVE PMCA - The present embodiments disclose methods for estimating PrP12-22-2011
20110311996OPTICAL PARTICLE DETECTOR AND DETECTION METHOD - A particle detector apparatus for optically ascertaining a number of particles arranged on a surface, for example, a particle filter. The particle detector apparatus includes a light source, an optical focusing device, a spatially resolving light detector and an evaluation device. The light source emits source light onto the surface. The optical focusing device focuses image light that is emitted from the surface in response to the source light onto the spatically resolving light detector. The spatially resolving light detector includes light sensors that measure brightness values based on the image light, such that the light detector produces image data based on the brightness values delivered by the light sensors. The evaluation device then ascertains the number of particles based on the image data.12-22-2011
20110311995METHOD FOR THE DIAGNOSIS OF SYSTEMIC SCLERODERMA OR OF PULMONARY ARTERIAL HYPERTENSION - The invention relates to an in vitro method for detecting systemic scleroderma (SSc) and/or pulmonary arterial hypertension (PAH), or a risk of developing SSc or PAH, which comprises determining the presence and/or the amount of antibodies in a biological sample originating from a patient.12-22-2011
20110311994AVIAN VACCINES POSSESSING A POSITIVE MARKER GENE - The present invention provides a poultry vaccine containing a positive marker gene. More specifically, recombinant turkey herpesvirus modified by the presence of an extraneous antigen gene that may be used as a positive marker to identify and track vaccinated animals is provided. When inoculated into host animals, a poultry vaccine comprising the recombinant turkey herpesvirus provided in the present invention can elicit serological immune responses to the marker gene product that may be detected by serological assays such as enzyme-linked immunosorbent assay and serum agglutination test, thus enabling easy identification and tracking of vaccinated animals.12-22-2011
20130189716METHOD FOR IDENTIFYING A SUBJECT AT RISK OF DEVELOPING HEART FAILURE BY DETERMINING THE LEVEL OF GALECTIN-3 OR THROMBOSPONDIN-2 - The present invention relates to a method for identifying a subject at risk of developing hypertensive and organ damage, such as and in particular heart failure, comprising: a) obtaining a biological sample of said subject; b) determining the level of at least one non-myocytal marker in said sample; c) comparing the level of said marker to a standard level; and d) determining whether the level of the marker is indicative of a risk for developing hypertensive end organ damage. The non-myocytical marker preferably is galectin-3 or thrombospondin-2.07-25-2013
20130189715Hemolysin and its Protein Fragments in Sero-Detection of Anaplasma Phagocytophilum - Disclosed is the cloning, expression and purification of a hemolysin protein and its protein fragments in 07-25-2013
20120288881Method for Evaluating the Cure Level of Stroke - A method for evaluating the cure level of a stroke patient comprises following steps: (1) obtaining isolated blood sample from said stroke patient; (2) determining the concentration of serum granulocyte colony-stimulating factor (G-CSF) of said blood sample; (3) comparing the relationship between said concentration of granulocyte colony-stimulating factor (G-CSF) and the stroke severity ranking of said stroke patient; wherein United State National Institute of Health Stroke Scale (NIHSS) or modified Ranking Scale (mRS) is used in said stroke severity ranking ; and (4) Using said concentration of granulocyte colony-stimulating factor (G-CSF) to predict the possible cure level of said stroke patient. The invention further provide a prognosis biomarker for evaluating the cure level of a stroke patient, and a kit containing said prognosis biomarker.11-15-2012
20110318763DETECTION OF CANCER BY ELEVATED LEVELS OF BCL-2 - The present invention relates to a method for the diagnosis, prognosis, and monitoring of cancer, such as early or late stage ovarian cancer, in a subject by detecting Bcl-2 in a biological sample from the subject, preferably a urine or blood sample. Bcl-2 may be measured using an agent that detects or binds to Bcl-2 protein or an agent that detects or binds to encoding nucleic acids, such as antibodies specifically reactive with Bcl-2 protein or a portion thereof. The invention further relates to kits for carrying out the methods of the invention. The invention further relates to a device for the rapid detection of Bcl-2 in a bodily fluid and methods for rapidly measuring Bcl-2 in a bodily fluid.12-29-2011
20120015381Methods and kits for the differential diagnosis of Alzheimer's disease versus frontotemporal dementia and for the diagnosis of frontotemporal dementia, comprising FAS-L and CK 18 as biomarkers - The invention relates to methods and kits for the differential diagnosis of Alzheimer's disease (AD) versus frontotemporal dementia (FTD), using biomarkers TNF-α, FAS-L and CK18, taken from a biological sample. Differences in biomarker levels can be used to distinguish between AD and FTD The invention is based on a discovered correlation between FTD and markers FAS-L and CK18. Therefore the invention also relates to the diagnosis of FTD using FAS-L and CK18. The serum concentrations of these biomarkers can further be used as an index of the severity of disease, and may occur in conjunction with clinical-based diagnostic testing and neuro-imaging assessment.01-19-2012
20120021443DIRECTIONAL SURFACE PLASMON COUPLED FLUORESCENCE AND CHEMILUMINESCENCE FROM THIN FILMS OF NICKEL, IRON OR PALLADIUM AND USES THEREOF - Nickel, iron and palladium thin films thermally evaporated onto glass supports are used to demonstrate surface plasmon coupled fluorescence (SPCF) and surface plasmon couple chemiluminescence (SPCC) over a broad wavelength range (400-800 nm) for potential assays or other detection systems. Nickel, iron and palladium thin films used in SPCF and SPCC convert otherwise isotropic emission into highly directional and polarized emission, an attractive concept for surface assays. The emission angles of detected emissions occur over a 10 degree range for tested emitted wavelengths.01-26-2012
20120021442MARKERS FOR DETECTION OF COMPLICATIONS RESULTING FROM IN UTERO ENCOUNTERS - Described herein are biomarkers, such as protein biomarkers, which are diagnostic of and predictive for complications that result from an in utero encounter, such as an infection by the fetus, that can lead to premature birth (PTB). The biomarkers can be used to identify fetuses and newborns at risk for complications of PTB, such as (Early Onset Neonatal Sepsis) EONS, intra-ventricular hemorrhage (IVH) and other poor outcomes.01-26-2012
20120021441IN-PROCESS CONTROL IN A METHOD FOR PRODUCING EPO - The invention relates to a method for determining the isoform composition of erythropoietin, comprising the following steps: 01-26-2012
20120028280XANTHURENIC ACID DERIVATIVE PHARMACEUTICAL COMPOSITIONS AND METHODS RELATED THERETO - The present invention relates to diuretic pharmaceutical compositions and methods and in particular to certain derivatives of the formula I:02-02-2012
20120028279BIOMARKER FOR MONITORING PATIENTS - The present invention is in the field of immunotherapy and relates to methods for determining the efficacy of certain immunotherapy treatments. The methods of the invention include measuring special biomarker at some time following the initiation of immunotherapy treatment to evaluate the clinical outcome of the said treatment. The invention thus has applications to the field of medicine.02-02-2012
20120028278CELL LINES EXPRESSING GUANYLATE CYCLASE-C AND METHODS OF USING THEM - Cell lines that stably express GC-C and methods for using those cell lines are disclosed herein. The invention includes cell lines that express GC-C and techniques for creating cell lines. The GC-C-expressing cell lines are highly sensitive, physiologically relevant and produce consistent results in cell-based assays, e.g., high throughput screening assays.02-02-2012
20130196353DETECTION OF SOLUBLE ADIPONECTIN RECEPTOR PEPTIDES AND USE IN DIAGNOSIS AND THERAPEUTICS - The present invention relates to soluble C-terminal fragments of the adiponectin receptor and their use in the diagnosis and management of disorders.08-01-2013
20130196354Detection of Synthetic Cannabinoids - The invention describes methods and kits for detecting and determining current and future synthetic cannabinoids from the JWH and RCS families. Unique antibodies derived from novel immunogens enable said methods and kits.08-01-2013
20130196355Method and a kit to quantify and qualify exosomes for diagnosis of prostate cancer and prostate hyperplasia - A method and a kit are provided to quantify and qualify exosomes. Specifically the method and the kit quantify PSA-carrying exosomes for a purpose to diagnose prostate cancer and to distinguish between patients having a tumor and those having a benign prostate condition with increased blood levels of PSA. The method and the kit provide a fast, easy to use and accurate method for clinical settings.08-01-2013
20130196356Assay for Prions - The invention relates to a method for detection of abnormal PrP in a sample of blood or urine, said method comprising: (a) diluting the sample with buffer to comprise final concentrations of (i) 10 mM to 500 mM buffer agent; (ii) 1% to 10% w/v bovine serum albumin; and (iii) 1% to 8% w/v CHAPS; (b) adding steel particles and incubating to allow PrP binding; (c) washing the steel particles to remove diluted sample; and (d) detecting abnormal PrP captured on the steel particles using antibody capable of binding said abnormal PrP. The invention also provides compositions and kits.08-01-2013
20120034629PREDICTION OF NON-FATAL AND FATAL ATHEROTHROMBOTIC EVENTS - The present invention relates to methods and systems for the prediction of atherothrombotic events in human subjects. Preferably the human subjects are afflicted with a cardiovascular disease, such as end-stage renal disease. Methods and systems of the invention are particularly suited to predict atherothrombotic events in patients on hemodialysis.02-09-2012
20120295286Methods for the Diagnosis, Prognosis and Monitoring of Cancer Therapy Using BP1 - The invention described herein relates to method for diagnosing or monitoring the progression of a cancer, e.g., breast cancer, prostate cancer or brain cancer, in a subject by determining the amount of one or more biomarkers in a bodily fluid sample, where the biomarkers comprise pBP1. The invention described herein also relates to method for assessing the efficacy of a treatment of a subject having or suspected of having a cancer, by determining the amount of one or more biomarkers in a bodily fluid sample.11-22-2012
20120040379METHODS FOR DIFFERENTIATING PLASMA- DERIVED PROTEIN FROM RECOMBINANT PROTEIN IN A SAMPLE - The present invention relates, in general, to methods for detecting and quantitating plasma-derived protein and recombinant protein in a sample based on the difference in protein glycosylation, when the plasma protein and the recombinant protein are essentially the same protein.02-16-2012
20120040377RECOGNITION OF CYP2E1 EPITOPES - A critical epitope of human cytochrome P4502E1 (CYP2E1) associated with the development of hepatic autoimmune disease, including methods and kits for diagnosis and prognosis using the critical epitope as a biomarker for hepatic autoimmune disease.02-16-2012
20130203083SERUM CLUSTERIN LEVELS IN SYSTEMIC AMYLOIDOSIS FEATURING CARDIOMYOPATHY - The present invention relates generally to diagnostic methods, systems, assays and kits for identification of subjects with cardiac amyloid deposits, where a low level of clusterin protein in a peripheral fluid sample, e.g., a serum sample from the subject, indicates the subject likely has cardiac amyloid deposits. Other aspects relate to methods of treatment of diseases or disorders characterized by cardiac amyloid deposits and transthyretin (TTR) amyloidosis, and more particularly to methods of treatment of cardiac-related amyloidosis and cardiac amyloid deposits in subjects with familial transthyretin (TTR), senile systemic amyloidosis (SSA), or familial amyloidodic polyneuropathy (FAP), or immunoglobulin light chain (AL) amyloidosis. Other aspects relate to methods and compositions comprising clusterin (CLU) or a clusterin agent (e.g. an agonist of clusterin activity or a biologically active fragment or derivative thereof), and their use in methods to treat a disease or disorder characterized by transthyretin (TTR) amyloidosis, e.g. senile systemic amyloidosis (SSA) or familial amyloidodic polyneuropathy (FAP), and their use in methods to treat amyloidotic cardiomyopathy associated with transthyretin (TTR) amyloidosis.08-08-2013
20130203084SPECIFIC DETECTION OF HUMAN CHORIONIC GONADOTROPIN BETA SUBUNIT TYPE II PRODUCED BY TROPHOBLASTIC AND NEOPLASTIC CELLS - The present invention provides a novel method to distinguish between HCG β type I and type II gene expression using specific antibody. The specific recognition of HCGβ encoded by type II genes and expressed by trophoblastic and neoplastic cells might improve the clinical usefulness of assays aimed at either diagnosing tumors or screening Down's syndrome. The present invention also provides a diagnostic kit for determining the amount of HCGβ type II in a biological sample. The present invention additionally provides process of preparation and screening hybridoma capable of specifically recognizing HCGβ type II and recombinant antibody thereof. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.08-08-2013
20130203085ANTIGENIC STRUCTURE AND USES THEREOF FOR SCREENING TRYPANOSOMIASES IN HUMANS AND ANIMALS - The invention relates to an antigenic structure that contains a tryptophan epitope, characterised in that said structure is made up of a tryptophan pattern W or a peptide of 3 or 4 amino acids comprising a pattern W, coupled with glutaraldehyde. The invention can he used for screening trypanosomiasis in humans or animals.08-08-2013
20130203091MOESIN FRAGMENTS ASSOCIATED WITH APLASTIC ANEMIA - The present application provides compositions and methods useful for detecting and monitoring acquired aplastic anemia.08-08-2013
20120064550METHOD FOR MEASUREMENT OF EQUOL IN BIOLOGICAL SAMPLE BY IMMUNOASSAY, KIT FOR THE MEASUREMENT, AND METHOD FOR DETERMINATION OF EQUOL PRODUCTION ABILITY OF SUBJECT - An object of the present invention is to provide a method for measuring equol in a biological sample by an immunological method, a kit for the measurement, and a method for determining equol-producing ability of a subject.03-15-2012
20120070855METHOD FOR IN VITRO ASSAY OF SOLUBLE FIBRIN BY GENERATING SPECIFIC DEGRADATION PRODUCTS - The invention concerns a method for assaying soluble fibrin in a sample, in which said sample is brought into the presence of a plasminogen activator with a high specificity for soluble fibrin (PA-Fb sp) and the soluble fibrin count in the sample is measured by measuring the difference between the count of fibrin degradation products obtained after degrading soluble fibrin with PA-Fb sp and the base count of fibrin degradation products determined before bringing the sample into the presence of PA-Fb sp.03-22-2012
20120301902Gemcitabine Immunoassay - The present invention comprises novel conjugates and immunogens derived from gemcitabine and unique antibodies generated by using gemcitabine linked immunogens, which conjugates immunogens and antibodies, are useful in immunoassays for the quantification and monitoring of gemcitabine in biological fluids.11-29-2012
20120094318E-CADHERIN AS A BIOMARKER OF GASTROESOPHAGEAL REFLUX DISEASE - The present invention provides methods of diagnosing and identifying subjects as having GERD comprising detecting E-cadherin fragments in a biological sample from the subject. The invention further provides methods for identifying subjects as having heartburn that is responsive to proton pump inhibitor therapy and subjects having an increased likelihood of a rapid relapse of GERD after reducing the dosage of PPIs or terminating PPI therapy. In addition, the present invention provides methods for monitoring the healing of erosive and nonerosive esophagitis of GERD without the need for esophagogastroduodenoscopy or esophagogastroduodenoscopy and biopsy, respectively.04-19-2012
20120094317Method and Apparatus for Detecting an Analyte - In one aspect, this disclosure provides a substrate for determining the concentration of an analyte within a sample. The substrate includes a conductive region and a recognition layer, the conductive region including at least one particle and having a first surface operatively coupled with the recognition layer, the recognition layer comprising at least one recognition molecule. The distance between the first surface of the conductive region and the recognition molecule is selected such that when the analyte is bound to the recognition layer the combination of the at least one particle and the analyte exhibits at least one of the following effects when radiation is directed through the conductive region and the recognition layer: (i) a particle plasmon effect, (ii) a particle bulk interband absorption, (iii) analyte molecular absorption, and (iv) absorption by the analyte-particle combination.04-19-2012
20120094316Drug Detection - The invention relates to an immunoassay method and kit for the detection and/or the determination of mephedrone, mephedrone metabolites and related compounds. The invention is underpinned by a novel antibody, derived from a novel immunogen, that is sensitive and binds to mephedrone, mephedrone metabolites and related compounds.04-19-2012
20120094315BIOMARKERS FOR THE DIAGNOSIS AND/OR PREDICTION OF SUSCEPTIBILITY TO MENTAL AND NEURODEGENERATIVE DISORDERS - Provided herein are, inter alia, methods for predicting the susceptibility of a subject to a mental or neurodegenerative disorder, the method comprising obtaining one or more biological samples from the subject; determining the levels of one or more biomarkers in the sample, wherein the biomarkers are selected from pyrroles, histamine, methionine adenosyltransferase (MAT) activity, homocysteine, copper and zinc; and comparing the level(s) of the biomarker(s) determined in (b) with the level(s) of said biomarker(s) from one or more control samples, wherein abnormal levels of the one or more biomarkers in the sample(s) from the subject compared to the one or more control samples is predictive of susceptibility of the subject to a mental or neurodegenerative disorder.04-19-2012
20120094314DIAGNOSIS OF SEPTIC COMPLICATIONS - The invention describes a method for diagnosing of septic complications in polytraumatised human or animal patients, said patients being free of traumatic brain injury, by determining the level of the C-type natriuretic peptide (CNP), its precursors or fragments thereof, especially the precursor of the C-type natriuretic peptide (NT-proCNP), in this patient and diagnosing the patient a having septic complications or being at risk of developing septic complications, if the level of CNP, its precursors or fragments thereof, especially NT-proCNP, is increased compared to normal levels.04-19-2012
20130210035CHIP AND METHOD FOR DETECTING GLYCOSYLATED HEMOGLOBIN - The present invention relates to a chip and a method for detecting HbA1c. The detection chip comprises: a substrate; and a biomolecular layer disposed on the substrate, wherein the biomolecular layer comprises a first anti-hemoglobin antibody. The biomolecular layer can bind both the glycosylated hemoglobin and the hemoglobin in the blood sample. The method for detecting HbA1c of the present invention comprises the use of a bio-detection layer that comprises anti-glycosylated hemoglobin antibody and a second hemoglobin antibody with different epitope to differentiate the glycosylated hemoglobin from the total hemoglobin. Thus, the relative amount of glycosylated hemoglobin to hemoglobin can be detected by using the detection chip and the detection method of the present invention.08-15-2013
20130210036Controlling Fluid Flow Through An Assay Device - An assay device includes: a detection zone which includes a first set of projections which are capable of generating capillary flow. A wicking zone (WZ) has a capacity to receive liquid sample flowing from the detection zone and includes a second set of projections which are capable of generating capillary flow. The WZ is rectangular in shape and the longer side of the rectangle extends in the direction of flow to thereby reduce the pressure gradient in the assay device which increases the total flow time of liquid sample compared to a WZ having equal length sides and same volume. At least a portion of the second set of projections have at least one dimension selected from a diameter, a center-to-center spacing, or a gap between projections that is different from the first set of projections, and is selected to increase the total flow time of the sample.08-15-2013
20130210037METHODS OF DIAGNOSING AND TREATING AUTISM - The present invention provides diagnostic methods for determining the risk of developing an autism spectrum disorder (ASD) in a fetus or child by detecting in a biological sample from the mother antibodies that bind to one or more biomarkers selected from the group consisting of lactate dehydrogenase (LDH), guanine deaminase (GDA), collapsin response mediator protein 1 (CRMP1), stress-induced phosphoprotein 1 (STIP1), alpha subunit of the barbed-end actin binding protein Cap Z (CAPZA2), Y Box Binding Protein 1 (YBX1), eukaryotic translation and elongation factor 1A1 (EEF1A1), microtubule-associated protein Tau (MAPT), dihydropyrimidinase-like protein 2 (DPYSL2), dynamin 1-like protein (DNM1L), radixin (RDX), moesin (MSN), and ezrin (EZR). The invention further provides methods of preventing or reducing the risk of a fetus or child developing an ASD by administering to the mother an agent that blocks the binding of maternal antibodies to the one or more fetal biomarkers listed above or by removing from the mother antibodies that bind to the one or more fetal biomarkers.08-15-2013
20130210038Novel Method for Diagnosing Q-fever Using a Cellular Immunological Test - The present invention relates to a method for diagnosing Q-fever in a subject, the method comprising the steps of: (a) obtaining a sample from said subject, (b) contacting said sample with a source of a 08-15-2013
20130210039BLOOD INSULIN RESISTANCE AND DIABETES MARKER PROGRANULIN, METHOD FOR ANALYZING CONCENTRATION OF PROGRANULIN IN BLOOD SAMPLE, AND METHOD FOR SCREENING FOR SUBSTANCE THAT IMPROVES INSULIN RESISTANCE AND IMPROVES OR SUPPRESSES DIABETES - The present invention provides a marker capable of detecting insulin resistance and diabetes in a collected blood sample, a method for analyzing said marker, a method for screening a substance improving insulin resistance, and improving or suppressing diabetes. A blood insulin resistance marker and a blood diabetes marker, which comprises a polypeptide comprising at least 15 continuous amino acids in an amino acid sequence constituting progranulin. A method for analyzing a blood marker, which comprises the steps of: measuring a concentration of an insulin resistance marker or a diabetes marker in a collected blood sample; and comparing the measured concentration with a normal blood concentration of the marker. A method for screening a substance improving insulin resistance, and improving or suppressing diabetes, which comprises the steps of: administering a candidate substance to a living body expressing insulin resistance or suffering from diabetes; measuring a blood concentration of a marker in the living body after administration; and comparing the measured concentration of the marker with a blood concentration of the marker not administered with the candidate substance.08-15-2013